plant O
from O
this O
genus O
produce O
toxic O
alkaloid O
and O
cardiac O
glycosid O
g O
- O
strophanthin O
( O
syn O
ouabain B-Plant
) O
, O
k O
- O
strophanthin O
, O
and O
e O
- O
strophanthin O
. O

some O
of O
the O
chemical O
in O
the O
plant O
be O
use O
to O
produce O
the O
drug O
ouabain B-Plant
, O
which O
be O
take O
as O
a O
cardiac O
stimulant O
to O
treat O
heart O
failure O
and O
sometimes O
g O
- O
strophanthin O
be O
advocate O
as O
an O
alternative O
treatment O
to O
more O
contemporary O
practice O
. O

the O
effect O
be O
similar O
to O
that O
of O
the O
drug O
digoxin O
, O
which O
be O
produce O
from O
digitalis B-Plant
purpurea I-Plant
. O

formerly O
include O
in O
genusstrophanthus O
aambe O
= O
papuechites B-Plant
aambe I-Plant
ginkgo B-Plant
biloba I-Plant
, O
commonly O
know O
as O
ginkgo O
or O
gingko O
( O
both O
pronounce O
) O
, O
also O
know O
as O
the O
maidenhair B-Plant
tree I-Plant
, O
be O
the O
only O
living O
specie O
in O
the O
division O
ginkgophyta O
, O
all O
other O
be O
extinct O
. O

dipsacus B-Plant
fullonum I-Plant
, O
syn O
dipsacus B-Plant
sylvestris I-Plant
, O
be O
a O
species O
of O
flower O
plant O
know O
by O
the O
common O
name O
wild B-Plant
teasel I-Plant
or O
full B-Plant
's I-Plant
teasel I-Plant
, O
although O
the O
latter O
name O
be O
usually O
apply O
to O
the O
cultivate O
species O
dipsacus B-Plant
sativus I-Plant
. O

the O
inflorescence O
be O
a O
cylindrical O
array O
of O
lavender B-Plant
flower O
which O
dry O
to O
a O
cone O
of O
spine O
- O
tip O
hard O
bract O
. O

bulbophyllum B-Plant
absconditum I-Plant
, O
know O
as O
the O
' O
hidden O
bulbophyllum O
, O
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

betula B-Plant
michauxii I-Plant
, O
newfoundland B-Plant
dwarf I-Plant
birch I-Plant
, O
be O
a O
species O
of O
birch B-Plant
which O
be O
native O
to O
newfoundland O
from O
which O
-PRON- O
get O
introduce O
to O
nova O
scotia O
and O
quebec O
. O

plinia B-Plant
cauliflora I-Plant
, O
the O
brazilian B-Plant
grapetree I-Plant
, O
jaboticaba B-Plant
or O
jabuticaba O
, O
be O
a O
tree O
in O
the O
family O
myrtaceae O
, O
native O
to O
minas O
gerais O
, O
goiás O
and O
são O
paulo O
state O
in O
brazil O
. O

three O
specie O
( O
g. B-Plant
odorata I-Plant
, O
g. B-Plant
scabra I-Plant
, O
g. B-Plant
speciosa I-Plant
) O
be O
know O
in O
cultivation O
. O

guettarda B-Plant
argentea I-Plant
provide O
edible O
fruit O
. O

the O
type O
specie O
for O
the O
genus O
be O
guettarda B-Plant
speciosa I-Plant
. O

fir O
be O
most O
closely O
related O
to O
the O
genus O
cedrus O
( O
cedar B-Plant
) O
. O

douglas B-Plant
fir I-Plant
be O
not O
TRUE O
fir O
, O
be O
of O
the O
genus O
pseudotsuga O
. O

fir O
can O
be O
distinguish O
from O
other O
member O
of O
the O
pine O
family O
by O
the O
way O
in O
which O
needle O
- O
like O
leaf O
be O
attach O
singly O
to O
the O
branch O
with O
a O
base O
resemble O
a O
suction O
cup O
, O
and O
by O
-PRON- O
cone O
, O
which O
, O
like O
those O
of O
atlas B-Plant
cedar I-Plant
( O
cedrus O
) O
, O
stand O
upright O
on O
the O
branch O
like O
candle O
and O
disintegrate O
at O
maturity O
. O

cryptarrhena O
be O
a O
genus O
of O
orchid B-Plant
( O
family O
orchidaceae O
) O
. O

bonnemaisoniaceae O
be O
a O
family O
of O
red O
algae B-Plant
in O
the O
order O
bonnemaisoniales O
. O

kelloggia O
be O
a O
plant O
genus O
in O
the O
bedstraw B-Plant
and O
madder O
family O
rubiaceae O
. O

be O
know O
by O
the O
native O
hawaiians O
as O
hau B-Plant
kuahiwi I-Plant
which O
mean O
mountain O
hibiscus O
. O

mirabilis B-Plant
longiflora I-Plant
, O
sweet B-Plant
four I-Plant
o'clock I-Plant
, O
be O
a O
species O
of O
flower O
plant O
native O
to O
the O
southwestern O
united O
states O
from O
arizona O
to O
texas O
and O
northern O
mexico O
. O

specie O
include O
gomesa B-Plant
radican I-Plant
. O

when O
carl O
linnaeus O
name O
this O
genus O
in O
1763 O
, O
include O
in O
this O
genus O
all O
the O
epiphytic O
orchid B-Plant
know O
to O
. O

although O
few O
of O
these O
orchid B-Plant
be O
still O
include O
in O
the O
genus O
epidendrum O
, O
some O
specie O
of O
epidendrum O
be O
nevertheless O
not O
epiphytic O
. O

lemon B-Plant
balm O
( O
melissa B-Plant
officinali I-Plant
) O
, O
balm O
, O
common B-Plant
balm I-Plant
, O
or O
balm O
mint B-Plant
, O
be O
a O
perennial O
herbaceous O
plant O
in O
the O
mint O
family O
lamiaceae O
and O
native O
to O
south O
- O
central O
europe O
, O
the O
mediterranean O
basin O
, O
iran O
, O
and O
central O
asia O
, O
but O
now O
naturalize O
in O
the O
americas O
and O
elsewhere O
. O

grow O
to O
a O
maximum O
height O
of O
70–150 O
cm O
( O
28–59 O
in O
) O
. O

the O
leaf O
have O
a O
mild O
lemon B-Plant
scent O
similar O
to O
mint B-Plant
. O

the O
tea B-Plant
of O
lemon B-Plant
balm O
, O
the O
essential O
oil O
, O
and O
the O
extract O
be O
use O
in O
traditional O
and O
alternative O
medicine O
, O
include O
aromatherapy O
. O

the O
plant O
have O
be O
cultivate O
at O
least O
since O
the O
16th O
century O
, O
but O
research O
be O
still O
be O
conduct O
to O
establish O
the O
safety O
and O
effect O
of O
lemon B-Plant
balm O
. O

crobylanthe B-Plant
pellacalyx I-Plant
, O
which O
be O
endemic O
to O
sarawak O
. O

asphodelus B-Plant
aestivus I-Plant
, O
the O
summer O
asphodel B-Plant
, O
be O
a O
species O
of O
asphodel B-Plant
, O
a O
common O
western O
mediterranean O
geophyte O
with O
a O
short O
vertical O
rhizome O
and O
basal O
leaf O
. O

there O
have O
be O
a O
lot O
of O
confusion O
over O
the O
nomenclature O
and O
taxonomy O
of O
the O
specie O
, O
especially O
in O
confusion O
with O
asphodelus B-Plant
ramosus I-Plant
. O

satyrium O
be O
a O
genus O
of O
orchid B-Plant
. O

elymus O
be O
a O
genus O
of O
perennial O
plant O
with O
approximately O
150 O
specie O
in O
the O
grass O
family O
, O
relate O
to O
rye B-Plant
, O
wheat B-Plant
, O
and O
other O
widely O
grow O
cereal O
grain O
. O

common O
name O
include O
couch B-Plant
grass I-Plant
, O
wildrye B-Plant
and O
wheatgrass B-Plant
. O

many O
specie O
once O
consider O
member O
of O
elymus O
be O
now O
regard O
as O
better O
suit O
to O
other O
genera O
: O
agropyron O
, O
anthosachne O
, O
brachypodium O
, O
cenchrus O
, O
crithopsis O
, O
heteranthelium O
, O
jouvea O
, O
kengyilia O
, O
leymus O
, O
psathyrostachys O
, O
stenostachys O
, O
taeniatherum O
, O
thinopyrum O
etc O
. O

the O
following O
specie O
be O
recognise O
by O
the O
plant O
list O
: O
moreover O
, O
scleroderma O
citrinum O
have O
much O
firm O
flesh O
and O
a O
dark O
gleba O
( O
interior O
) O
much O
earlier O
in O
development O
than O
puffball B-Plant
. O

pinellia B-Plant
ternata I-Plant
( O
chinese O
: O
, O
japanese O
: O
) O
, O
crow B-Plant
- I-Plant
dipper I-Plant
, O
be O
a O
plant O
native O
to O
china O
, O
japan O
, O
and O
korea O
, O
but O
also O
grow O
as O
an O
invasive O
weed O
in O
part O
of O
europe O
( O
austria O
, O
germany O
) O
and O
north O
america O
( O
california O
, O
ontario O
, O
northeastern O
united O
states O
) O
. O

general O
common O
name O
include O
indian B-Plant
mallow I-Plant
and O
velvetleaf B-Plant
in O
russian O
, O
ornamental O
variety O
be O
commonly O
know O
as O
the O
room B-Plant
maple I-Plant
. O

the O
generic O
name O
be O
derive O
from O
the O
latin O
word O
moru O
mulberry B-Plant
, O
from O
the O
appearance O
of O
the O
fruit O
, O
and O
indica O
, O
mean O
of O
india O
. O

grow O
in O
acidic O
soil O
, O
with O
different O
specie O
in O
wet O
acid O
bog O
habitat O
( O
k. B-Plant
angustifolia I-Plant
, O
k. B-Plant
polifolia I-Plant
) O
and O
dry O
, O
sandy O
soil O
( O
k. B-Plant
ericoide I-Plant
, O
k. B-Plant
latifolia I-Plant
) O
. O
describe O
, O
a O
costly O
rarity O
, O
in O
-PRON- O
natural O
history O
of O
carolina O
, O
as O
chamaedaphne O
foliis O
tini O
, O
that O
be O
to O
say O
with O
leaf O
like O
the O
laurustinus B-Plant
the O
foliage O
be O
toxic O
if O
eat O
, O
with O
sheep O
be O
particularly O
prone O
to O
poisoning O
, O
hence O
the O
name O
lambkill B-Plant
use O
for O
some O
of O
the O
specie O
. O

other O
name O
for O
kalmia O
, O
particularly O
kalmia B-Plant
angustifolia I-Plant
, O
be O
sheep B-Plant
- I-Plant
laurel I-Plant
, O
lamb B-Plant
- I-Plant
kill I-Plant
, O
calf B-Plant
- I-Plant
kill I-Plant
, O
kill B-Plant
- I-Plant
kid I-Plant
, O
and O
sheep B-Plant
- I-Plant
poison I-Plant
, O
which O
may O
be O
write O
with O
or O
without O
the O
hyphen O
. O

have O
also O
be O
call O
spoonwood B-Plant
because O
kalm O
be O
tell O
by O
dutch O
settler O
of O
north O
america O
that O
native O
americans O
make O
spoon O
from O
the O
wood O
. O

impatien B-Plant
noli I-Plant
- I-Plant
tangere I-Plant
( O
touch B-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
balsam I-Plant
also O
call O
touch B-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
, O
yellow B-Plant
balsam I-Plant
, O
jewelwe B-Plant
, O
western B-Plant
touch I-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
or O
wild B-Plant
balsam I-Plant
. O

guthriea B-Plant
capensis I-Plant
be O
an O
acaulescent O
perennial O
herb O
endemic O
to O
south O
africa O
and O
occur O
in O
cool O
and O
damp O
site O
face O
south O
or O
east O
in O
the O
mountain O
of O
the O
cape O
province O
, O
lesotho O
and O
kwazulu O
- O
natal O
. O

this O
ground O
- O
hugging O
specie O
with O
a O
rhizome O
and O
fleshy O
root O
form O
a O
compact O
rosette O
of O
some O
20 O
- O
30 O
broadly O
elliptic O
or O
cordate O
discolorous O
leaf O
with O
crenate O
margin O
, O
measure O
about O
50 O
x O
75 O
mm O
, O
glossy O
above O
with O
deeply O
indented O
venation O
hide O
creamy O
- O
green O
flower O
which O
be O
solitary O
and O
stalk O
. O

guthriea O
belong O
to O
the O
family O
achariaceae O
, O
a O
family O
which O
now O
include O
various O
specie O
previously O
place O
in O
the O
flacourtiaceae O
, O
such O
as O
kiggelaria B-Plant
africana I-Plant
, O
rawsonia B-Plant
lucida I-Plant
and O
xylotheca B-Plant
kraussiana I-Plant
. O

several O
specie O
be O
grow O
in O
garden O
, O
especially O
b. B-Plant
frutescen I-Plant
. O

the O
genus O
include O
the O
important O
group O
of O
culinary O
herb O
: O
marjoram B-Plant
( O
origanum B-Plant
majorana I-Plant
) O
and O
oregano B-Plant
( O
origanum O
vulgare O
origanum O
species O
be O
use O
as O
food O
plant O
by O
the O
larvae O
of O
some O
lepidoptera O
specie O
, O
include O
coleophora O
albitarsella O
. O

be O
sometimes O
call O
cottonros O
or O
cudweed B-Plant
. O

the O
name O
cudweed B-Plant
come O
from O
the O
fact O
that O
-PRON- O
be O
once O
use O
to O
feed O
cow O
that O
have O
lose O
the O
ability O
to O
chew O
the O
cud O
. O

jensenia O
be O
a O
bryophyte O
plant O
genus O
in O
the O
liverwort B-Plant
family O
pallaviciniaceae O
. O

one O
of O
the O
specie O
, O
catopsis B-Plant
berteroniana I-Plant
, O
be O
think O
to O
be O
carnivorous O
. O

phlox B-Plant
hoodii I-Plant
, O
the O
spiny B-Plant
phlox I-Plant
or O
carpet B-Plant
phlox I-Plant
, O
be O
a O
species O
of O
phlox B-Plant
. O

be O
a O
plant O
of O
western O
north O
america O
, O
where O
-PRON- O
be O
a O
common O
flower O
in O
sagebrush B-Plant
country O
. O

gastrodia O
be O
a O
genus O
of O
achlorophyllous O
orchid B-Plant
with O
64 O
currently O
accept O
specie O
. O

gastrodia B-Plant
elata I-Plant
be O
a O
traditional O
chinese O
herb O
, O
tian O
ma O
( O
chinese O
: O
天麻 O
) O
, O
and O
be O
commonly O
use O
in O
china O
to O
treat O
hypertension O
, O
improve O
circulation O
and O
resolve O
headache O
. O

anthoceros O
be O
a O
genus O
of O
hornwort B-Plant
in O
the O
family O
anthocerotaceae O
. O

name O
mean O
' O
flower O
horn O
' O
, O
and O
refer O
to O
the O
characteristic O
horn O
- O
shape O
sporophyte O
that O
all O
hornwort B-Plant
produce O
. O

rumex B-Plant
dentatus I-Plant
be O
a O
species O
of O
flower O
plant O
in O
the O
knotweed O
family O
know O
by O
the O
common O
name O
tooth B-Plant
dock I-Plant
and O
aegean O
dock O
. O

the O
group O
include O
many O
well O
- O
know O
desert O
and O
dry O
zone O
type O
such O
as O
the O
agave O
, O
yucca B-Plant
, O
and O
joshua B-Plant
tree I-Plant
. O

cryptocoryne B-Plant
beckettii I-Plant
( O
also O
know O
as O
beckett B-Plant
's I-Plant
water I-Plant
trumpet I-Plant
) O
be O
a O
plant O
specie O
belong O
to O
the O
aroid O
genus O
cryptocoryne O
. O

crataegus B-Plant
× I-Plant
lavalleei O
, O
sometimes O
know O
as O
hybrid O
cockspurthorn B-Plant
or O
lavallée B-Plant
's I-Plant
hawthorn I-Plant
, O
be O
a O
hybrid O
that O
arise O
between O
cultivate O
specimen O
of O
two O
specie O
in O
the O
genus O
crataegus O
( O
hawthorn B-Plant
) O
. O

the O
female O
parent O
be O
c. B-Plant
mexicana I-Plant
( O
sometimes O
mistakenly O
call O
c. B-Plant
pubescen I-Plant
) O
, O
and O
the O
male O
parent O
be O
think O
to O
be O
c. B-Plant
calpodendron I-Plant
( O
which O
be O
sometimes O
mistakenly O
call O
c. O
crus O
- O
galli O
) O
's O
hawthorn B-Plant
, O
c. B-Plant
× I-Plant
carrierei O
have O
the O
same O
parentage O
, O
and O
be O
therefore O
a O
synonym O
, O
i.e. O
there O
be O
minor O
difference O
between O
lavallée B-Plant
's I-Plant
hawthorn I-Plant
and O
carrière B-Plant
's I-Plant
hawthorn I-Plant
, O
and O
the O
latter O
be O
consider O
a O
separate O
cultivar O
, O
which O
be O
formally O
write O
as O
crataegus O
' O
carrierei O
' O
. O

crataegus B-Plant
× I-Plant
lavalleei O
be O
an O
ornamental O
small O
tree O
with O
glossy O
dark O
green O
unlob O
leaf O
that O
be O
use O
horticulturally O
. O

cedronella O
be O
a O
genus O
of O
flower O
plant O
in O
the O
mentheae O
tribe O
of O
family O
lamiaceae O
, O
comprise O
a O
single O
specie O
, O
cedronella B-Plant
canariensis I-Plant
, O
native O
to O
the O
canary O
islands O
, O
the O
azores O
, O
and O
madeira O
. O

common O
name O
include O
canary B-Plant
islands I-Plant
- I-Plant
balm I-Plant
, O
canary B-Plant
balm I-Plant
, O
and O
balm B-Plant
- I-Plant
of I-Plant
- I-Plant
gilead I-Plant
. O

the O
genus O
name O
be O
a O
diminutive O
of O
cedrus O
, O
though O
the O
only O
connection O
between O
this O
herb O
and O
the O
large O
conifer B-Plant
of O
cedrus O
be O
a O
vaguely O
similar O
resinous O
scent O
of O
the O
foliage O
. O

the O
genus O
platanthera O
belong O
to O
the O
subfamily O
orchidoideae O
of O
the O
family O
orchidaceae O
, O
and O
comprise O
about O
100 O
specie O
of O
orchid B-Plant
. O

the O
member O
of O
this O
genus O
, O
know O
as O
the O
butterfly B-Plant
orchid I-Plant
or O
fringed B-Plant
orchid I-Plant
, O
be O
previously O
include O
in O
the O
genus O
orchis O
, O
which O
be O
a O
close O
relative O
( O
along O
with O
the O
genus O
habenaria O
) O
. O

one O
specie O
, O
pitcairnia B-Plant
feliciana I-Plant
be O
find O
in O
tropical O
west O
africa O
and O
be O
the O
only O
member O
of O
the O
bromeliaceae O
family O
not O
native O
to O
the O
western O
hemisphere O
. O

marchantiopsida O
be O
one O
of O
three O
class O
within O
the O
liverwort B-Plant
phylum O
marchantiophyta O
. O

quercus B-Plant
garryana I-Plant
, O
the O
garry B-Plant
oak I-Plant
, O
oregon B-Plant
white I-Plant
oak I-Plant
, O
oregon B-Plant
oak I-Plant
, O
or O
hu'dshnam O
, O
from O
the O
traditional O
klamath O
language O
, O
be O
a O
tree O
specie O
with O
a O
range O
stretch O
from O
southern O
california O
to O
southwestern O
british O
columbia O
. O

the O
tree O
get O
one O
of O
name O
from O
nicholas O
garry O
, O
deputy O
governor O
of O
the O
hudson B-Plant
's O
bay O
company O
, O
1822–35 O
. O

alligator B-Plant
- I-Plant
flag I-Plant
be O
a O
common O
name O
for O
plant O
in O
this O
genus O
. O

drosophyllum O
( O
, O
rarely O
) O
be O
a O
genus O
of O
carnivorous O
plant O
contain O
the O
single O
specie O
drosophyllum B-Plant
lusitanicum I-Plant
( O
portuguese O
sundew B-Plant
or O
dewy O
pine B-Plant
) O
. O

drosophyllum B-Plant
lusitanicum I-Plant
bear O
bright O
- O
yellow O
flower O
, O
4 O
cm O
( O
1.6 O
in O
) O
in O
diameter O
, O
bear O
in O
group O
of O
3–15 O
between O
february O
and O
May O
the O
translucent O
seedpod O
bear O
3–10 O
opaque O
black O
, O
pear B-Plant
- O
shape O
seed O
, O
2.5 O
mm O
( O
98 O
in O
) O
in O
diameter O
. O

drosera B-Plant
paradoxa I-Plant
be O
a O
carnivorous O
plant O
in O
the O
genus O
drosera O
and O
be O
endemic O
to O
the O
northern O
territory O
and O
western O
australia O
. O

inflorescence O
be O
20–40 O
cm O
( O
8–16 O
in O
) O
long O
with O
pink O
or O
white O
flower O
be O
produce O
on O
-50 O
to O
70-flowered O
crowded O
raceme O
from O
july O
to O
september O
during O
the O
dry O
season O
. O

drosera B-Plant
paradoxa I-Plant
be O
find O
in O
skeletal O
sandy O
soil O
over O
sandstone O
in O
or O
along O
the O
bank O
of O
seasonally O
dry O
creek O
or O
in O
sandstone O
crack O
. O

drosera B-Plant
paradoxa I-Plant
be O
native O
to O
the O
west O
and O
north O
coast O
of O
the O
kimberley O
region O
inland O
to O
beverley O
springs O
, O
western O
australia O
and O
east O
to O
arnhem O
land O
and O
kakadu O
national O
park O
in O
the O
northern O
territory O
. O

be O
first O
describe O
by O
australian O
botanist O
allen O
lowrie O
in O
a O
1997 O
issue O
of O
nuytsia O
, O
the O
journal O
of O
the O
western O
australian O
herbarium O
. O

several O
trip O
into O
the O
field O
from O
1993 O
to O
1997 O
be O
require O
to O
reveal O
these O
different O
form O
to O
be O
only O
stage O
in O
this O
specie O
' O
perennial O
growth O
cycle O
from O
seedl O
to O
pincushion B-Plant
basal O
rosette O
to O
erect O
woody O
- O
stemmed O
speciman O
. O

be O
closely O
related O
to O
d. B-Plant
petiolaris I-Plant
, O
but O
differ O
from O
that O
specie O
most O
notably O
by O
-PRON- O
tall O
woody O
stem O
whereas O
d. B-Plant
petiolaris I-Plant
form O
clump O
of O
many O
basal O
rosette B-Plant
from O
a O
common O
perennial O
rootstock O
. O

illicium B-Plant
anisatum I-Plant
, O
with O
common O
name O
japanese B-Plant
star I-Plant
anise I-Plant
, O
aniseed O
tree O
, O
and O
sacred O
anise B-Plant
tree I-Plant
, O
know O
in O
japan O
as O
shikimi O
( O
be O
a O
tree O
closely O
related O
to O
the O
chinese B-Plant
star I-Plant
anise I-Plant
( O
illicium B-Plant
verum I-Plant
) O
. O

tuber B-Plant
melanosporum I-Plant
: O
mat O
type O
distribution O
in O
a O
natural O
plantation O
and O
dynamic O
of O
strain O
of O
different O
mating O
type O
on O
the O
root O
of O
nursery O
- O
inoculate O
host O
plant O
. O

in O
light O
of O
the O
recent O
finding O
that O
tuber B-Plant
melanosporum I-Plant
, O
the O
ectomycorrhizal O
ascomycete O
that O
produce O
the O
most O
highly O
prize O
black O
truffle O
, O
be O
a O
heterothallic O
specie O
, O
monitor O
the O
spatial O
distribution O
of O
strain O
with O
opposite O
mating O
type O
( O
mat O
) O
in O
a O
natural O
truffle O
ground O
and O
follow O
strain O
dynamic O
in O
artificially O
inoculate O
host O
plant O
grow O
under O
control O
condition O
. O

the O
present O
study O
deepen O
understanding O
of O
the O
vegetative O
and O
sexual O
propagation O
mode O
of O
t. B-Plant
melanosporum I-Plant
. O

sgt1 O
contribute O
to O
coronatine O
signaling O
and O
pseudomonas O
syringae O
pv. O
tomato B-Plant
disease O
symptom O
development O
in O
tomato B-Plant
and O
arabidopsis O
. O

pseudomona O
syringae O
pv. O
tomato B-Plant
dc3000 O
( O
pst O
dc3000 O
) O
cause O
an O
economically O
important O
bacterial O
speck O
disease O
on O
tomato B-Plant
and O
produce O
symptom O
with O
necrotic O
lesion O
surround O
by O
chlorosis O
. O

in O
this O
study O
, O
take O
advantage O
of O
a O
chlorotic O
phenotype O
elicit O
by O
cor O
on O
nicotiana B-Plant
benthamiana I-Plant
leaf O
and O
virus O
- O
induce O
gene O
silencing O
( O
vigs O
) O
as O
a O
rapid O
reverse O
genetic O
screening O
tool O
and O
identify O
a O
role O
for O
sgt1 O
( O
suppressor O
of O
g2 O
allele O
of O
skp1 O
) O
in O
cor O
- O
induce O
chlorosis O
. O

silence O
of O
sgt1 O
in O
tomato B-Plant
result O
in O
reduction O
of O
disease O
- O
associate O
symptom O
( O
cell O
death O
and O
chlorosis O
) O
, O
suggest O
a O
molecular O
connection O
between O
cor O
- O
induce O
chlorosis O
and O
cell O
death O
. O

take O
together O
, O
result O
demonstrate O
that O
sgt1/sgt1b O
be O
require O
for O
cor O
- O
induce O
chlorosis O
and O
subsequent O
necrotic O
disease O
development O
in O
tomato B-Plant
and O
arabidopsis O
. O

oshma3 O
, O
a O
p1b O
- O
type O
of O
atpase O
affect O
root O
- O
to O
- O
shoot O
cadmium O
translocation O
in O
rice B-Plant
by O
mediate O
efflux O
into O
vacuole O
. O

the O
cadmium O
( O
cd O
) O
over O
- O
accumulate O
rice B-Plant
( O
oryza B-Plant
sativa I-Plant
) O
cv O
cho O
- O
ko O
- O
koku O
be O
previously O
show O
to O
have O
an O
enhanced O
rate O
of O
root O
- O
to O
- O
shoot O
cd O
translocation O
. O

propose O
that O
the O
root O
cell O
cytoplasm O
of O
cd O
- O
overaccumulat O
rice B-Plant
plant O
have O
more O
cd O
available O
for O
loading O
into O
the O
xylem O
as O
a O
result O
of O
the O
lack O
of O
oshma3-mediated O
transportation O
of O
cd O
to O
the O
vacuole O
. O

these O
datum O
demonstrate O
the O
importance O
of O
vacuolar O
sequestration O
for O
cd O
accumulation O
in O
rice B-Plant
. O

spatial O
distribution O
of O
arsenic O
and O
temporal O
variation O
of O
concentration O
in O
rice B-Plant
. O

in O
order O
to O
gain O
insight O
into O
the O
transport O
and O
distribution O
of O
arsenic O
( O
as O
) O
in O
intact O
rice B-Plant
( O
oryza B-Plant
sativa I-Plant
) O
plant O
and O
unloading O
into O
the O
rice B-Plant
grain O
, O
investigate O
the O
spatial O
distribution O
of O
as O
and O
the O
temporal O
variation O
of O
as O
concentration O
in O
whole O
rice B-Plant
plant O
at O
different O
growth O
stage O
. O

moreover O
, O
node O
appear O
to O
serve O
as O
a O
check O
- O
point O
in O
as O
distribution O
in O
rice B-Plant
shoot O
. O

intra O
- O
ring O
delta(13 O
) O
c O
be O
measure O
in O
-30 O
to O
60-mum O
- O
thick O
slice O
in O
eight O
oak B-Plant
tree O
( O
quercus B-Plant
petraea I-Plant
) O
. O

resistance O
and O
recovery O
of O
soil O
microbial O
community O
in O
the O
face O
of O
alliaria B-Plant
petiolata I-Plant
invasion O
. O

in O
soil O
community O
sample O
from O
site O
along O
a O
gradient O
of O
invasion O
history O
with O
alliaria B-Plant
petiolata I-Plant
, O
microbial O
richness O
tend O
to O
decline O
, O
but O
the O
community O
's O
resistance O
to O
a. B-Plant
petiolata I-Plant
's O
effect O
generally O
increase O
with O
increase O
history O
of O
invasion O
. O

this O
may O
be O
because O
of O
evolutionary O
change O
in O
the O
a. B-Plant
petiolata I-Plant
population O
, O
which O
tend O
to O
reduce O
investment O
to O
allelopathic O
compound O
over O
time O
. O

analyse O
the O
precise O
kinetic O
and O
physiological O
control O
of O
petiole O
elongation O
response O
to O
shade O
and O
submergence O
in O
the O
flood O
- O
tolerant O
specie O
rumex B-Plant
palustris I-Plant
. O

the O
magnitude O
of O
the O
' O
ionic O
effect O
' O
be O
link O
with O
vessel O
and O
pit O
dimension O
in O
20 O
angiosperm O
specie O
cover O
13 O
family O
include O
six O
lauraceae B-Plant
specie O
. O

in  O
1917 O
and O
1918 O
with O
herbert O
carr O
, O
r O
a O
frazer O
, O
i O
a O
richards O
( O
and O
his O
spaniel O
sancho O
panza O
) O
, O
c O
f O
holland O
and O
others O
, O
she O
explored O
tryfan O
, O
lliwedd O
, O
the O
devil O
's O
kitchen O
, O
cwm O
idwal O
151 O
and O
was O
one O
of O
the O
first O
party O
up O
holly B-Plant
tree I-Plant
wall O
. O

the O
trees O
were O
the O
real O
enemy O
, O
old O
trees O
, O
young O
trees O
, O
rotten O
and O
burnt O
trees O
, O
douglas B-Plant
firs I-Plant
, O
jack O
pines B-Plant
, O
spruce B-Plant
, O
poplar B-Plant
and O
birch B-Plant
; O
the O
lower O
slopes O
between O
2700 O
and O
3000 O
metres O
are O
dominated O
by O
the O
yunnan B-Plant
pine I-Plant
pinus B-Plant
yunnanensis I-Plant
which O
is O
interspersed O
with O
hardwood O
trees O
such O
as O
poplar B-Plant
and O
lime B-Plant
as O
well O
as O
a O
very O
wide O
range O
of O
interesting O
shrubs O
. O

above O
the O
deciduous O
tree O
- O
line O
, O
pine B-Plant
forests O
compete O
with O
swashes O
of O
yellow B-Plant
azalea I-Plant
giving O
way O
to O
meadows O
bejewelled O
with O
alpine O
flowers O
swept O
by O
wave O
- O
tossed O
tracts O
of O
the O
white O
blossomed O
rhododendron B-Plant
caucasicum I-Plant
. O

wild B-Plant
jasmine I-Plant
( O
jasminum B-Plant
fruticans I-Plant
) O
and O
bar B-Plant
- I-Plant
berry I-Plant
( O
berberis B-Plant
vulgaris I-Plant
) O
bloom O
amidst O
the O
glossy O
evergreen O
foliage O
of O
straw B-Plant
- I-Plant
berry I-Plant
trees O
( O
arbutus O
unedd O
) O
and O
spanish B-Plant
laurel I-Plant
( O
laurus B-Plant
nobilis I-Plant
) O
, O
whilst O
the O
turpentine B-Plant
tree I-Plant
( O
pistacia B-Plant
terebinthus I-Plant
) O
, O
a O
close O
relative O
of O
the O
pistachio B-Plant
, O
spreads O
its O
leaves O
in O
the O
sunniest O
spots O
together O
with O
wild O
figs B-Plant
( O
ficus B-Plant
carica I-Plant
) O
, O
walnuts B-Plant
( O
juglans B-Plant
regia I-Plant
) O
and O
olives B-Plant
( O
olea B-Plant
europaea I-Plant
ssp. I-Plant
sylvestris I-Plant
) O
. O

its O
abun O
- O
dant O
forests O
, O
exploited O
by O
seafaring O
nations O
from O
the O
romans O
onwards O
, O
combine O
chestnut B-Plant
, O
oak B-Plant
, O
beech B-Plant
and O
, O
above O
all O
, O
the O
transcendental O
corsican B-Plant
pine I-Plant
, O
a O
monarch O
of O
european O
trees O
, O
which O
attains O
700 O
years O
of O
age O
and O
over O
50 O
m O
in O
height O
. O

from O
a O
distance O
the O
tree O
silhouettes O
could O
have O
been O
scots O
pines B-Plant
, O
but O
were O
actually O
evergreen O
beech B-Plant
nothofagus B-Plant
betuloides I-Plant
, O
intermingled O
with O
the O
autumn O
crimson O
and O
gold O
of O
deciduous O
southern B-Plant
beech I-Plant
nothofaguspumilla O
and O
antarctica O
. O

up O
in O
the O
fragile O
alpine O
zone O
, O
where O
even O
a O
small O
two O
- O
foot O
- O
diameter O
conifer B-Plant
( O
deodar B-Plant
or O
pine B-Plant
) O
will O
be O
some O
200 O
years O
old O
, O
we O
watched O
in O
horror O
as O
many O
of O
these O
trees O
were O
cut O
down O
merely O
to O
melt O
tar O
to O
put O
on O
the O
road O
. O

and O
, O
by O
the O
sacred O
lake O
of O
mabartsho O
, O
yellow O
tree O
paeonies O
, O
a O
variety O
of O
paeonia B-Plant
lutea I-Plant
. O

and O
on O
the O
walk O
- O
out O
next O
day O
there O
were O
fine O
tree B-Plant
ferns I-Plant
and O
bright O
blue O
iris B-Plant
decora I-Plant
. O

he O
pointed O
out O
a O
bequartodendron O
tree O
, O
enmeshed O
in O
a O
strangler O
fig B-Plant
which O
he O
had O
watched O
grow O
since O
he O
first O
came O
here O
in O
1962 O
. O

a O
pleasant O
scramble O
zigzags O
through O
boulders O
, O
prickly O
euphorbia O
and O
the O
surreal O
, O
fleshy O
kokerboom O
or O
' O
quiver O
' O
trees O
, O
whose O
pith B-Plant
was O
made O
into O
arrow O
quivers O
by O
the O
bushmen O
. O

13 O
we O
found O
a O
small O
group O
of O
mountain B-Plant
cabbage I-Plant
trees O
( O
cordyline B-Plant
indivisa I-Plant
) O
growing O
on O
the O
ridge O
above O
the O
tree O
line O
. O

not O
a O
sturdy O
english B-Plant
oak I-Plant
or O
anything O
of O
the O
kind O
, O
but O
a O
tree O
, O
a O
bush O
of O
a O
tree O
, O
of O
sorts O
. O

thick O
tangles O
of O
nothofagus B-Plant
antarctica I-Plant
had O
to O
be O
fought O
through O
, O
but O
on O
crossing O
the O
lapataia O
river O
we O
found O
guanaco O
trails O
, O
speeding O
progress O
through O
the O
forest O
and O
low O
tree O
scrub O
. O

run O
by O
mr O
conrad O
pinches O
, O
this O
school O
occupied O
one O
of O
the O
large O
terraced O
houses O
on O
the O
west O
side O
of O
the O
road O
running O
south O
from O
walnut B-Plant
tree O
walk O
. O

vol O
99 O
of O
the O
, O
4/(1994)contains O
an O
article O
by O
rosemary B-Plant
setting O
out O
the O
relationships O
and O
climbing O
achievements O
of O
her O
convoluted O
quaker O
family O
, O
together O
with O
a O
family O
tree O
. O

there O
was O
a O
small O
pink O
- O
headed O
onion B-Plant
here O
also O
( O
allium B-Plant
carolinianum I-Plant
) O
, O
collected O
by O
the O
kirghiz O
for O
food O
, O
as O
well O
as O
numerous O
aromatic O
herbs O
whose O
fragrance O
drifted O
across O
the O
slopes O
. O

herbs O
such O
as O
the O
beautiful O
george O
forrest O
's O
primrose B-Plant
primula B-Plant
forrestii I-Plant
with O
flowers O
of O
rich O
golden O
- O
yellow O
also O
flourish O
at O
this O
altitude O
, O
as O
does O
the O
rare O
and O
bizarre O
- O
looking O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
margaritaceum I-Plant
. O

the O
list O
of O
herbs O
which O
grow O
within O
this O
rich O
area O
of O
temperate O
forest O
is O
truly O
encyclopaedic O
, O
for O
here O
are O
to O
be O
found O
such O
treasures O
as O
primula B-Plant
bella I-Plant
, O
iris B-Plant
chrysographes I-Plant
, O
arisaema B-Plant
wilsonii I-Plant
and O
the O
yellow O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
flavum I-Plant
. O

until O
further O
work O
is O
done O
with O
the O
existing O
herbarium O
material O
it O
is O
doubtful O
whether O
we O
shall O
hear O
anything O
further O
of O
gentiana B-Plant
tilmanii I-Plant
. O

fruit O
and O
herbs O
that O
grew O
naturally O
in O
borrowdale O
rounded O
off O
an O
austere O
but O
healthy O
diet O
prepared O
over O
an O
open O
fire O
, O
a O
woodbine B-Plant
clasped O
between O
his O
toes B-Plant
to O
prevent O
ash O
falling O
into O
his O
food O
. O

and O
for O
its O
associations O
with O
the O
high O
places O
, O
the O
highland O
heather B-Plant
, O
so O
disagreeable O
to O
captain O
bun O
, O
was O
crowned O
by O
ruskin O
, O
with O
the O
blue O
gentian B-Plant
and O
the O
alpine B-Plant
rose I-Plant
, O
in O
uncontested O
queenliness O
, O
flowers O
wholly O
without O
similitude O
. O

even O
alpine O
flowers O
are O
at O
home O
here O
especially O
the O
' O
k'fcchenschelle O
' O
, O
the O
pasque B-Plant
flower I-Plant
( O
anemone O
pulsatilla O
) O
. O

a O
yellow O
starry O
- O
flowered O
clematis O
( O
c. B-Plant

hilariae I-Plant
) O
formed O
tumbled O
entanglements O
along O
field O
boundaries O
. O

along O
the O
rivers O
and O
streams O
there O
are O
the O
usual O
sedge B-Plant
pastures O
mixed O
with O
a O
few O
grasses O
but O
in O
the O
wet O
places O
, O
large O
drifts O
of O
deep O
blue O
primroses O
( O
primula B-Plant
macrophylla I-Plant
) O
and O
a O
small O
bright O
yellow O
buttercup B-Plant
( O
ranunculus B-Plant
pulchellus I-Plant
) O
were O
almost O
past O
flowering O
. O

most O
memorable O
was O
the O
carpet O
of O
crocus O
sieberi O
that O
grew O
so O
thick O
amidst O
the O
tussock B-Plant
grass I-Plant
of O
the O
upper O
pastures O
that O
it O
was O
impossible O
to O
avoid O
treading O
its O
flowers O
underfoot O
. O

in O
june O
the O
meadows O
at O
this O
altitude O
are O
alight O
with O
the O
colour O
of O
flowers O
- O
rhododendron B-Plant
adenogynutn I-Plant
occurs O
in O
flowing O
masses O
of O
pale O
pink O
, O
the O
yellow B-Plant
bells I-Plant
of O
lilium O
lopophorum O
stud O
the O
slopes O
in O
association O
with O
the O
purple O
lloydia B-Plant
tibetica I-Plant
var. I-Plant
purpurescens I-Plant
( O
an O
asian O
counterpart O
of O
the O
snowdon O
lily B-Plant
) O
and O
the O
golden O
meconopsis B-Plant
integrifolia I-Plant
. O

on O
the O
cliffs O
cling O
cushions O
of O
androsace B-Plant
delavayi I-Plant
and O
the O
almost O
impossibly O
- O
named O
solmslaubachia B-Plant
pulcherrima I-Plant
, O
one O
of O
forrest O
's O
favourite O
alpines O
with O
cress B-Plant
- O
like O
ice O
- O
blue O
flowers O
. O

best O
of O
all O
is O
the O
exquisite O
dwarf O
alpine O
' O
blue B-Plant
poppy I-Plant
' O
meconopsis B-Plant
delavayi I-Plant
which O
kingdon O
- O
ward O
described O
as O
' O
a O
shimmering O
bluish O
- O
violet B-Plant
flower O
with O
the O
texture O
of O
japanese O
silk O
' O
. O

higher O
still O
in O
the O
north O
- O
facing O
base O
- O
rich O
wetter O
flushes O
the O
seemingly O
uncultivatable O
primula B-Plant
dryadifolia I-Plant
shows O
its O
mauve O
- O
pink O
flowers O
against O
broad O
prostrate O
mats O
of O
foliage O
( O
25 O
cm O
across O
) O
, O
accompanied O
by O
three O
' O
sisters O
' O
of O
the O
same O
genus O
, O
primula B-Plant
pinnatifida I-Plant
, O
p O
secundiflora O
and O
p O
pseudo O
- O
sikkimensis O
. O

while O
we O
were O
on O
rajrambha O
the O
tiny O
blades O
of O
iris B-Plant
kumaonensis I-Plant
had O
suddenly O
sprouted O
purple O
flowers O
, O
streaked O
and O
mottled O
like O
the O
skin O
of O
exotic O
reptiles O
. O

) O
, O
towering O
white O
asphodels O
( O
asphodelus B-Plant
albus I-Plant
) O
( O
plate O
63 O
) O
and O
pyrenean B-Plant
lilies I-Plant
( O
lilium B-Plant
pyrenaicum I-Plant
) O
decorate O
these O
meadows O
, O
whilst O
the O
montane O
grasslands O
are O
renowned O
for O
their O
pasque B-Plant
- I-Plant
flowers I-Plant
( O
pulsatilla B-Plant
rubra I-Plant
, O
p. B-Plant
alpina I-Plant
( O
plate O
66 O
) O
and O
p. B-Plant
vernalis I-Plant
) O
, O
anemones B-Plant
( O
anemone B-Plant
pavoniana I-Plant
) O
, O
dog B-Plant
's I-Plant
violets I-Plant
( O
erythronium O
dens O
- O
can O
is O
) O
and O
pyrenean B-Plant
fritillaries I-Plant
( O
fritillaria B-Plant
pyrenaica I-Plant
) O
. O

as O
heroin O
addicts O
sometimes O
faint O
while O
using O
illicit O
drugs O
, O
doctors O
might O
attribute O
too O
many O
episodes O
of O
syncope B-Disease
to O
illicit O
drug O
use O
and O
thereby O
underestimate O
the O
incidence O
of O
tdp B-Disease
in O
this O
special O
population O
, O
and O
the O
high O
mortality O
in O
this O
population O
may O
, O
in O
part O
, O
be O
caused O
by O
the O
proarrhythmic O
effect O
of O
methadone O
. O

all O
participants O
were O
interviewed O
about O
any O
experience O
of O
syncope B-Disease
. O

the O
association O
between O
opioid O
dose O
and O
qt O
, O
and O
methadone O
dose O
and O
reporting O
of O
syncope B-Disease
was O
assessed O
using O
multivariate O
linear O
regression O
and O
logistic O
regression O
, O
respectively O
. O

among O
the O
subjects O
treated O
with O
methadone O
, O
28 O
% O
men O
and O
32 O
% O
women O
had O
prolonged B-Disease
qtc I-Disease
interval I-Disease
. O

a O
50 O
mg O
higher O
methadone O
dose O
was O
associated O
with O
a O
1 O
. O

2 O
( O
95 O
% O
ci O
1 O
. O

1 O
to O
1 O
. O

4 O
) O
times O
higher O
odds O
for O
syncope B-Disease
. O

conclusions O
: O
methadone O
is O
associated O
with O
qt B-Disease
prolongation I-Disease
and O
higher O
reporting O
of O
syncope B-Disease
in O
a O
population O
of O
heroin O
addicts O
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
induced O
by O
ziprasidone O
on O
the O
second O
day O
of O
treatment O
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
( O
nms B-Disease
) O
is O
the O
rarest O
and O
most O
serious O
of O
the O
neuroleptic O
- O
induced O
movement B-Disease
disorders I-Disease
. O

we O
describe O
a O
case O
of O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
( O
nms B-Disease
) O
associated O
with O
the O
use O
of O
ziprasidone O
. O

although O
conventional O
neuroleptics O
are O
more O
frequently O
associated O
with O
nms B-Disease
, O
atypical O
antipsychotic O
drugs O
like O
ziprasidone O
may O
also O
be O
a O
cause O
. O

the O
patient O
is O
a O
24 O
- O
year O
- O
old O
male O
with O
a O
history O
of O
schizophrenia B-Disease
who O
developed O
signs O
and O
symptoms O
of O
nms B-Disease
after O
2 O
days O
of O
treatment O
with O
an O
80 O
- O
mg O
/ O
day O
dose O
of O
orally O
administrated O
ziprasidone O
. O

this O
case O
is O
the O
earliest O
( O
second O
day O
of O
treatment O
) O
nms B-Disease
due O
to O
ziprasidone O
reported O
in O
the O
literature O
. O

peripheral O
iron O
dextran O
induced O
degeneration B-Disease
of I-Disease
dopaminergic I-Disease
neurons I-Disease
in O
rat O
substantia O
nigra O
. O

iron O
accumulation O
is O
considered O
to O
be O
involved O
in O
the O
pathogenesis O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

to O
demonstrate O
the O
relationship O
between O
peripheral O
iron O
overload O
and O
dopaminergic O
neuron O
loss O
in O
rat O
substantia O
nigra O
( O
sn O
) O
, O
in O
the O
present O
study O
we O
used O
fast O
cyclic O
voltammetry O
, O
tyrosine O
hydroxylase O
( O
th O
) O
immunohistochemistry O
, O
perls O
' O
iron O
staining O
, O
and O
high O
performance O
liquid O
chromatography O
- O
electrochemical O
detection O
to O
study O
the O
degeneration B-Disease
of I-Disease
dopaminergic I-Disease
neurons I-Disease
and O
increased O
iron O
content O
in O
the O
sn O
of O
iron O
dextran O
overloaded O
animals O
. O

these O
results O
suggest O
that O
peripheral O
iron O
dextran O
can O
increase O
the O
iron O
level O
in O
the O
sn O
, O
where O
excessive O
iron O
causes O
the O
degeneration B-Disease
of I-Disease
dopaminergic I-Disease
neurons I-Disease
. O

the O
development O
of O
schizophrenia B-Disease
may O
include O
an O
early O
neurodevelopmental O
stress O
component O
which O
increases O
vulnerability O
to O
later O
stressful O
life O
events O
, O
in O
combination O
leading O
to O
overt O
disease O
. O

amphetamine O
- O
induced O
locomotor B-Disease
hyperactivity I-Disease
was O
similar O
in O
all O
groups O
. O

an O
extremely O
rare O
case O
of O
delusional B-Disease
parasitosis I-Disease
in O
a O
chronic B-Disease
hepatitis I-Disease
c I-Disease
patient O
during O
pegylated O
interferon O
alpha O
- O
2b O
and O
ribavirin O
treatment O
. O

during O
treatment O
of O
chronic B-Disease
hepatitis I-Disease
c I-Disease
patients O
with O
interferon O
and O
ribavirin O
, O
a O
lot O
of O
side O
effects O
are O
described O
. O

twenty O
- O
three O
percent O
to O
44 O
% O
of O
patients O
develop O
depression B-Disease
. O

a O
minority O
of O
patients O
evolve O
to O
psychosis B-Disease
. O

to O
the O
best O
of O
our O
knowledge O
, O
no O
cases O
of O
psychogenic B-Disease
parasitosis I-Disease
occurring O
during O
interferon O
therapy O
have O
been O
described O
in O
the O
literature O
. O

we O
present O
a O
49 O
- O
year O
- O
old O
woman O
who O
developed O
a O
delusional B-Disease
parasitosis I-Disease
during O
treatment O
with O
pegylated O
interferon O
alpha O
- O
2b O
weekly O
and O
ribavirin O
. O

hepatonecrosis B-Disease
and O
cholangitis B-Disease
related O
to O
long O
- O
term O
phenobarbital O
therapy O
: O
an O
autopsy O
report O
of O
two O
patients O
. O

phenobarbital O
( O
pb O
) O
has O
a O
reputation O
for O
safety O
, O
and O
it O
is O
commonly O
believed O
that O
pb O
- O
related O
increases O
in O
serum O
aminotransferase O
levels O
do O
not O
indicate O
or O
predict O
the O
development O
of O
significant O
chronic O
liver B-Disease
disease I-Disease
. O

here O
we O
report O
of O
two O
adult O
patients O
with O
a O
long O
history O
of O
epilepsy B-Disease
treated O
with O
pb O
who O
died O
suddenly O
: O
one O
as O
consequence O
of O
cardiac B-Disease
arrest I-Disease
, O
the O
other O
of O
acute O
bronchopneumonia B-Disease
. O

at O
autopsy O
, O
analysis O
of O
liver O
parenchyma O
revealed O
rich O
portal O
inflammatory O
infiltrate O
, O
which O
consisted O
of O
mixed O
eosinophil O
and O
monocyte O
cells O
, O
associated O
with O
several O
foci O
of O
necrosis B-Disease
surrounded O
by O
a O
hard O
ring O
of O
non O
- O
specific O
granulomatous O
tissue O
. O

our O
findings O
illustrate O
that O
pb O
may O
be O
associated O
with O
chronic O
liver B-Disease
damage I-Disease
, O
which O
may O
lead O
to O
more O
serious O
and O
deleterious O
consequences O
. O

for O
this O
reason O
, O
each O
clinician O
should O
recognize O
this O
entity O
in O
the O
differential O
diagnosis O
of O
pb O
- O
related O
asymptomatic O
chronic B-Disease
hepatic I-Disease
enzyme I-Disease
dysfunction I-Disease
. O

delayed O
leukoencephalopathy B-Disease
with O
stroke B-Disease
- O
like O
presentation O
in O
chemotherapy O
recipients O
. O

background O
: O
a O
transient O
leukoencephalopathy B-Disease
mimicking O
cerebrovascular B-Disease
accident I-Disease
has O
been O
described O
as O
a O
complication O
of O
chemotherapy O
, O
most O
commonly O
in O
recipients O
of O
intrathecal O
methotrexate O
for O
childhood O
leukaemia B-Disease
. O

methods O
: O
we O
reviewed O
the O
medical O
literature O
for O
single O
reports O
and O
case O
series O
of O
patients O
presenting O
with O
stroke B-Disease
- O
like O
episodes O
while O
receiving O
systemic O
or O
intrathecal O
chemotherapy O
. O

patients O
with O
cerebrovascular B-Disease
accidents I-Disease
were O
excluded O
. O

results O
: O
we O
identified O
27 O
reports O
of O
toxic O
leukoencephalopathy B-Disease
in O
patients O
treated O
with O
methotrexate O
( O
intrathecal O
, O
systemic O
) O
, O
5 O
- O
fluorouracil O
and O
its O
derivative O
carmofur O
, O
and O
capecitabine O
. O

diffusion O
weighted O
imaging O
( O
dwi O
) O
of O
all O
patients O
revealed O
well O
demarcated O
hyperintense O
lesions B-Disease
within I-Disease
the I-Disease
subcortical I-Disease
white I-Disease
matter I-Disease
of O
the O
cerebral O
hemispheres O
and O
the O
corpus O
callosum O
, O
corresponding O
to O
areas O
of O
decreased O
proton O
diffusion O
on O
apparent O
diffusion O
coefficient O
( O
adc O
) O
maps O
( O
available O
in O
21 O
/ O
27 O
patients O
) O
. O

however O
, O
fluid O
attenuated O
inversion O
recovery O
( O
flair O
) O
sequences O
frequently O
revealed O
persistent O
white B-Disease
matter I-Disease
abnormalities I-Disease
. O

conclusions O
: O
several O
pathophysiological O
models O
of O
delayed O
leukoencephalopathy B-Disease
after O
exposure O
to O
intrathecal O
or O
systemic O
chemotherapy O
have O
been O
proposed O
. O

dwi O
findings O
in O
this O
cohort O
are O
indicative O
of O
cytotoxic B-Disease
oedema I-Disease
within I-Disease
cerebral I-Disease
white I-Disease
matter I-Disease
and O
lend O
support O
to O
an O
at O
least O
partially O
reversible O
metabolic O
derangement O
as O
the O
basis O
for O
this O
syndrome O
. O

prenatal O
exposure O
to O
fluoxetine O
induces O
fetal B-Disease
pulmonary I-Disease
hypertension I-Disease
in O
the O
rat O
. O

epidemiological O
data O
suggest O
that O
fluoxetine O
exposure O
prenatally O
increases O
the O
prevalence O
of O
persistent O
pulmonary B-Disease
hypertension I-Disease
syndrome I-Disease
of O
the O
newborn O
. O

the O
mechanism O
responsible O
for O
this O
effect O
is O
unclear O
and O
paradoxical O
, O
considering O
the O
current O
evidence O
of O
a O
pulmonary B-Disease
hypertension I-Disease
protective O
fluoxetine O
effect O
in O
adult O
rodents O
. O

as O
compared O
with O
controls O
, O
fluoxetine O
exposure O
resulted O
in O
fetal B-Disease
pulmonary I-Disease
hypertension I-Disease
as O
evidenced O
by O
an O
increase O
in O
the O
weight O
ratio O
of O
the O
right O
ventricle O
to O
the O
left O
ventricle O
plus O
septum O
( O
p O
= O
0 O
. O

2 O
) O
and O
by O
an O
increase O
in O
pulmonary O
arterial O
medial O
thickness O
( O
p O
< O
0 O
. O

1 O
) O
. O

conclusions O
: O
in O
contrast O
to O
the O
adult O
, O
fluoxetine O
exposure O
in O
utero O
induces O
pulmonary B-Disease
hypertension I-Disease
in O
the O
fetal O
rat O
as O
a O
result O
of O
a O
developmentally O
regulated O
increase O
in O
pulmonary O
vascular O
smooth O
muscle O
proliferation O
. O

disulfiram O
- O
induced O
transient O
optic B-Disease
and I-Disease
peripheral I-Disease
neuropathy I-Disease
: O
a O
case O
report O
. O

aim O
: O
to O
report O
a O
case O
of O
optic B-Disease
and I-Disease
peripheral I-Disease
neuropathy I-Disease
after O
chronic O
use O
of O
disulfiram O
for O
alcohol B-Disease
dependence I-Disease
management O
. O

results O
: O
a O
57 O
- O
year O
- O
old O
male O
presented O
with O
gradual O
loss B-Disease
of I-Disease
vision I-Disease
in O
both O
eyes O
with O
intermittent O
headaches B-Disease
for O
2 O
months O
. O

he O
also O
complained O
of O
paraesthesia B-Disease
with O
numbness B-Disease
in O
both O
feet O
. O

visual O
field O
testing O
confirmed O
bilateral O
central O
- O
caecal O
scotomata B-Disease
. O

he O
had O
been O
taking O
disulfiram O
for O
alcohol B-Disease
dependence I-Disease
for O
the O
preceding O
3 O
years O
. O

intraocular O
pressure O
in O
patients O
with O
uveitis B-Disease
treated O
with O
fluocinolone O
acetonide O
implants O
. O

objective O
: O
to O
report O
the O
incidence O
and O
management O
of O
elevated B-Disease
intraocular I-Disease
pressure I-Disease
( O
iop O
) O
in O
patients O
with O
uveitis B-Disease
treated O
with O
the O
fluocinolone O
acetonide O
( O
fa O
) O
intravitreal O
implant O
. O

the O
rate O
of O
hypotony B-Disease
( O
iop O
< O
/ O
= O
5 O
mm O
hg O
) O
following O
iop O
- O
lowering O
surgery O
( O
42 O
. O

5 O
% O
) O
was O
not O
different O
from O
that O
of O
implanted O
eyes O
not O
subjected O
to O
surgery O
( O
35 O
. O

4 O
% O
) O
( O
p O
= O
. O

9 O
) O
. O

myocardial O
fas O
ligand O
expression O
increases O
susceptibility O
to O
azt O
- O
induced O
cardiomyopathy B-Disease
. O

background O
: O
dilated B-Disease
cardiomyopathy I-Disease
( O
dcm B-Disease
) O
and O
myocarditis B-Disease
occur O
in O
many O
hiv B-Disease
- I-Disease
infected I-Disease
individuals O
, O
resulting O
in O
symptomatic O
heart B-Disease
failure I-Disease
in O
up O
to O
5 O
% O
of O
patients O
. O

highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
has O
significantly O
reduced O
morbidity O
and O
mortality O
of O
acquired B-Disease
immunodeficiency I-Disease
syndrome I-Disease
( O
aids B-Disease
) O
, O
but O
has O
resulted O
in O
an O
increase O
in O
cardiac B-Disease
and I-Disease
skeletal I-Disease
myopathies I-Disease
. O

methods O
and O
results O
: O
in O
order O
to O
investigate O
whether O
the O
haart O
component O
zidovudine O
( O
3 O
' O
- O
azido O
- O
2 O
' O
, O
3 O
' O
- O
deoxythymidine O
; O
azt O
) O
triggers O
the O
fas O
- O
dependent O
cell O
- O
death O
pathway O
and O
cause O
cytoskeletal O
disruption O
in O
a O
murine O
model O
of O
dcm B-Disease
, O
8 O
- O
week O
- O
old O
transgenic O
( O
expressing O
fas O
ligand O
in O
the O
myocardium O
: O
fasl O
tg O
) O
and O
non O
- O
transgenic O
( O
ntg O
) O
mice O
received O
water O
ad O
libitum O
containing O
different O
concentrations O
of O
azt O
( O
0 O
, O
0 O
. O

7 O
, O
0 O
. O

2 O
, O
and O
0 O
. O

7 O
mg O
/ O
ml O
) O
. O

in O
contrast O
, O
azt O
- O
treated O
fasl O
tg O
mice O
developed O
cardiac B-Disease
dilation I-Disease
and O
depressed O
cardiac O
function O
in O
a O
dose O
- O
dependent O
manner O
, O
with O
concomitant O
inflammatory O
infiltration O
of O
both O
ventricles O
. O

conclusions O
: O
the O
expression O
of O
fas O
ligand O
in O
the O
myocardium O
, O
as O
identified O
in O
hiv O
- O
positive O
patients O
, O
might O
increase O
the O
susceptibility O
to O
haart O
- O
induced O
cardiomyopathy B-Disease
due O
to O
activation O
of O
apoptotic O
pathways O
, O
resulting O
in O
cardiac B-Disease
dilation I-Disease
and I-Disease
dysfunction I-Disease
. O

gastrointestinal O
tolerability O
of O
etoricoxib O
in O
rheumatoid B-Disease
arthritis I-Disease
patients O
: O
results O
of O
the O
etoricoxib O
vs O
diclofenac O
sodium O
gastrointestinal O
tolerability O
and O
effectiveness O
trial O
( O
edge O
- O
ii O
) O
. O

objective O
: O
a O
randomised O
, O
double O
- O
blind O
study O
to O
compare O
the O
gastrointestinal O
( O
gi O
) O
tolerability O
, O
safety O
and O
efficacy O
of O
etoricoxib O
and O
diclofenac O
in O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
( O
ra B-Disease
) O
. O

patients O
and O
methods O
: O
a O
total O
of O
4086 O
patients O
( O
mean O
age O
60 O
. O

8 O
years O
) O
diagnosed O
with O
ra B-Disease
were O
enrolled O
and O
received O
etoricoxib O
90 O
mg O
daily O
( O
n O
= O
2032 O
) O
or O
diclofenac O
75 O
mg O
twice O
daily O
( O
n O
= O
2054 O
) O
. O

general O
safety O
was O
also O
assessed O
, O
including O
adjudicated O
thrombotic B-Disease
cardiovascular I-Disease
event O
data O
. O

the O
cumulative O
discontinuation O
rate O
due O
to O
gi B-Disease
aes I-Disease
was O
significantly O
lower O
with O
etoricoxib O
than O
diclofenac O
( O
5 O
. O

2 O
vs O
8 O
. O

5 O
events O
per O
100 O
patient O
- O
years O
, O
respectively O
; O
hazard O
ratio O
0 O
. O

62 O
( O
95 O
% O
ci O
: O
0 O
. O

47 O
, O
0 O
. O

81 O
; O
p O
< O
or O
= O
0 O
. O

1 O
) O
) O
. O

the O
incidence O
of O
discontinuations O
for O
hypertension B-Disease
- O
related O
and O
oedema B-Disease
- O
related O
aes O
were O
significantly O
higher O
with O
etoricoxib O
( O
2 O
. O

5 O
% O
and O
1 O
. O

1 O
% O
respectively O
) O
compared O
with O
diclofenac O
( O
1 O
. O

5 O
% O
and O
0 O
. O

4 O
% O
respectively O
; O
p O
< O
0 O
. O

1 O
for O
hypertension B-Disease
and O
p O
< O
0 O
. O

1 O
for O
oedema B-Disease
) O
. O

conclusions O
: O
etoricoxib O
90 O
mg O
demonstrated O
a O
significantly O
lower O
risk O
for O
discontinuing O
treatment O
due O
to O
gi B-Disease
aes I-Disease
compared O
with O
diclofenac O
150 O
mg O
. O

discontinuations O
from O
renovascular O
aes O
, O
although O
less O
common O
than O
discontinuations O
from O
gi B-Disease
aes I-Disease
, O
were O
significantly O
higher O
with O
etoricoxib O
. O

results O
: O
the O
results O
indicate O
that O
ciprofloxacin O
- O
and O
norfloxacin O
- O
treated O
rats O
showed O
anxious B-Disease
behaviour I-Disease
in O
comparison O
to O
control O
rats O
in O
all O
the O
parameters O
studied O
. O

reduction O
of O
pain B-Disease
during O
induction O
with O
target O
- O
controlled O
propofol O
and O
remifentanil O
. O

background O
: O
pain B-Disease
on O
injection O
of O
propofol O
is O
unpleasant O
. O

we O
hypothesized O
that O
propofol O
infusion O
pain B-Disease
might O
be O
prevented O
by O
infusing O
remifentanil O
before O
starting O
the O
propofol O
infusion O
in O
a O
clinical O
setting O
where O
target O
- O
controlled O
infusions O
( O
tci O
) O
of O
both O
drugs O
were O
used O
. O

a O
prospective O
, O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
was O
performed O
to O
determine O
the O
effect O
- O
site O
concentration O
( O
ce O
) O
of O
remifentanil O
to O
prevent O
the O
pain B-Disease
without O
producing O
complications O
. O

remifentanil O
- O
related O
complications O
were O
assessed O
during O
the O
remifentanil O
infusion O
, O
and O
pain B-Disease
caused O
by O
propofol O
was O
evaluated O
using O
a O
four O
- O
point O
scale O
during O
the O
propofol O
infusion O
. O

results O
: O
the O
incidence O
of O
pain B-Disease
was O
significantly O
lower O
in O
groups O
r4 O
and O
r6 O
than O
in O
the O
control O
and O
r2 O
groups O
( O
12 O
/ O
32 O
and O
6 O
/ O
31 O
vs O
26 O
/ O
31 O
and O
25 O
/ O
32 O
, O
respectively O
, O
p O
< O
0 O
. O

1 O
) O
. O

pain B-Disease
was O
less O
severe O
in O
groups O
r4 O
and O
r6 O
than O
in O
the O
control O
and O
r2 O
groups O
( O
p O
< O
0 O
. O

1 O
) O
. O

however O
, O
both O
incidence O
and O
severity O
of O
pain B-Disease
were O
not O
different O
between O
groups O
r4 O
and O
r6 O
. O

conclusions O
: O
during O
induction O
of O
anaesthesia O
with O
tci O
of O
propofol O
and O
remifentanil O
, O
a O
significant O
reduction O
in O
propofol O
infusion O
pain B-Disease
was O
achieved O
without O
significant O
complications O
by O
prior O
administration O
of O
remifentanil O
at O
a O
target O
ce O
of O
4 O
ng O
ml O
( O
- O
1 O
) O
. O

dexmedetomidine O
was O
associated O
with O
a O
trend O
towards O
improved O
cardiac O
outcomes O
; O
all O
- O
cause O
mortality O
( O
or O
0 O
. O

27 O
, O
95 O
% O
ci O
0 O
. O

1 O
- O
7 O
. O

13 O
, O
p O
= O
0 O
. O

44 O
) O
, O
non O
- O
fatal O
myocardial B-Disease
infarction I-Disease
( O
or O
0 O
. O

26 O
, O
95 O
% O
ci O
0 O
. O

4 O
- O
1 O
. O

60 O
, O
p O
= O
0 O
. O

14 O
) O
, O
and O
myocardial B-Disease
ischaemia I-Disease
( O
or O
0 O
. O

65 O
, O
95 O
% O
ci O
0 O
. O

26 O
- O
1 O
. O

63 O
, O
p O
= O
0 O
. O

36 O
) O
. O

peri O
- O
operative O
hypotension B-Disease
( O
26 O
% O
, O
or O
3 O
. O

80 O
, O
95 O
% O
ci O
1 O
. O

91 O
- O
7 O
. O

54 O
, O
p O
= O
0 O
. O

1 O
) O
and O
bradycardia B-Disease
( O
17 O
% O
, O
or O
5 O
. O

45 O
, O
95 O
% O
ci O
2 O
. O

98 O
- O
9 O
. O

95 O
, O
p O
< O
0 O
. O

1 O
) O
were O
significantly O
increased O
. O

an O
anticholinergic O
did O
not O
reduce O
the O
incidence O
of O
bradycardia B-Disease
( O
p O
= O
0 O
. O

43 O
) O
. O

myocardial B-Disease
infarction I-Disease
in O
pregnancy O
associated O
with O
clomiphene O
citrate O
for O
ovulation O
induction O
: O
a O
case O
report O
. O

thromboembolism B-Disease
is O
a O
rare O
but O
life O
- O
threatening O
complication O
that O
has O
been O
reported O
after O
ovulation O
induction O
with O
cc O
. O

spontaneous O
coronary B-Disease
thrombosis I-Disease
or O
thromboembolism B-Disease
with O
subsequent O
clot O
lysis O
has O
been O
suggested O
as O
one O
of O
the O
most O
common O
causes O
of O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
during O
pregnancy O
, O
with O
a O
subsequently O
normal O
coronary O
angiogram O
. O

case O
: O
a O
33 O
- O
year O
- O
old O
woman O
with O
a O
5 O
- O
week O
gestation O
had O
recently O
received O
cc O
for O
ovulation O
induction O
and O
presented O
with O
chest B-Disease
pain I-Disease
. O

an O
electrocardiogram O
showed O
a O
lateral O
and O
anterior O
wall O
myocardial B-Disease
infarction I-Disease
. O

at O
the O
time O
of O
admission O
, O
the O
patient O
was O
at O
high O
risk O
of O
radiation B-Disease
injury I-Disease
to O
the O
fetus O
, O
so O
a O
coronary O
angiogram O
was O
postponed O
until O
the O
second O
trimester O
. O

conclusion O
: O
this O
appears O
to O
be O
the O
first O
reported O
case O
documenting O
a O
possible O
association O
between O
cc O
and O
myocardial B-Disease
infarction I-Disease
. O

thrombosis B-Disease
might O
be O
a O
rare O
but O
hazardous O
complication O
of O
cc O
. O

reverse O
or O
inverted O
left B-Disease
ventricular I-Disease
apical I-Disease
ballooning I-Disease
syndrome I-Disease
( O
reverse O
takotsubo B-Disease
cardiomyopathy I-Disease
) O
in O
a O
young O
woman O
in O
the O
setting O
of O
amphetamine O
use O
. O

transient O
left B-Disease
ventricular I-Disease
apical I-Disease
ballooning I-Disease
syndrome I-Disease
was O
first O
described O
in O
japan O
as O
nan O
takotsubo B-Disease
cardiomyopathy I-Disease
. O

nan O
this O
syndrome O
has O
been O
identified O
in O
many O
other O
countries O
. O

one O
of O
the O
rarest O
is O
the O
reverse O
type O
of O
this O
syndrome O
, O
with O
hyperdynamic O
apex O
and O
complete O
akinesia B-Disease
of O
the O
base O
( O
as O
opposed O
to O
the O
classic O
apical B-Disease
ballooning I-Disease
) O
. O

in O
this O
article O
, O
we O
report O
an O
interesting O
case O
of O
a O
young O
woman O
who O
presented O
with O
this O
rare O
type O
of O
reverse O
apical B-Disease
ballooning I-Disease
syndrome I-Disease
occurring O
after O
amphetamine O
use O
. O

results O
of O
a O
comparative O
, O
phase O
iii O
, O
12 O
- O
week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double O
- O
blind O
assessment O
of O
the O
efficacy O
and O
tolerability O
of O
a O
fixed O
- O
dose O
combination O
of O
telmisartan O
and O
amlodipine O
versus O
amlodipine O
monotherapy O
in O
indian O
adults O
with O
stage O
ii O
hypertension B-Disease
. O

objective O
: O
the O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
and O
tolerability O
of O
a O
new O
fixed O
- O
dose O
combination O
( O
fdc O
) O
of O
telmisartan O
40 O
mg O
+ O
amlodipine O
5 O
mg O
( O
t O
+ O
a O
) O
compared O
with O
amlodipine O
5 O
- O
mg O
monotherapy O
( O
a O
) O
in O
adult O
indian O
patients O
with O
stage O
ii O
hypertension B-Disease
. O

methods O
: O
this O
comparative O
, O
phase O
iii O
, O
12 O
- O
week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double O
- O
blind O
study O
was O
conducted O
in O
indian O
patients O
aged O
18 O
to O
65 O
years O
with O
established O
stage O
ii O
hypertension B-Disease
. O

peripheral O
edema B-Disease
was O
reported O
in O
8 O
. O

5 O
% O
patients O
( O
9 O
/ O
106 O
) O
in O
the O
t O
+ O
a O
group O
compared O
with O
13 O
. O

5 O
% O
( O
14 O
/ O
104 O
) O
in O
the O
a O
group O
, O
and O
cough B-Disease
was O
reported O
in O
3 O
. O

8 O
% O
patients O
( O
4 O
/ O
106 O
) O
in O
the O
t O
+ O
a O
group O
and O
1 O
. O

0 O
% O
( O
1 O
/ O
104 O
) O
patients O
in O
the O
a O
group O
; O
these O
differences O
did O
not O
reach O
statistical O
significance O
. O

the O
incidences O
of O
headache B-Disease
, O
dizziness B-Disease
, O
and O
diarrhea B-Disease
were O
similar O
between O
the O
2 O
groups O
. O

conclusions O
: O
among O
these O
indian O
patients O
with O
stage O
ii O
hypertension B-Disease
, O
the O
fdc O
of O
t O
+ O
a O
was O
found O
to O
be O
significantly O
more O
effective O
, O
with O
regard O
to O
bp O
reductions O
, O
than O
a O
, O
and O
both O
treatments O
were O
well O
tolerated O
. O

increased O
mental B-Disease
slowing I-Disease
associated O
with O
the O
apoe O
epsilon4 O
allele O
after O
trihexyphenidyl O
oral O
anticholinergic O
challenge O
in O
healthy O
elderly O
. O

objectives O
: O
the O
objectives O
of O
this O
study O
were O
to O
examine O
the O
relationship O
between O
apoe O
epsilon4 O
and O
subjective O
effects O
of O
trihexyphenidyl O
on O
measures O
reflecting O
sedation O
and O
confusion B-Disease
and O
to O
investigate O
the O
relationship O
between O
trihexyphenidyl O
- O
induced O
subjective O
effects O
and O
objective O
memory O
performance O
. O

results O
: O
a O
2 O
. O

0 O
- O
mg O
oral O
dose O
of O
trihexyphenidyl O
resulted O
in O
increased O
subjective O
ratings O
of O
mental B-Disease
slowness I-Disease
in O
carriers O
of O
the O
apoe O
epsilon4 O
allele O
only O
. O

drug O
effects O
as O
determined O
by O
difference O
scores O
between O
2 O
. O

0 O
mg O
trihexyphenidyl O
and O
placebo O
on O
ratings O
of O
mental B-Disease
slowness I-Disease
significantly O
correlated O
with O
total O
and O
delayed O
recall O
on O
the O
buschke O
selective O
reminding O
test O
in O
carriers O
of O
the O
apoe O
epsilon4 O
allele O
only O
. O

conclusion O
: O
the O
epsilon4 O
allele O
in O
healthy O
elderly O
was O
associated O
with O
increased O
subjective O
mental B-Disease
slowing I-Disease
after O
trihexyphenidyl O
anticholinergic O
challenge O
. O

an O
evaluation O
of O
amikacin O
nephrotoxicity B-Disease
in O
the O
hematology O
/ O
oncology O
population O
. O

amikacin O
is O
an O
aminoglycoside O
commonly O
used O
to O
provide O
empirical O
double O
gram O
- O
negative O
treatment O
for O
febrile B-Disease
neutropenia I-Disease
and O
other O
suspected O
infections B-Disease
. O

to O
evaluate O
amikacin O
- O
associated O
nephrotoxicity B-Disease
in O
an O
adult O
hematology O
/ O
oncology O
population O
, O
a O
prospective O
, O
randomized O
, O
open O
- O
label O
trial O
was O
conducted O
at O
a O
university O
- O
affiliated O
medical O
center O
. O

forty O
patients O
with O
a O
diagnosis O
consistent O
with O
a O
hematologic B-Disease
/ I-Disease
oncologic I-Disease
disorder I-Disease
that O
required O
treatment O
with O
an O
aminoglycoside O
were O
randomized O
to O
either O
conventional O
or O
extended O
- O
interval O
amikacin O
. O

the O
occurrence O
of O
nephrotoxicity B-Disease
by O
means O
of O
an O
increase O
in O
serum O
creatinine O
and O
evaluation O
of O
efficacy O
via O
amikacin O
serum O
concentrations O
with O
respective O
pathogens O
were O
assessed O
. O

the O
occurrence O
of O
nephrotoxicity B-Disease
was O
similar O
between O
the O
conventional O
and O
extended O
- O
interval O
groups O
, O
at O
10 O
% O
and O
5 O
% O
, O
respectively O
( O
p O
= O
1 O
. O

0 O
) O
. O

the O
occurrence O
of O
nephrotoxicity B-Disease
was O
similar O
between O
the O
two O
dosing O
regimens O
, O
but O
the O
distribution O
of O
risk O
factors O
was O
variable O
between O
the O
two O
groups O
. O

although O
dexmedetomidine O
sedation O
was O
associated O
with O
a O
16 O
% O
incidence O
of O
bradycardia B-Disease
, O
all O
concomitant O
mean O
arterial O
blood O
pressures O
were O
within O
20 O
% O
of O
age O
- O
adjusted O
normal O
range O
and O
oxygen O
saturations O
were O
95 O
% O
or O
higher O
. O

hepatotoxicity B-Disease
associated O
with O
sulfasalazine O
in O
inflammatory O
arthritis B-Disease
: O
a O
case O
series O
from O
a O
local O
surveillance O
of O
serious O
adverse O
events O
. O

we O
report O
an O
investigation O
from O
a O
local O
surveillance O
for O
serious O
adverse O
drug O
reactions O
associated O
with O
disease O
modifying O
anti O
- O
rheumatic O
drugs O
that O
was O
triggered O
by O
the O
occurrence O
of O
liver B-Disease
failure I-Disease
in O
two O
of O
our O
patients O
. O

patients O
' O
, O
who O
had O
hepatotoxicity B-Disease
on O
sulfasalazine O
and O
met O
a O
definition O
of O
a O
serious O
adr O
, O
were O
identified O
. O

the O
likely O
frequency O
of O
hepatotoxicity B-Disease
with O
sulfasalazine O
was O
estimated O
by O
making O
a O
series O
of O
conservative O
assumptions O
. O

eight O
patients O
were O
hospitalised O
, O
two O
in O
hepatic B-Disease
failure I-Disease
- O
one O
died O
after O
a O
liver O
transplant O
. O

seven O
patients O
had O
a O
skin B-Disease
rash I-Disease
, O
three O
eosinophilia B-Disease
and O
one O
interstitial B-Disease
nephritis I-Disease
. O

drug O
- O
related O
hepatotoxicity B-Disease
was O
judged O
probable O
or O
highly O
probable O
in O
8 O
patients O
. O

the O
likely O
frequency O
of O
serious O
hepatotoxicity B-Disease
with O
sulfasalazine O
was O
estimated O
at O
0 O
. O

4 O
% O
of O
treated O
patients O
. O

conclusion O
: O
serious O
hepatotoxicity B-Disease
associated O
with O
sulfasalazine O
appears O
to O
be O
under O
- O
appreciated O
and O
intensive O
monitoring O
and O
vigilance O
in O
the O
first O
6 O
weeks O
of O
treatment O
is O
especially O
important O
. O

complete O
atrioventricular B-Disease
block I-Disease
secondary O
to O
lithium O
therapy O
. O

sinus B-Disease
node I-Disease
dysfunction I-Disease
has O
been O
reported O
most O
frequently O
among O
the O
adverse O
cardiovascular O
effects O
of O
lithium O
. O

in O
the O
present O
case O
, O
complete O
atrioventricular B-Disease
( I-Disease
av I-Disease
) I-Disease
block I-Disease
with O
syncopal B-Disease
attacks I-Disease
developed O
secondary O
to O
lithium O
therapy O
, O
necessitating O
permanent O
pacemaker O
implantation O
. O

serum O
lithium O
levels O
remained O
under O
or O
within O
the O
therapeutic O
range O
during O
the O
syncopal B-Disease
attacks I-Disease
. O

exaggerated O
expression O
of O
inflammatory O
mediators O
in O
vasoactive O
intestinal O
polypeptide O
knockout O
( O
vip O
- O
/ O
- O
) O
mice O
with O
cyclophosphamide O
( O
cyp O
) O
- O
induced O
cystitis B-Disease
. O

vip O
( O
- O
/ O
- O
) O
mice O
exhibit O
altered O
bladder O
function O
and O
neurochemical O
properties O
in O
micturition O
pathways O
after O
cyclophosphamide O
( O
cyp O
) O
- O
induced O
cystitis B-Disease
. O

given O
vip O
' O
s O
role O
as O
an O
anti O
- O
inflammatory O
mediator O
, O
we O
hypothesized O
that O
vip O
( O
- O
/ O
- O
) O
mice O
would O
exhibit O
enhanced O
inflammatory O
mediator O
expression O
after O
cystitis B-Disease
. O

a O
mouse O
inflammatory O
cytokine O
and O
receptor O
rt2 O
profiler O
array O
was O
used O
to O
determine O
regulated O
transcripts O
in O
the O
urinary O
bladder O
of O
wild O
type O
( O
wt O
) O
and O
vip O
( O
- O
/ O
- O
) O
mice O
with O
or O
without O
cyp O
- O
induced O
cystitis B-Disease
( O
150 O
mg O
/ O
kg O
; O
i O
. O

p O
. O

; O
48 O
h O
) O
. O

the O
data O
suggest O
that O
in O
vip O
( O
- O
/ O
- O
) O
mice O
with O
bladder B-Disease
inflammation I-Disease
, O
inflammatory O
mediators O
are O
increased O
above O
that O
observed O
in O
wt O
with O
cyp O
. O

this O
shift O
in O
balance O
may O
contribute O
to O
increased O
bladder B-Disease
dysfunction I-Disease
in O
vip O
( O
- O
/ O
- O
) O
mice O
with O
bladder B-Disease
inflammation I-Disease
and O
altered O
neurochemical O
expression O
in O
micturition O
pathways O
. O

the O
drug O
effect O
studied O
was O
the O
antagonism O
by O
metoprolol O
of O
terbutaline O
- O
induced O
hypokalemia B-Disease
. O

oxytocin O
is O
a O
commonly O
used O
uterotonic O
that O
can O
cause O
significant O
and O
even O
fatal O
hypotension B-Disease
, O
particularly O
when O
given O
as O
a O
bolus O
. O

the O
resulting O
hypotension B-Disease
can O
be O
produced O
by O
a O
decrease O
in O
systemic O
vascular O
resistance O
or O
cardiac O
output O
through O
a O
decrease O
in O
venous O
return O
. O

parturients O
with O
normal O
volume O
status O
, O
heart O
valves O
and O
pulmonary O
vasculature O
most O
often O
respond O
to O
this O
hypotension B-Disease
with O
a O
compensatory O
increase O
in O
heart O
rate O
and O
stroke B-Disease
volume O
. O

oxytocin O
- O
induced O
hypotension B-Disease
at O
cesarean O
delivery O
may O
be O
incorrectly O
attributed O
to O
blood B-Disease
loss I-Disease
. O

hypotension B-Disease
in O
response O
to O
oxytocin O
was O
associated O
with O
a O
decrease O
in O
systemic O
vascular O
resistance O
and O
a O
compensatory O
increase O
in O
stroke B-Disease
volume O
, O
heart O
rate O
and O
cardiac O
output O
. O

pulse O
power O
analysis O
may O
be O
helpful O
in O
determining O
the O
etiology O
of O
and O
treating O
hypotension B-Disease
during O
cesarean O
delivery O
under O
neuraxial O
anesthesia O
. O

protective O
effects O
of O
antithrombin O
on O
puromycin O
aminonucleoside O
nephrosis B-Disease
in O
rats O
. O

we O
investigated O
the O
effects O
of O
antithrombin O
, O
a O
plasma O
inhibitor O
of O
coagulation O
factors O
, O
in O
rats O
with O
puromycin O
aminonucleoside O
- O
induced O
nephrosis B-Disease
, O
which O
is O
an O
experimental O
model O
of O
human O
nephrotic B-Disease
syndrome I-Disease
. O

treatment O
with O
antithrombin O
attenuated O
the O
puromycin O
aminonucleoside O
- O
induced O
hematological B-Disease
abnormalities I-Disease
. O

puromycin O
aminonucleoside O
- O
induced O
renal B-Disease
dysfunction I-Disease
and O
hyperlipidemia B-Disease
were O
also O
suppressed O
. O

histopathological O
examination O
revealed O
severe O
renal B-Disease
damage I-Disease
such O
as O
proteinaceous O
casts O
in O
tubuli O
and O
tubular O
expansion O
in O
the O
kidney O
of O
control O
rats O
, O
while O
an O
improvement O
of O
the O
damage O
was O
seen O
in O
antithrombin O
- O
treated O
rats O
. O

these O
findings O
suggest O
that O
thrombin O
plays O
an O
important O
role O
in O
the O
pathogenesis O
of O
puromycin O
aminonucleoside O
- O
induced O
nephrotic B-Disease
syndrome I-Disease
. O

treatment O
with O
antithrombin O
may O
be O
clinically O
effective O
in O
patients O
with O
nephrotic B-Disease
syndrome I-Disease
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
after O
liver O
transplantation O
. O

background O
: O
unfractionated O
heparin O
sodium O
( O
ufh O
) O
or O
low O
- O
molecular O
weight O
heparin O
( O
lmwh O
) O
is O
used O
in O
anticoagulant O
protocols O
at O
several O
institutions O
to O
prevent O
thrombosis B-Disease
after O
liver O
transplantation O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
( O
hit B-Disease
) O
is O
an O
adverse O
immune O
- O
mediated O
reaction O
to O
heparin O
, O
resulting O
in O
platelet O
count O
decreases O
of O
more O
than O
50 O
% O
. O

the O
frequencies O
of O
hit B-Disease
after O
liver O
transplantation O
and O
platelet O
factor O
4 O
/ O
heparin O
- O
reactive O
antibody O
( O
hit B-Disease
antibody O
) O
positivity O
in O
liver O
transplantation O
patients O
, O
however O
, O
are O
unknown O
. O

hit B-Disease
antibody O
levels O
were O
measured O
the O
day O
before O
surgery O
and O
on O
pod O
7 O
and O
14 O
. O

two O
patients O
developed O
hepatic O
artery O
thrombosis B-Disease
on O
pod O
11 O
and O
19 O
, O
respectively O
, O
although O
they O
were O
hit B-Disease
antibody O
- O
negative O
and O
their O
platelet O
counts O
were O
stable O
. O

the O
heparin O
- O
induced O
platelet B-Disease
aggregation I-Disease
test O
was O
negative O
in O
these O
patients O
. O

the O
percentage O
of O
hit B-Disease
antibody O
- O
positive O
patients O
was O
0 O
. O

5 O
% O
preoperatively O
, O
5 O
. O

6 O
% O
on O
pod O
7 O
, O
and O
5 O
. O

6 O
% O
on O
pod O
14 O
. O

none O
of O
the O
subjects O
/ O
patients O
developed O
ufh O
- O
related O
hit B-Disease
. O

conclusions O
: O
in O
our O
series O
, O
the O
occurrence O
of O
hit B-Disease
after O
liver O
transplantation O
was O
uncommon O
. O

doxorubicin O
cardiomyopathy B-Disease
- O
induced O
inflammation B-Disease
and O
apoptosis O
are O
attenuated O
by O
gene O
deletion O
of O
the O
kinin O
b1 O
receptor O
. O

clinical O
use O
of O
the O
anthracycline O
doxorubicin O
( O
dox O
) O
is O
limited O
by O
its O
cardiotoxic B-Disease
effects O
, O
which O
are O
attributed O
to O
the O
induction O
of O
apoptosis O
. O

to O
elucidate O
the O
possible O
role O
of O
the O
kinin O
b1 O
receptor O
( O
b1r O
) O
during O
the O
development O
of O
dox O
cardiomyopathy B-Disease
, O
we O
studied O
b1r O
knockout O
mice O
( O
b1r O
( O
- O
/ O
- O
) O
) O
by O
investigating O
cardiac O
inflammation B-Disease
and O
apoptosis O
after O
induction O
of O
dox O
- O
induced O
cardiomyopathy B-Disease
. O

dox O
control O
mice O
showed O
cardiac B-Disease
dysfunction I-Disease
measured O
by O
pressure O
- O
volume O
loops O
in O
vivo O
. O

this O
was O
associated O
with O
a O
reduced O
activation O
state O
of O
akt O
, O
as O
well O
as O
an O
increased O
bax O
/ O
bcl2 O
ratio O
in O
western O
blots O
, O
indicating O
cardiac B-Disease
apoptosis I-Disease
. O

in O
dox O
b1r O
( O
- O
/ O
- O
) O
mice O
, O
cardiac B-Disease
dysfunction I-Disease
was O
improved O
compared O
to O
dox O
control O
mice O
, O
which O
was O
associated O
with O
normalization O
of O
the O
bax O
/ O
bcl O
- O
2 O
ratio O
and O
interleukin O
6 O
, O
as O
well O
as O
akt O
activation O
state O
. O

these O
findings O
suggest O
that O
b1r O
is O
detrimental O
in O
dox O
cardiomyopathy B-Disease
in O
that O
it O
mediates O
the O
inflammatory O
response O
and O
apoptosis O
. O

these O
insights O
might O
have O
useful O
implications O
for O
future O
studies O
utilizing O
b1r O
antagonists O
for O
treatment O
of O
human O
dox O
cardiomyopathy B-Disease
. O

detailed O
spectral O
profile O
analysis O
of O
penicillin O
- O
induced O
epileptiform B-Disease
activity I-Disease
in O
anesthetized O
rats O
. O

penicillin O
model O
is O
a O
widely O
used O
experimental O
model O
for O
epilepsy B-Disease
research O
. O

in O
the O
present O
study O
we O
aimed O
to O
portray O
a O
detailed O
spectral O
analysis O
of O
penicillin O
- O
induced O
epileptiform B-Disease
activity I-Disease
in O
comparison O
with O
basal O
brain O
activity O
in O
anesthetized O
wistar O
rats O
. O

after O
a O
short O
period O
of O
basal O
activity O
recording O
, O
epileptic B-Disease
focus O
was O
induced O
by O
injecting O
400iu O
/ O
2 O
microl O
penicillin O
- O
g O
potassium O
into O
the O
left O
lateral O
ventricle O
while O
the O
cortical O
activity O
was O
continuously O
recorded O
. O

basal O
activity O
, O
latent O
period O
and O
the O
penicillin O
- O
induced O
epileptiform B-Disease
activity I-Disease
periods O
were O
then O
analyzed O
using O
both O
conventional O
methods O
and O
spectral O
analysis O
. O

our O
results O
show O
that O
the O
most O
affected O
frequency O
bands O
were O
delta O
, O
theta O
, O
beta O
- O
2 O
and O
gamma O
- O
2 O
bands O
during O
the O
epileptiform B-Disease
activity I-Disease
and O
there O
were O
marked O
differences O
in O
terms O
of O
spectral O
densities O
between O
three O
investigated O
episodes O
( O
basal O
activity O
, O
latent O
period O
and O
epileptiform B-Disease
activity I-Disease
) O
. O

our O
results O
may O
help O
to O
analyze O
novel O
data O
obtained O
using O
similar O
experimental O
models O
and O
the O
simple O
analysis O
method O
described O
here O
can O
be O
used O
in O
similar O
studies O
to O
investigate O
the O
basic O
neuronal O
mechanism O
of O
this O
or O
other O
types O
of O
experimental O
epilepsies B-Disease
. O

high O
fat O
diet O
- O
fed O
obese B-Disease
rats O
are O
highly O
sensitive O
to O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

often O
, O
chemotherapy O
by O
doxorubicin O
( O
adriamycin O
) O
is O
limited O
due O
to O
life O
threatening O
cardiotoxicity B-Disease
in O
patients O
during O
and O
posttherapy O
. O

recently O
, O
we O
have O
shown O
that O
moderate O
diet O
restriction O
remarkably O
protects O
against O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

in O
the O
current O
study O
, O
we O
investigated O
whether O
a O
physiological O
intervention O
by O
feeding O
40 O
% O
high O
fat O
diet O
( O
hfd O
) O
, O
which O
induces O
obesity B-Disease
in O
male O
sprague O
- O
dawley O
rats O
( O
250 O
- O
275 O
g O
) O
, O
sensitizes O
to O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

a O
ld O
( O
10 O
) O
dose O
( O
8 O
mg O
doxorubicin O
/ O
kg O
, O
ip O
) O
administered O
on O
day O
43 O
of O
the O
hfd O
feeding O
regimen O
led O
to O
higher O
cardiotoxicity B-Disease
, O
cardiac B-Disease
dysfunction I-Disease
, O
lipid O
peroxidation O
, O
and O
80 O
% O
mortality O
in O
the O
obese B-Disease
( O
ob B-Disease
) O
rats O
in O
the O
absence O
of O
any O
significant O
renal B-Disease
or I-Disease
hepatic I-Disease
toxicity I-Disease
. O

doxorubicin O
toxicokinetics O
studies O
revealed O
no O
change O
in O
accumulation O
of O
doxorubicin O
and O
doxorubicinol O
( O
toxic O
metabolite O
) O
in O
the O
normal O
diet O
- O
fed O
( O
nd O
) O
and O
ob B-Disease
hearts O
. O

mechanistic O
studies O
revealed O
that O
ob B-Disease
rats O
are O
sensitized O
due O
to O
: O
( O
1 O
) O
higher O
oxyradical O
stress O
leading O
to O
upregulation O
of O
uncoupling O
proteins O
2 O
and O
3 O
, O
( O
2 O
) O
downregulation O
of O
cardiac O
peroxisome O
proliferators O
activated O
receptor O
- O
alpha O
, O
( O
3 O
) O
decreased O
plasma O
adiponectin O
levels O
, O
( O
4 O
) O
decreased O
cardiac O
fatty O
- O
acid O
oxidation O
( O
666 O
. O

9 O
+ O
/ O
- O
14 O
. O

0 O
nmol O
/ O
min O
/ O
g O
heart O
in O
nd O
versus O
400 O
. O

2 O
+ O
/ O
- O
11 O
. O

8 O
nmol O
/ O
min O
/ O
g O
heart O
in O
ob B-Disease
) O
, O
( O
5 O
) O
decreased O
mitochondrial O
amp O
- O
alpha2 O
protein O
kinase O
, O
and O
( O
6 O
) O
86 O
% O
drop O
in O
cardiac O
atp O
levels O
accompanied O
by O
decreased O
atp O
/ O
adp O
ratio O
after O
doxorubicin O
administration O
. O

in O
conclusion O
, O
hfd O
- O
induced O
obese B-Disease
rats O
are O
highly O
sensitized O
to O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
by O
substantially O
downregulating O
cardiac O
mitochondrial O
atp O
generation O
, O
increasing O
oxidative O
stress O
and O
downregulating O
the O
jak O
/ O
stat3 O
pathway O
. O

isoproterenol O
induces O
primary O
loss O
of O
dystrophin O
in O
rat O
hearts O
: O
correlation O
with O
myocardial B-Disease
injury I-Disease
. O

the O
mechanism O
of O
isoproterenol O
- O
induced O
myocardial B-Disease
damage I-Disease
is O
unknown O
, O
but O
a O
mismatch O
of O
oxygen O
supply O
vs O
. O

demand O
following O
coronary O
hypotension B-Disease
and O
myocardial B-Disease
hyperactivity I-Disease
is O
the O
best O
explanation O
for O
the O
complex O
morphological O
alterations O
observed O
. O

these O
changes O
, O
related O
to O
ischaemic B-Disease
injury I-Disease
, O
explain O
the O
severe O
alterations O
in O
the O
structural O
integrity O
of O
the O
sarcolemma O
of O
cardiomyocytes O
and O
hence O
severe O
and O
irreversible O
injury O
induced O
by O
isoproterenol O
. O

etiologic O
factors O
in O
the O
pathogenesis O
of O
liver B-Disease
tumors I-Disease
associated O
with O
oral O
contraceptives O
. O

within O
the O
last O
several O
years O
, O
previously O
rare O
liver B-Disease
tumors I-Disease
have O
been O
seen O
in O
young O
women O
using O
oral O
contraceptive O
steroids O
. O

the O
registry O
for O
liver B-Disease
tumors I-Disease
associated O
with O
oral O
contraceptives O
at O
the O
university O
of O
california O
, O
irvine O
, O
has O
clearly O
identified O
27 O
cases O
. O

common O
to O
these O
71 O
cases O
has O
been O
a O
histopathologic O
diagnosis O
of O
focal B-Disease
nodular I-Disease
hyperplasia I-Disease
, O
adenoma B-Disease
, O
hamartoma B-Disease
, O
and O
hepatoma B-Disease
. O

eight O
deaths O
and O
liver O
rupture B-Disease
in O
18 O
patients O
attest O
to O
the O
seriousness O
of O
this O
new O
potentially O
lethal O
adverse O
phenomenon O
. O

four O
patients O
developed O
transient O
microscopic O
hematuria B-Disease
at O
400 O
, O
450 O
, O
and O
500 O
mg O
/ O
m2 O
/ O
d O
. O

there O
were O
no O
instances O
of O
macroscopic O
hematuria B-Disease
. O

at O
550 O
mg O
/ O
m2 O
/ O
d O
, O
three O
patients O
experienced O
nonurologic O
toxicity B-Disease
; O
confusion B-Disease
( O
1 O
) O
, O
nausea B-Disease
( O
1 O
) O
, O
and O
grade O
2 O
leukopenia B-Disease
( O
1 O
) O
. O

the O
frequency O
and O
predictability O
of O
hematuria B-Disease
are O
not O
precise O
, O
and O
at O
least O
daily O
monitoring O
by O
urine O
hematest O
is O
essential O
, O
adding O
mesna O
to O
the O
infusate O
in O
patients O
with O
persistent O
hematuria B-Disease
. O

a O
case O
of O
ventricular B-Disease
tachycardia I-Disease
related O
to O
caffeine O
pretreatment O
. O

suboptimal O
seizure B-Disease
duration O
is O
commonly O
encountered O
in O
electroconvulsive O
therapy O
practice O
, O
especially O
in O
older O
patients O
with O
higher O
seizure B-Disease
thresholds O
. O

intravenous O
caffeine O
is O
commonly O
used O
to O
improve O
seizure B-Disease
duration O
and O
quality O
in O
such O
patients O
and O
is O
generally O
well O
tolerated O
aside O
from O
occasional O
reports O
of O
relatively O
benign O
ventricular B-Disease
ectopy I-Disease
. O

we O
describe O
a O
patient O
with O
no O
previous O
history O
of O
cardiac B-Disease
disease I-Disease
or O
arrhythmia B-Disease
who O
developed O
sustained O
bigeminy O
and O
2 O
brief O
runs O
of O
ventricular B-Disease
tachycardia I-Disease
after O
caffeine O
administration O
. O

although O
intravenous O
caffeine O
is O
generally O
well O
tolerated O
, O
the O
clinician O
should O
be O
aware O
of O
the O
potential O
for O
unpredictable O
and O
serious O
ventricular B-Disease
arrhythmias I-Disease
. O

fatal O
haemopericardium B-Disease
and O
gastrointestinal B-Disease
haemorrhage I-Disease
due O
to O
possible O
interaction O
of O
cranberry O
juice O
with O
warfarin O
. O

we O
report O
a O
case O
of O
fatal O
internal O
haemorrhage B-Disease
in O
an O
elderly O
man O
who O
consumed O
only O
cranberry O
juice O
for O
two O
weeks O
while O
maintaining O
his O
usual O
dosage O
of O
warfarin O
. O

effect O
of O
increasing O
intraperitoneal O
infusion O
rates O
on O
bupropion O
hydrochloride O
- O
induced O
seizures B-Disease
in O
mice O
. O

background O
: O
it O
is O
not O
known O
if O
there O
is O
a O
relationship O
between O
input O
rate O
and O
incidence O
of O
bupropion O
- O
induced O
seizures B-Disease
. O

methods O
: O
we O
investigated O
the O
effect O
of O
varying O
the O
intraperitoneal O
infusion O
rates O
of O
bupropion O
hcl O
120 O
mg O
/ O
kg O
, O
a O
known O
convulsive B-Disease
dose O
50 O
( O
cd50 O
) O
, O
on O
the O
incidence O
and O
severity O
of O
bupropion O
- O
induced O
convulsions B-Disease
in O
the O
swiss O
albino O
mice O
. O

the O
number O
, O
time O
of O
onset O
, O
duration O
and O
the O
intensity O
of O
the O
convulsions B-Disease
or O
absence O
of O
convulsions B-Disease
were O
recorded O
. O

results O
: O
the O
results O
showed O
that O
ip O
administration O
of O
bupropion O
hcl O
120 O
mg O
/ O
kg O
by O
bolus O
injection O
induced O
convulsions B-Disease
in O
6 O
out O
of O
10 O
mice O
( O
60 O
% O
of O
convulsing O
mice O
) O
in O
group O
1 O
. O

logistic O
regression O
analysis O
revealed O
that O
infusion O
time O
was O
significant O
( O
p O
= O
0 O
. O

4 O
; O
odds O
ratio O
= O
0 O
. O

974 O
) O
and O
increasing O
the O
ip O
infusion O
time O
of O
bupropion O
hcl O
120 O
mg O
/ O
kg O
was O
associated O
with O
a O
91 O
% O
reduced O
odds O
of O
convulsions B-Disease
at O
infusion O
times O
of O
15 O
to O
90 O
min O
compared O
to O
bolus O
injection O
. O

further O
increase O
in O
infusion O
time O
resulted O
in O
further O
reduction O
in O
the O
odds O
of O
convulsions B-Disease
to O
99 O
. O

8 O
% O
reduction O
at O
240 O
min O
. O

conclusion O
: O
in O
conclusion O
, O
the O
demonstration O
of O
an O
inverse O
relationship O
between O
infusion O
time O
of O
a O
fixed O
and O
convulsive B-Disease
dose O
of O
bupropion O
and O
the O
risk O
of O
convulsions B-Disease
in O
a O
prospective O
study O
is O
novel O
. O

graft B-Disease
- I-Disease
versus I-Disease
- I-Disease
host I-Disease
disease I-Disease
prophylaxis O
with O
everolimus O
and O
tacrolimus O
is O
associated O
with O
a O
high O
incidence O
of O
sinusoidal B-Disease
obstruction I-Disease
syndrome I-Disease
and O
microangiopathy B-Disease
: O
results O
of O
the O
evtac O
trial O
. O

a O
calcineurin O
inhibitor O
combined O
with O
methotrexate O
is O
the O
standard O
prophylaxis O
for O
graft B-Disease
- I-Disease
versus I-Disease
- I-Disease
host I-Disease
disease I-Disease
( O
gvhd B-Disease
) O
after O
allogeneic O
hematopoietic O
stem O
cell O
transplantation O
( O
hsct O
) O
. O

we O
report O
on O
a O
combination O
of O
everolimus O
and O
tacrolimus O
in O
24 O
patients O
( O
median O
age O
, O
62 O
years O
) O
with O
either O
myelodysplastic B-Disease
syndrome I-Disease
( O
mds B-Disease
; O
n O
= O
17 O
) O
or O
acute B-Disease
myeloid I-Disease
leukemia I-Disease
( O
aml B-Disease
; O
n O
= O
7 O
) O
undergoing O
intensive O
conditioning O
followed O
by O
hsct O
from O
related O
( O
n O
= O
4 O
) O
or O
unrelated O
( O
n O
= O
20 O
) O
donors O
. O

all O
patients O
engrafted O
, O
and O
only O
1 O
patient O
experienced O
grade O
iv O
mucositis B-Disease
. O

nine O
patients O
( O
37 O
% O
) O
developed O
acute O
grade O
ii O
- O
iv O
gvhd B-Disease
, O
and O
11 O
of O
17 O
evaluable O
patients O
( O
64 O
% O
) O
developed O
chronic O
extensive O
gvhd B-Disease
. O

transplantation B-Disease
- I-Disease
associated I-Disease
microangiopathy I-Disease
( O
tma B-Disease
) O
occurred O
in O
7 O
patients O
( O
29 O
% O
) O
, O
with O
2 O
cases O
of O
acute B-Disease
renal I-Disease
failure I-Disease
. O

the O
study O
was O
terminated O
prematurely O
because O
an O
additional O
6 O
patients O
( O
25 O
% O
) O
developed O
sinusoidal B-Disease
obstruction I-Disease
syndrome I-Disease
( O
sos B-Disease
) O
, O
which O
was O
fatal O
in O
2 O
cases O
. O

although O
this O
new O
combination O
appears O
to O
be O
effective O
as O
a O
prophylactic O
regimen O
for O
acute O
gvhd B-Disease
, O
the O
incidence O
of O
tma B-Disease
and O
sos B-Disease
is O
considerably O
higher O
than O
seen O
with O
other O
regimens O
. O

longitudinal O
assessment O
of O
air O
conduction O
audiograms O
in O
a O
phase O
iii O
clinical O
trial O
of O
difluoromethylornithine O
and O
sulindac O
for O
prevention O
of O
sporadic O
colorectal B-Disease
adenomas I-Disease
. O

a O
phase O
iii O
clinical O
trial O
assessed O
the O
recurrence O
of O
adenomatous B-Disease
polyps I-Disease
after O
treatment O
for O
36 O
months O
with O
difluoromethylornithine O
( O
dfmo O
) O
plus O
sulindac O
or O
matched O
placebos O
. O

temporary O
hearing B-Disease
loss I-Disease
is O
a O
known O
toxicity B-Disease
of O
treatment O
with O
dfmo O
, O
thus O
a O
comprehensive O
approach O
was O
developed O
to O
analyze O
serial O
air O
conduction O
audiograms O
. O

there O
was O
no O
significant O
difference O
in O
the O
proportion O
of O
subjects O
in O
the O
dfmo O
plus O
sulindac O
group O
who O
experienced O
clinically O
significant O
hearing B-Disease
loss I-Disease
compared O
with O
the O
placebo O
group O
. O

the O
estimated O
attributable O
risk O
of O
ototoxicity B-Disease
from O
exposure O
to O
the O
drug O
is O
8 O
. O

4 O
% O
( O
95 O
% O
confidence O
interval O
, O
- O
2 O
. O

0 O
% O
to O
18 O
. O

8 O
% O
; O
p O
= O
0 O
. O

12 O
) O
. O

proteinase O
3 O
- O
antineutrophil O
cytoplasmic O
antibody O
- O
( O
pr3 O
- O
anca O
) O
positive O
necrotizing O
glomerulonephritis B-Disease
after O
restarting O
sulphasalazine O
treatment O
. O

a O
59 O
- O
year O
- O
old O
woman O
with O
ulcerative B-Disease
colitis I-Disease
developed O
red B-Disease
eyes I-Disease
, O
pleural B-Disease
effusion I-Disease
, O
eosinophilia B-Disease
and O
urinary B-Disease
abnormalities I-Disease
after O
restarting O
of O
sulphasalazine O
treatment O
. O

light O
microscopy O
of O
a O
kidney O
biopsy O
revealed O
segmental B-Disease
necrotizing I-Disease
glomerulonephritis I-Disease
without O
deposition O
of O
immunoglobulin O
or O
complement O
. O

pr3 O
- O
anca O
titer O
was O
250 O
and O
1 O
, O
70 O
eu O
in O
pleural B-Disease
effusions I-Disease
on O
right O
and O
left O
side O
, O
respectively O
. O

although O
cessation O
of O
sulphasalazine O
treatment O
resulted O
in O
improvements O
in O
fever B-Disease
, O
red B-Disease
eyes I-Disease
, O
chest B-Disease
pain I-Disease
, O
titer O
of O
c O
- O
reactive O
protein O
and O
volume O
of O
the O
pleural B-Disease
effusions I-Disease
, O
we O
initiated O
steroid O
therapy O
, O
because O
pr3 O
- O
anca O
titer O
rose O
to O
320 O
eu O
, O
eosinophil O
count O
increased O
to O
1 O
, O
100 O
cells O
/ O
microl O
, O
and O
the O
pleural B-Disease
effusion I-Disease
remained O
. O

one O
month O
after O
steroid O
therapy O
, O
the O
pleural B-Disease
effusion I-Disease
disappeared O
, O
and O
pr3 O
- O
anca O
titer O
normalized O
3 O
months O
later O
. O

this O
case O
suggests O
that O
sulphasalazine O
can O
induce O
pr3 O
- O
anca O
- O
positive O
necrotizing O
glomerulonephritis B-Disease
. O

comparison O
of O
unilateral O
pallidotomy O
and O
subthalamotomy O
findings O
in O
advanced O
idiopathic B-Disease
parkinson I-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

a O
prospective O
, O
randomized O
, O
double O
- O
blind O
pilot O
study O
to O
compare O
the O
results O
of O
stereotactic O
unilateral O
pallidotomy O
and O
subthalamotomy O
in O
advanced O
idiopathic B-Disease
parkinson I-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
refractory O
to O
medical O
treatment O
was O
designed O
. O

ten O
consecutive O
patients O
( O
mean O
age O
, O
58 O
. O

4 O
+ O
/ O
- O
6 O
. O

8 O
years O
; O
7 O
men O
, O
3 O
women O
) O
with O
similar O
characteristics O
at O
the O
duration O
of O
disease O
( O
mean O
disease O
time O
, O
8 O
. O

4 O
+ O
/ O
- O
3 O
. O

5 O
years O
) O
, O
disabling O
motor O
fluctuations O
( O
hoehn O
_ O
yahr O
stage O
3 O
- O
5 O
in O
off O
- O
drug O
phases O
) O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
were O
selected O
. O

clinical O
evaluation O
included O
the O
use O
of O
the O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
( O
updrs O
) O
, O
hoehn O
_ O
yahr O
score O
and O
schwab O
england O
activities O
of O
daily O
living O
( O
adl O
) O
score O
in O
' O
on O
' O
- O
and O
' O
off O
' O
- O
drug O
conditions O
before O
surgery O
and O
6 O
months O
after O
surgery O
. O

there O
was O
statistically O
significant O
improvement O
in O
all O
contralateral O
major O
parkinsonian B-Disease
motor O
signs O
in O
all O
patients O
followed O
for O
6 O
months O
. O

complications O
were O
observed O
in O
two O
patients O
: O
one O
had O
a O
left O
homonymous B-Disease
hemianopsia I-Disease
after O
pallidotomy O
and O
another O
one O
developed O
left O
hemiballistic O
movements O
3 O
days O
after O
subthalamotomy O
which O
partly O
improved O
within O
1 O
month O
with O
valproate O
1000 O
mg O
/ O
day O
. O

the O
findings O
of O
this O
study O
suggest O
that O
lesions O
of O
the O
unilateral O
stn O
and O
gpi O
are O
equally O
effective O
treatment O
for O
patients O
with O
advanced O
pd B-Disease
refractory O
to O
medical O
treatment O
. O

dsmm O
xi O
study O
: O
dose O
definition O
for O
intravenous O
cyclophosphamide O
in O
combination O
with O
bortezomib O
/ O
dexamethasone O
for O
remission O
induction O
in O
patients O
with O
newly O
diagnosed O
myeloma B-Disease
. O

a O
clinical O
trial O
was O
initiated O
to O
evaluate O
the O
recommended O
dose O
of O
cyclophosphamide O
in O
combination O
with O
bortezomib O
and O
dexamethasone O
as O
induction O
treatment O
before O
stem O
cell O
transplantation O
for O
younger O
patients O
with O
newly O
diagnosed O
multiple B-Disease
myeloma I-Disease
( O
mm B-Disease
) O
. O

the O
most O
frequent O
adverse O
events O
were O
hematological B-Disease
and I-Disease
gastrointestinal I-Disease
toxicities I-Disease
as O
well O
as O
neuropathy B-Disease
. O

the O
results O
suggest O
that O
bortezomib O
in O
combination O
with O
cyclophosphamide O
at O
900 O
mg O
/ O
m O
( O
2 O
) O
and O
dexamethasone O
is O
an O
effective O
induction O
treatment O
for O
patients O
with O
newly O
diagnosed O
mm B-Disease
that O
warrants O
further O
investigation O
. O

naloxone O
reversal O
of O
hypotension B-Disease
due O
to O
captopril O
overdose B-Disease
. O

the O
opioid O
antagonist O
naloxone O
has O
been O
shown O
to O
block O
or O
reverse O
the O
hypotensive B-Disease
actions O
of O
captopril O
. O

we O
report O
a O
case O
of O
an O
intentional O
captopril O
overdose B-Disease
, O
manifested O
by O
marked O
hypotension B-Disease
, O
that O
resolved O
promptly O
with O
the O
administration O
of O
naloxone O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
captopril O
- O
induced O
hypotension B-Disease
treated O
with O
naloxone O
. O

our O
experience O
demonstrates O
a O
possible O
role O
of O
naloxone O
in O
the O
reversal O
of O
hypotension B-Disease
resulting O
from O
captopril O
. O

recently O
, O
a O
number O
of O
commercial O
lots O
of O
heparin O
products O
were O
found O
to O
be O
contaminated O
with O
an O
oversulfated O
chondroitin O
sulfate O
( O
oscs O
) O
derivative O
that O
could O
elicit O
a O
hypotensive B-Disease
response O
in O
pigs O
following O
a O
single O
high O
- O
dose O
infusion O
. O

using O
both O
contaminated O
heparin O
products O
and O
the O
synthetically O
produced O
derivative O
, O
we O
showed O
that O
the O
oscs O
produces O
dose O
- O
dependent O
hypotension B-Disease
in O
pigs O
. O

5 O
flourouracil O
- O
induced O
apical B-Disease
ballooning I-Disease
syndrome I-Disease
: O
a O
case O
report O
. O

the O
apical B-Disease
ballooning I-Disease
syndrome I-Disease
( O
abs B-Disease
) O
is O
a O
recently O
described O
stress O
- O
mediated O
acute B-Disease
cardiac I-Disease
syndrome I-Disease
characterized O
by O
transient O
wall O
- O
motion O
abnormalities O
involving O
the O
apex O
and O
midventricle O
with O
hyperkinesis B-Disease
of O
the O
basal O
left O
ventricular O
( O
lv O
) O
segments O
without O
obstructive O
epicardial B-Disease
coronary I-Disease
disease I-Disease
. O

cardiotoxicity B-Disease
is O
not O
an O
uncommon O
adverse O
effect O
of O
chemotherapeutic O
agents O
. O

however O
, O
there O
are O
no O
reports O
of O
abs B-Disease
secondary O
to O
chemotherapeutic O
agents O
. O

we O
describe O
the O
case O
of O
a O
woman O
who O
developed O
the O
syndrome O
after O
chemotherapy O
for O
metastatic O
cancer B-Disease
. O

a O
79 O
- O
year O
- O
old O
woman O
presented O
with O
typical O
ischemic B-Disease
chest B-Disease
pain I-Disease
, O
elevated O
cardiac O
enzymes O
with O
significant O
st O
- O
segment O
abnormalities O
on O
her O
electrocardiogram O
. O

she O
underwent O
recent O
chemotherapy O
with O
fluorouracil O
for O
metastatic O
colorectal B-Disease
cancer I-Disease
. O

echocardiography O
revealed O
a O
wall O
- O
motion O
abnormality O
involving O
the O
apical O
and O
periapical O
segments O
which O
appeared O
akinetic B-Disease
. O

echocardiogram O
revealed O
a O
normal O
ejection O
fraction O
and O
a O
resolution O
of O
the O
apical O
akinesis B-Disease
. O

pathogenetic O
mechanisms O
of O
cardiac B-Disease
complications I-Disease
in O
cancer B-Disease
patients O
undergoing O
chemotherapy O
include O
coronary B-Disease
vasospasm I-Disease
, O
endothelial O
damage O
and O
consequent O
thrombus B-Disease
formation O
. O

in O
our O
patient O
, O
both O
supraphysiologic O
levels O
of O
plasma O
catecholamines O
and O
stress O
related O
neuropeptides O
caused O
by O
cancer B-Disease
diagnosis O
as O
well O
as O
chemotherapy O
may O
have O
contributed O
the O
development O
of O
abs B-Disease
. O

rapid O
reversal O
of O
anticoagulation O
reduces O
hemorrhage B-Disease
volume O
in O
a O
mouse O
model O
of O
warfarin O
- O
associated O
intracerebral B-Disease
hemorrhage I-Disease
. O

warfarin O
- O
associated O
intracerebral B-Disease
hemorrhage I-Disease
( O
w O
- O
ich B-Disease
) O
is O
a O
severe O
type O
of O
stroke B-Disease
. O

there O
is O
no O
consensus O
on O
the O
optimal O
treatment O
for O
w O
- O
ich B-Disease
. O

second O
, O
a O
stereotactic O
injection O
of O
collagenase O
was O
administered O
to O
induce O
hemorrhage B-Disease
in O
the O
right O
striatum O
. O

twenty O
- O
four O
hours O
after O
hemorrhage B-Disease
induction O
, O
hemorrhagic O
blood O
volume O
was O
quantified O
using O
a O
photometric O
hemoglobin O
assay O
. O

in O
the O
saline O
group O
, O
45 O
% O
of O
the O
mice O
developed O
large O
hematomas B-Disease
( O
i O
. O

e O
. O

, O
> O
15 O
microl O
) O
. O

we O
provide O
experimental O
data O
suggesting O
pcc O
to O
be O
an O
effective O
acute O
treatment O
for O
w O
- O
ich B-Disease
in O
terms O
of O
reducing O
hemorrhagic O
blood O
volume O
. O

future O
studies O
are O
needed O
to O
assess O
the O
therapeutic O
potential O
emerging O
from O
our O
finding O
for O
human O
w O
- O
ich B-Disease
. O

background O
: O
hormone O
therapy O
( O
ht O
) O
is O
widely O
used O
for O
controlling O
menopausal O
symptoms O
and O
has O
also O
been O
used O
for O
the O
management O
and O
prevention O
of O
cardiovascular B-Disease
disease I-Disease
, O
osteoporosis B-Disease
and O
dementia B-Disease
in O
older O
women O
. O

objectives O
: O
to O
assess O
the O
effect O
of O
long O
- O
term O
ht O
on O
mortality O
, O
cardiovascular O
outcomes O
, O
cancer B-Disease
, O
gallbladder B-Disease
disease I-Disease
, O
cognition O
, O
fractures B-Disease
and O
quality O
of O
life O
. O

search O
strategy O
: O
we O
searched O
the O
following O
databases O
to O
november O
2007 O
: O
trials O
register O
of O
the O
cochrane O
menstrual B-Disease
disorders I-Disease
and O
subfertility O
group O
, O
cochrane O
central O
register O
of O
controlled O
trials O
, O
medline O
, O
embase O
, O
biological O
abstracts O
. O

in O
relatively O
healthy O
women O
, O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thrombo I-Disease
- I-Disease
embolism I-Disease
or O
coronary O
event O
( O
after O
one O
year O
' O
s O
use O
) O
, O
stroke B-Disease
( O
after O
three O
years O
) O
, O
breast B-Disease
cancer I-Disease
and O
gallbladder B-Disease
disease I-Disease
. O

long O
- O
term O
oestrogen O
- O
only O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thrombo I-Disease
- I-Disease
embolism I-Disease
, O
stroke B-Disease
and O
gallbladder B-Disease
disease I-Disease
( O
after O
one O
to O
two O
years O
, O
three O
years O
and O
seven O
years O
' O
use O
respectively O
) O
, O
but O
did O
not O
significantly O
increase O
the O
risk O
of O
breast B-Disease
cancer I-Disease
. O

the O
only O
statistically O
significant O
benefits O
of O
ht O
were O
a O
decreased O
incidence O
of O
fractures B-Disease
and O
( O
for O
combined O
ht O
) O
colon B-Disease
cancer I-Disease
, O
with O
long O
- O
term O
use O
. O

among O
women O
aged O
over O
65 O
who O
were O
relatively O
healthy O
( O
i O
. O

e O
. O

generally O
fit O
, O
without O
overt O
disease O
) O
and O
taking O
continuous O
combined O
ht O
, O
there O
was O
a O
statistically O
significant O
increase O
in O
the O
incidence O
of O
dementia B-Disease
. O

among O
women O
with O
cardiovascular B-Disease
disease I-Disease
, O
long O
- O
term O
use O
of O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thrombo I-Disease
- I-Disease
embolism I-Disease
. O

one O
trial O
analysed O
subgroups O
of O
2839 O
relatively O
healthy O
50 O
to O
59 O
year O
old O
women O
taking O
combined O
continuous O
ht O
and O
1637 O
taking O
oestrogen O
- O
only O
ht O
, O
versus O
similar O
- O
sized O
placebo O
groups O
. O

the O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B-Disease
thrombo I-Disease
- I-Disease
embolism I-Disease
in O
women O
taking O
combined O
continuous O
ht O
: O
their O
absolute O
risk O
remained O
low O
, O
at O
less O
than O
1 O
/ O
500 O
. O

acute B-Disease
renal I-Disease
failure I-Disease
in O
patients O
with O
aids B-Disease
on O
tenofovir O
while O
receiving O
prolonged O
vancomycin O
course O
for O
osteomyelitis B-Disease
. O

renal B-Disease
failure I-Disease
developed O
after O
a O
prolonged O
course O
of O
vancomycin O
therapy O
in O
2 O
patients O
who O
were O
receiving O
tenofovir O
disoproxil O
fumarate O
as O
part O
of O
an O
antiretroviral O
regimen O
. O

tenofovir O
has O
been O
implicated O
in O
the O
development O
of O
fanconi B-Disease
syndrome I-Disease
and O
renal B-Disease
insufficiency I-Disease
because O
of O
its O
effects O
on O
the O
proximal O
renal O
tubule O
. O

vancomycin O
nephrotoxicity B-Disease
is O
infrequent O
but O
may O
result O
from O
coadministration O
with O
a O
nephrotoxic B-Disease
agent O
. O

clinicians O
should O
be O
aware O
that O
tenofovir O
may O
raise O
the O
risk O
of O
renal B-Disease
failure I-Disease
during O
prolonged O
administration O
of O
vancomycin O
. O

recurrent O
dysosmia B-Disease
induced O
by O
pyrazinamide O
. O

pyrazinamide O
can O
have O
adverse O
effects O
such O
as O
hepatic B-Disease
toxicity I-Disease
, O
hyperuricemia B-Disease
or O
digestive O
disorders O
. O

we O
report O
a O
case O
of O
reversible O
olfactory B-Disease
disorder I-Disease
related O
to O
pyrazinamide O
in O
a O
woman O
, O
with O
a O
positive O
rechallenge O
. O

dysosmia B-Disease
disappeared O
completely O
after O
pyrazinamide O
withdrawal O
and O
recurred O
after O
its O
rechallenge O
. O

mice O
lacking O
mpges O
- O
1 O
are O
resistant O
to O
lithium O
- O
induced O
polyuria B-Disease
. O

cyclooxygenase O
- O
2 O
activity O
is O
required O
for O
the O
development O
of O
lithium O
- O
induced O
polyuria B-Disease
. O

the O
present O
study O
was O
undertaken O
to O
assess O
lithium O
- O
induced O
polyuria B-Disease
in O
mice O
deficient O
in O
microsomal O
prostaglandin O
e O
synthase O
- O
1 O
( O
mpges O
- O
1 O
) O
. O

a O
2 O
- O
wk O
administration O
of O
licl O
( O
4 O
mmol O
. O

kg O
( O
- O
1 O
) O
. O

day O
( O
- O
1 O
) O
ip O
) O
in O
mpges O
- O
1 O
+ O
/ O
+ O
mice O
led O
to O
a O
marked O
polyuria B-Disease
with O
hyposmotic O
urine O
. O

in O
contrast O
, O
mpges O
- O
1 O
- O
/ O
- O
mice O
were O
largely O
resistant O
to O
lithium O
- O
induced O
polyuria B-Disease
and O
a O
urine O
concentrating O
defect O
, O
accompanied O
by O
nearly O
complete O
blockade O
of O
high O
urine O
pge O
( O
2 O
) O
and O
camp O
output O
. O

we O
conclude O
that O
mpges O
- O
1 O
- O
derived O
pge O
( O
2 O
) O
mediates O
lithium O
- O
induced O
polyuria B-Disease
likely O
via O
inhibition O
of O
aqp2 O
and O
nkcc2 O
expression O
. O

preservation O
of O
renal O
blood O
flow O
during O
hypotension B-Disease
induced O
with O
fenoldopam O
in O
dogs O
. O

the O
introduction O
of O
drugs O
that O
could O
induce O
hypotension B-Disease
with O
different O
pharmacological O
actions O
would O
be O
advantageous O
because O
side O
effects O
unique O
to O
a O
specific O
drug O
could O
be O
minimized O
by O
selecting O
appropriate O
therapy O
. O

the O
hypothesis O
that O
fenoldopam O
could O
be O
used O
to O
induce O
hypotension B-Disease
and O
preserve O
blood O
flow O
to O
the O
kidney O
was O
tested O
. O

renal O
blood O
flow O
( O
rbf O
) O
increased O
during O
fenoldopam O
- O
induced O
hypotension B-Disease
11 O
+ O
/ O
- O
7 O
per O
cent O
and O
decreased O
21 O
+ O
/ O
- O
8 O
per O
cent O
during O
sodium O
nitroprusside O
- O
induced O
hypotension B-Disease
( O
p O
less O
than O
0 O
. O

1 O
) O
. O

sodium O
nitroprusside O
is O
a O
non O
- O
selective O
arteriolar O
and O
venous O
vasodilator O
that O
can O
produce O
redistribution O
of O
blood O
flow O
away O
from O
the O
kidney O
during O
induced O
hypotension B-Disease
. O

fenoldopam O
is O
a O
selective O
dopamine O
- O
1 O
( O
da1 O
) O
receptor O
agonist O
that O
causes O
vasodilatation O
to O
the O
kidney O
and O
other O
organs O
with O
da1 O
receptors O
and O
preserves O
blood O
flow O
to O
the O
kidney O
during O
induced O
hypotension B-Disease
. O

seizures B-Disease
associated O
with O
levofloxacin O
: O
case O
presentation O
and O
literature O
review O
. O

purpose O
: O
we O
present O
a O
case O
of O
a O
patient O
who O
developed O
seizures B-Disease
shortly O
after O
initiating O
treatment O
with O
levofloxacin O
and O
to O
discuss O
the O
potential O
drug O
- O
drug O
interactions O
related O
to O
the O
inhibition O
of O
cytochrome O
p450 O
( O
cyp O
) O
1a2 O
in O
this O
case O
, O
as O
well O
as O
in O
other O
cases O
, O
of O
levofloxacin O
- O
induced O
seizures B-Disease
. O

results O
: O
six O
cases O
of O
levofloxacin O
- O
induced O
seizures B-Disease
have O
been O
reported O
in O
the O
literature O
. O

acute O
analgesic O
and O
antiinflammatory O
activities O
were O
ascertained O
using O
acetic O
acid O
induced O
writhing B-Disease
model O
( O
mice O
) O
and O
carrageenan O
- O
induced O
rat O
paw O
edema B-Disease
model O
, O
respectively O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
pilocarpine O
and O
explore O
the O
underlying O
ionic O
mechanism O
, O
using O
both O
aconitine O
- O
induced O
rat O
and O
ouabain O
- O
induced O
guinea O
pig O
arrhythmia B-Disease
models O
. O

the O
current O
data O
showed O
that O
pilocarpine O
significantly O
delayed O
onset O
of O
arrhythmias B-Disease
, O
decreased O
the O
time O
course O
of O
ventricular B-Disease
tachycardia I-Disease
and I-Disease
fibrillation I-Disease
, O
reduced O
arrhythmia B-Disease
score O
, O
and O
increased O
the O
survival O
time O
of O
arrhythmic B-Disease
rats O
and O
guinea O
pigs O
. O

these O
data O
suggest O
that O
pilocarpine O
produced O
antiarrhythmic O
actions O
on O
arrhythmic B-Disease
rat O
and O
guinea O
pig O
models O
induced O
by O
aconitine O
or O
ouabain O
via O
stimulating O
the O
cardiac O
m O
( O
3 O
) O
- O
machr O
. O

effect O
of O
methanolic O
extract O
of O
hibiscus O
rosa O
sinensis O
( O
100 O
- O
300 O
mg O
/ O
kg O
) O
was O
studied O
on O
reserpine O
- O
induced O
orofacial O
dyskinesia B-Disease
and O
neurochemical O
alterations O
. O

the O
results O
of O
the O
present O
study O
suggested O
that O
hibiscus O
rosa O
sinensis O
had O
a O
protective O
role O
against O
reserpine O
- O
induced O
orofacial O
dyskinesia B-Disease
and O
oxidative O
stress O
. O

dynamic O
response O
of O
blood O
vessel O
in O
acute B-Disease
renal I-Disease
failure I-Disease
. O

in O
this O
study O
we O
postulated O
that O
during O
acute B-Disease
renal I-Disease
failure I-Disease
induced O
by O
gentamicin O
the O
transient O
or O
dynamic O
response O
of O
blood O
vessels O
could O
be O
affected O
, O
and O
that O
antioxidants O
can O
prevent O
the O
changes O
in O
dynamic O
responses O
of O
blood O
vessels O
. O

reversible O
myocardial B-Disease
hypertrophy I-Disease
induced O
by O
tacrolimus O
in O
a O
pediatric O
heart O
transplant O
recipient O
: O
case O
report O
. O

however O
, O
adverse O
effects O
include O
cardiac B-Disease
toxicity I-Disease
. O

herein O
we O
describe O
transient O
myocardial B-Disease
hypertrophy I-Disease
induced O
by O
tacrolimus O
after O
heart O
transplantation O
. O

the O
hypertrophy B-Disease
caused O
no O
clinical O
symptoms O
but O
was O
noted O
because O
of O
elevation O
of O
plasma O
brain O
natriuretic O
peptide O
concentration O
and O
confirmed O
at O
echocardiography O
. O

initially O
, O
allograft O
rejection O
was O
feared O
; O
however O
, O
myocardial O
biopsy O
samples O
revealed O
only O
interstitial O
edema B-Disease
and O
mild O
myocardial B-Disease
hypertrophy I-Disease
; O
neither O
cellular O
nor O
humoral O
rejection O
was O
detected O
. O

myocardial B-Disease
hypertrophy I-Disease
completely O
resolved O
upon O
reducing O
the O
target O
concentration O
of O
tacrolimus O
and O
did O
not O
recur O
, O
as O
confirmed O
at O
echocardiography O
and O
myocardial O
biopsy O
. O

thus O
, O
we O
conclude O
that O
tacrolimus O
induces O
reversible O
myocardial B-Disease
hypertrophy I-Disease
. O

nimodipine O
prevents O
memory B-Disease
impairment I-Disease
caused O
by O
nitroglycerin O
- O
induced O
hypotension B-Disease
in O
adult O
mice O
. O

background O
: O
hypotension B-Disease
and O
a O
resultant O
decrease O
in O
cerebral O
blood O
flow O
have O
been O
implicated O
in O
the O
development O
of O
cognitive B-Disease
dysfunction I-Disease
. O

we O
tested O
the O
hypothesis O
that O
nimodipine O
( O
nimo O
) O
administered O
at O
the O
onset O
of O
nitroglycerin O
( O
ntg O
) O
- O
induced O
hypotension B-Disease
would O
preserve O
long O
- O
term O
associative O
memory O
. O

the O
extent O
of O
hypotension B-Disease
and O
changes O
in O
brain O
tissue O
oxygenation O
( O
pbto O
( O
2 O
) O
) O
and O
in O
cerebral O
blood O
flow O
were O
studied O
in O
a O
separate O
group O
of O
animals O
. O

mice O
subjected O
to O
hypotensive B-Disease
episodes O
showed O
a O
significant O
decrease O
in O
latency O
time O
( O
178 O
+ O
/ O
- O
156 O
s O
) O
compared O
with O
those O
injected O
with O
saline O
, O
ntg O
+ O
nimo O
, O
or O
delayed O
ntg O
( O
580 O
+ O
/ O
- O
81 O
s O
, O
557 O
+ O
/ O
- O
67 O
s O
, O
and O
493 O
+ O
/ O
- O
146 O
s O
, O
respectively O
) O
. O

conclusion O
: O
in O
a O
pa O
retention O
paradigm O
, O
the O
injection O
of O
ntg O
immediately O
after O
learning O
produced O
a O
significant O
impairment O
of O
long O
- O
term O
associative O
memory O
in O
mice O
, O
whereas O
delayed O
induced O
hypotension B-Disease
had O
no O
effect O
. O

nimo O
attenuated O
the O
disruption O
in O
consolidation O
of O
long O
- O
term O
memory O
caused O
by O
ntg O
but O
did O
not O
improve O
latency O
in O
the O
absence O
of O
hypotension B-Disease
. O

the O
observed O
effect O
of O
nimo O
may O
have O
been O
attributable O
to O
the O
preservation O
of O
calcium O
homeostasis O
during O
hypotension B-Disease
, O
because O
there O
were O
no O
differences O
in O
the O
pbto O
( O
2 O
) O
indices O
among O
groups O
. O

metabotropic O
glutamate O
7 O
receptor O
subtype O
modulates O
motor O
symptoms O
in O
rodent O
models O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

metabotropic O
glutamate O
( O
mglu O
) O
receptors O
modulate O
synaptic O
transmission O
in O
the O
central O
nervous O
system O
and O
represent O
promising O
therapeutic O
targets O
for O
symptomatic O
treatment O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
. O

among O
the O
eight O
mglu O
receptor O
subtypes O
, O
mglu7 O
receptor O
is O
prominently O
expressed O
in O
the O
basal O
ganglia O
, O
but O
its O
role O
in O
restoring O
motor O
function O
in O
animal O
models O
of O
pd B-Disease
is O
not O
known O
. O

the O
effects O
of O
n O
, O
n O
' O
- O
dibenzhydrylethane O
- O
1 O
, O
2 O
- O
diamine O
dihydrochloride O
( O
amn082 O
) O
, O
the O
first O
selective O
allosteric O
activator O
of O
mglu7 O
receptors O
, O
were O
thus O
tested O
in O
different O
rodent O
models O
of O
pd B-Disease
. O

here O
, O
we O
show O
that O
oral O
( O
5 O
mg O
/ O
kg O
) O
or O
intrastriatal O
administration O
( O
0 O
. O

1 O
and O
0 O
. O

5 O
nmol O
) O
of O
amn082 O
reverses O
haloperidol O
- O
induced O
catalepsy B-Disease
in O
rats O
. O

in O
a O
more O
complex O
task O
commonly O
used O
to O
evaluate O
major O
akinetic B-Disease
symptoms O
of O
pd B-Disease
patients O
, O
5 O
mg O
/ O
kg O
amn082 O
reverses O
the O
increased O
reaction O
time O
to O
respond O
to O
a O
cue O
of O
bilateral O
6 O
- O
ohda O
- O
lesioned O
rats O
. O

in O
addition O
, O
amn082 O
reduces O
the O
duration O
of O
haloperidol O
- O
induced O
catalepsy B-Disease
in O
a O
mglu7 O
receptor O
- O
dependent O
manner O
in O
wild O
- O
type O
but O
not O
mglu7 O
receptor O
knockout O
mice O
. O

higher O
doses O
of O
amn082 O
( O
10 O
and O
20 O
mg O
/ O
kg O
p O
. O

o O
. O

) O
have O
no O
effect O
on O
the O
same O
models O
of O
pd B-Disease
. O

sorafenib O
- O
induced O
acute O
myocardial B-Disease
infarction I-Disease
due O
to O
coronary B-Disease
artery I-Disease
spasm I-Disease
. O

a O
65 O
- O
year O
- O
old O
man O
with O
advanced O
renal B-Disease
cell I-Disease
carcinoma I-Disease
was O
admitted O
due O
to O
continuing O
chest B-Disease
pain I-Disease
at O
rest O
. O

he O
was O
diagnosed O
with O
non O
- O
st O
- O
elevation O
myocardial B-Disease
infarction I-Disease
by O
laboratory O
data O
and O
electrocardiogram O
. O

enhanced O
heart O
magnetic O
resonance O
imaging O
also O
showed O
subendocardial B-Disease
infarction I-Disease
. O

coronary B-Disease
artery I-Disease
spasm I-Disease
was O
induced O
by O
a O
provocative O
test O
. O

addition O
of O
oral O
nicorandil O
reduced O
his O
symptoms O
and O
maintained O
stable B-Disease
angina I-Disease
status O
. O

we O
report O
the O
first O
case O
of O
sorafenib O
- O
induced O
coronary B-Disease
artery I-Disease
spasm I-Disease
. O

on O
the O
other O
hand O
, O
the O
rho O
/ O
rock O
pathway O
has O
an O
important O
role O
in O
the O
pathogenesis O
of O
coronary B-Disease
artery I-Disease
spasm I-Disease
. O

tacrine O
, O
administered O
in O
licl O
pre O
- O
treated O
rats O
, O
induces O
electrocorticographic O
seizures B-Disease
and O
delayed O
hippocampal B-Disease
damage I-Disease
. O

all O
the O
animals O
treated O
with O
tacrine O
- O
loaded O
nanoparticles O
showed O
an O
earlier O
outcome O
of O
cns O
adverse O
symptoms O
, O
i O
. O

e O
. O

epileptic B-Disease
onset O
, O
with O
respect O
to O
those O
animals O
treated O
with O
the O
free O
compound O
( O
10 O
min O
vs O
. O

22 O
min O
respectively O
) O
. O

in O
addition O
, O
tacrine O
- O
loaded O
nanoparticles O
administration O
induced O
damage B-Disease
of I-Disease
neuronal I-Disease
cells I-Disease
in O
ca1 O
field O
of O
the O
hippocampus O
in O
all O
treated O
animals O
, O
while O
the O
saline O
solution O
of O
tacrine O
only O
in O
60 O
% O
of O
animals O
. O

in O
conclusion O
, O
the O
evaluation O
of O
time O
- O
to O
- O
onset O
of O
symptoms O
and O
the O
severity O
of O
neurodegenerative O
processes O
induced O
by O
the O
tacrine O
- O
lithium O
model O
of O
epilepsy B-Disease
in O
the O
rat O
, O
could O
be O
used O
to O
evaluate O
preliminarily O
the O
capability O
of O
a O
drug O
delivery O
system O
to O
trespass O
( O
or O
not O
) O
the O
bbb O
in O
vivo O
. O

high O
- O
dose O
tranexamic O
acid O
is O
associated O
with O
nonischemic O
clinical O
seizures B-Disease
in O
cardiac O
surgical O
patients O
. O

background O
: O
in O
2 O
separate O
centers O
, O
we O
observed O
a O
notable O
increase O
in O
the O
incidence O
of O
postoperative O
convulsive B-Disease
seizures B-Disease
from O
1 O
. O

3 O
% O
to O
3 O
. O

8 O
% O
in O
patients O
having O
undergone O
major O
cardiac O
surgical O
procedures O
. O

the O
purpose O
of O
this O
review O
was O
to O
perform O
a O
retrospective O
analysis O
to O
examine O
whether O
there O
was O
a O
relation O
between O
txa O
usage O
and O
seizures B-Disease
after O
cardiac O
surgery O
. O

methods O
: O
an O
in O
- O
depth O
chart O
review O
was O
undertaken O
in O
all O
24 O
patients O
who O
developed O
perioperative O
seizures B-Disease
. O

results O
: O
twenty O
- O
one O
of O
the O
24 O
patients O
did O
not O
have O
evidence O
of O
new O
cerebral B-Disease
ischemic I-Disease
injury I-Disease
, O
but O
seizures B-Disease
were O
likely O
due O
to O
ischemic B-Disease
brain I-Disease
injury I-Disease
in O
3 O
patients O
. O

all O
patients O
with O
seizures B-Disease
did O
not O
have O
permanent O
neurological B-Disease
abnormalities I-Disease
. O

all O
24 O
patients O
with O
seizures B-Disease
received O
high O
doses O
of O
txa O
intraoperatively O
ranging O
from O
61 O
to O
259 O
mg O
/ O
kg O
, O
had O
a O
mean O
age O
of O
69 O
. O

9 O
years O
, O
and O
21 O
of O
24 O
had O
undergone O
open O
chamber O
rather O
than O
coronary O
bypass O
procedures O
. O

no O
evidence O
of O
brain B-Disease
ischemic I-Disease
, O
metabolic O
, O
or O
hyperthermia B-Disease
- O
induced O
causes O
for O
their O
seizures B-Disease
was O
apparent O
. O

conclusion O
: O
our O
results O
suggest O
that O
use O
of O
high O
- O
dose O
txa O
in O
older O
patients O
in O
conjunction O
with O
cardiopulmonary O
bypass O
and O
open O
- O
chamber O
cardiac O
surgery O
is O
associated O
with O
clinical O
seizures B-Disease
in O
susceptible O
patients O
. O

electrocardiographic O
changes O
and O
cardiac B-Disease
arrhythmias I-Disease
in O
patients O
receiving O
psychotropic O
drugs O
. O

although O
most O
patients O
were O
receiving O
several O
drugs O
, O
mellaril O
( O
thioridazine O
) O
appeared O
to O
be O
responsible O
for O
five O
cases O
of O
ventricular B-Disease
tachycardia I-Disease
, O
one O
of O
which O
was O
fatal O
in O
a O
35 O
year O
old O
woman O
. O

supraventricular B-Disease
tachycardia I-Disease
developed O
in O
one O
patient O
receiving O
thorazine O
( O
chlorpromazine O
) O
. O

aventyl O
( O
nortriptyline O
) O
and O
elavil O
( O
amitriptyline O
) O
each O
produced O
left B-Disease
bundle I-Disease
branch I-Disease
block I-Disease
in O
a O
73 O
year O
old O
woman O
. O

the O
ventricular B-Disease
arrhythmias I-Disease
responded O
to O
intravenous O
administration O
of O
lidocaine O
and O
to O
direct O
current O
electric O
shock O
; O
ventricular O
pacing O
was O
required O
in O
some O
instances O
and O
intravenous O
administration O
of O
propranolol O
combined O
with O
ventricular O
pacing O
in O
one O
. O

the O
tachyarrhythmias B-Disease
generally O
subsided O
within O
48 O
hours O
after O
administration O
of O
the O
drugs O
was O
stopped O
. O

five O
of O
the O
eight O
patients O
were O
50 O
years O
of O
age O
or O
younger O
; O
only O
one O
clearly O
had O
antecedent O
heart B-Disease
disease I-Disease
. O

major O
cardiac B-Disease
arrhythmias I-Disease
are O
a O
potential O
hazard O
in O
patients O
without O
heart B-Disease
disease I-Disease
who O
are O
receiving O
customary O
therapeutic O
doses O
of O
psychotropic O
drugs O
. O

a O
prospective O
clinical O
trial O
is O
suggested O
to O
quantify O
the O
risk O
of O
cardiac B-Disease
complications I-Disease
to O
patients O
receiving O
phenothiazines O
or O
tricyclic O
antidepressant O
drugs O
. O

sensitivity O
of O
erythroid O
progenitor O
colonies O
to O
erythropoietin O
in O
azidothymidine O
treated O
immunodeficient B-Disease
mice O
. O

the O
anaemia B-Disease
induced O
by O
3 O
' O
- O
azido O
- O
3 O
' O
dideoxythymidine O
( O
azt O
) O
is O
poorly O
understood O
. O

we O
have O
used O
a O
murine O
model O
of O
aids B-Disease
, O
infection B-Disease
of O
female O
c57bl O
/ O
6 O
mice O
with O
lp O
- O
bm5 O
murine O
leukaemia B-Disease
( O
mulv O
) O
virus O
, O
to O
determine O
if O
azt O
- O
induced O
anaemia B-Disease
is O
due O
, O
in O
part O
, O
to O
decreased O
responsiveness O
of O
erythropoietic O
precursors O
( O
bfu O
- O
e O
) O
to O
erythropoietin O
( O
epo O
) O
. O

azt O
produced O
anaemia B-Disease
in O
both O
groups O
, O
in O
a O
dose O
- O
dependent O
fashion O
. O

despite O
the O
anaemia B-Disease
, O
the O
number O
of O
splenic O
and O
bone O
marrow O
bfu O
- O
e O
in O
azt O
treated O
mice O
increased O
up O
to O
five O
- O
fold O
over O
levels O
observed O
in O
infected O
untreated O
animals O
after O
15 O
d O
of O
treatment O
. O

the O
mean O
plasma O
levels O
of O
epo O
observed O
in O
azt O
treated O
mice O
were O
appropriate O
for O
the O
degree O
of O
anaemia B-Disease
observed O
when O
compared O
with O
phenylhydrazine O
( O
phz O
) O
treated O
mice O
. O

the O
numbers O
of O
bfu O
- O
e O
and O
the O
percentage O
of O
bone O
marrow O
erythroblasts O
observed O
were O
comparable O
in O
azt O
and O
phz O
treated O
mice O
with O
similar O
degrees O
of O
anaemia B-Disease
. O

however O
, O
reticulocytosis B-Disease
was O
inappropriate O
for O
the O
degree O
of O
anaemia B-Disease
observed O
in O
azt O
treated O
infected O
mice O
. O

azt O
- O
induced O
peripheral O
anaemia B-Disease
in O
the O
face O
of O
increased O
numbers O
of O
bfu O
- O
e O
and O
increased O
levels O
of O
plasma O
epo O
suggest O
a O
lesion O
in O
terminal O
differentiation O
. O

sedation O
depth O
during O
spinal O
anesthesia O
and O
the O
development O
of O
postoperative B-Disease
delirium I-Disease
in O
elderly O
patients O
undergoing O
hip B-Disease
fracture I-Disease
repair O
. O

objective O
: O
to O
determine O
whether O
limiting O
intraoperative O
sedation O
depth O
during O
spinal O
anesthesia O
for O
hip B-Disease
fracture I-Disease
repair O
in O
elderly O
patients O
can O
decrease O
the O
prevalence O
of O
postoperative B-Disease
delirium I-Disease
. O

patients O
and O
methods O
: O
we O
performed O
a O
double O
- O
blind O
, O
randomized O
controlled O
trial O
at O
an O
academic O
medical O
center O
of O
elderly O
patients O
( O
> O
or O
= O
65 O
years O
) O
without O
preoperative O
delirium B-Disease
or O
severe O
dementia B-Disease
who O
underwent O
hip B-Disease
fracture I-Disease
repair O
under O
spinal O
anesthesia O
with O
propofol O
sedation O
. O

postoperative B-Disease
delirium I-Disease
was O
assessed O
as O
defined O
by O
diagnostic O
and O
statistical O
manual O
of O
mental B-Disease
disorders I-Disease
( O
third O
edition O
revised O
) O
criteria O
using O
the O
confusion O
assessment O
method O
beginning O
at O
any O
time O
from O
the O
second O
day O
after O
surgery O
. O

the O
prevalence O
of O
postoperative B-Disease
delirium I-Disease
was O
significantly O
lower O
in O
the O
light O
sedation O
group O
( O
11 O
/ O
57 O
[ O
19 O
% O
] O
vs O
23 O
/ O
57 O
[ O
40 O
% O
] O
in O
the O
deep O
sedation O
group O
; O
p O
= O
. O

2 O
) O
, O
indicating O
that O
1 O
incident O
of O
delirium B-Disease
will O
be O
prevented O
for O
every O
4 O
. O

7 O
patients O
treated O
with O
light O
sedation O
. O

the O
mean O
+ O
/ O
- O
sd O
number O
of O
days O
of O
delirium B-Disease
during O
hospitalization O
was O
lower O
in O
the O
light O
sedation O
group O
than O
in O
the O
deep O
sedation O
group O
( O
0 O
. O

5 O
+ O
/ O
- O
1 O
. O

5 O
days O
vs O
1 O
. O

4 O
+ O
/ O
- O
4 O
. O

0 O
days O
; O
p O
= O
. O

1 O
) O
. O

conclusion O
: O
the O
use O
of O
light O
propofol O
sedation O
decreased O
the O
prevalence O
of O
postoperative B-Disease
delirium I-Disease
by O
50 O
% O
compared O
with O
deep O
sedation O
. O

limiting O
depth O
of O
sedation O
during O
spinal O
anesthesia O
is O
a O
simple O
, O
safe O
, O
and O
cost O
- O
effective O
intervention O
for O
preventing O
postoperative B-Disease
delirium I-Disease
in O
elderly O
patients O
that O
could O
be O
widely O
and O
readily O
adopted O
. O

the O
protective O
role O
of O
nrf2 O
in O
streptozotocin O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
. O

objective O
: O
diabetic B-Disease
nephropathy I-Disease
is O
one O
of O
the O
major O
causes O
of O
renal B-Disease
failure I-Disease
, O
which O
is O
accompanied O
by O
the O
production O
of O
reactive O
oxygen O
species O
( O
ros O
) O
. O

here O
, O
we O
report O
our O
findings O
demonstrating O
a O
protective O
role O
of O
nrf2 O
against O
diabetic B-Disease
nephropathy I-Disease
. O

research O
design O
and O
methods O
: O
we O
explore O
the O
protective O
role O
of O
nrf2 O
against O
diabetic B-Disease
nephropathy I-Disease
using O
human O
kidney O
biopsy O
tissues O
from O
diabetic B-Disease
nephropathy I-Disease
patients O
, O
a O
streptozotocin O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
model O
in O
nrf2 O
( O
- O
/ O
- O
) O
mice O
, O
and O
cultured O
human O
mesangial O
cells O
. O

results O
: O
the O
glomeruli O
of O
human O
diabetic B-Disease
nephropathy I-Disease
patients O
were O
under O
oxidative O
stress O
and O
had O
elevated O
nrf2 O
levels O
. O

in O
the O
animal O
study O
, O
nrf2 O
was O
demonstrated O
to O
be O
crucial O
in O
ameliorating O
streptozotocin O
- O
induced O
renal B-Disease
damage I-Disease
. O

this O
is O
evident O
by O
nrf2 O
( O
- O
/ O
- O
) O
mice O
having O
higher O
ros O
production O
and O
suffering O
from O
greater O
oxidative O
dna O
damage O
and O
renal B-Disease
injury I-Disease
compared O
with O
nrf2 O
( O
+ O
/ O
+ O
) O
mice O
. O

mechanistic O
studies O
in O
both O
in O
vivo O
and O
in O
vitro O
systems O
showed O
that O
the O
nrf2 O
- O
mediated O
protection O
against O
diabetic B-Disease
nephropathy I-Disease
is O
, O
at O
least O
, O
partially O
through O
inhibition O
of O
transforming O
growth O
factor O
- O
beta1 O
( O
tgf O
- O
beta1 O
) O
and O
reduction O
of O
extracellular O
matrix O
production O
. O

conclusions O
: O
this O
work O
clearly O
indicates O
a O
protective O
role O
of O
nrf2 O
in O
diabetic B-Disease
nephropathy I-Disease
, O
suggesting O
that O
dietary O
or O
therapeutic O
activation O
of O
nrf2 O
could O
be O
used O
as O
a O
strategy O
to O
prevent O
or O
slow O
down O
the O
progression O
of O
diabetic B-Disease
nephropathy I-Disease
. O

metformin O
prevents O
experimental O
gentamicin O
- O
induced O
nephropathy B-Disease
by O
a O
mitochondria O
- O
dependent O
pathway O
. O

the O
antidiabetic O
drug O
metformin O
can O
diminish O
apoptosis O
induced O
by O
oxidative O
stress O
in O
endothelial O
cells O
and O
prevent O
vascular B-Disease
dysfunction I-Disease
even O
in O
nondiabetic O
patients O
. O

here O
we O
tested O
whether O
it O
has O
a O
beneficial O
effect O
in O
a O
rat O
model O
of O
gentamicin O
toxicity B-Disease
. O

metformin O
treatment O
fully O
blocked O
gentamicin O
- O
mediated O
acute B-Disease
renal I-Disease
failure I-Disease
. O

these O
in O
vivo O
markers O
of O
kidney B-Disease
dysfunction I-Disease
and O
their O
correction O
by O
metformin O
were O
complemented O
by O
in O
vitro O
studies O
of O
mitochondrial O
function O
. O

thus O
, O
our O
study O
suggests O
that O
pleiotropic O
effects O
of O
metformin O
can O
lessen O
gentamicin O
nephrotoxicity B-Disease
and O
improve O
mitochondrial O
homeostasis O
. O

risk O
of O
nephropathy B-Disease
after O
consumption O
of O
nonionic O
contrast O
media O
by O
children O
undergoing O
cardiac O
angiography O
: O
a O
prospective O
study O
. O

despite O
increasing O
reports O
on O
nonionic O
contrast O
media O
- O
induced O
nephropathy B-Disease
( O
cin B-Disease
) O
in O
hospitalized O
adult O
patients O
during O
cardiac O
procedures O
, O
the O
studies O
in O
pediatrics O
are O
limited O
, O
with O
even O
less O
focus O
on O
possible O
predisposing O
factors O
and O
preventive O
measures O
for O
patients O
undergoing O
cardiac O
angiography O
. O

this O
prospective O
study O
determined O
the O
incidence O
of O
cin B-Disease
for O
two O
nonionic O
contrast O
media O
( O
cm O
) O
, O
iopromide O
and O
iohexol O
, O
among O
80 O
patients O
younger O
than O
18 O
years O
and O
compared O
the O
rates O
for O
this O
complication O
in O
relation O
to O
the O
type O
and O
dosage O
of O
cm O
and O
the O
presence O
of O
cyanosis B-Disease
. O

risk O
of O
renal B-Disease
failure I-Disease
, O
injury B-Disease
to I-Disease
the I-Disease
kidney I-Disease
, O
failure B-Disease
of I-Disease
kidney I-Disease
function I-Disease
, O
loss B-Disease
of I-Disease
kidney I-Disease
function I-Disease
, O
and O
end O
- O
stage O
renal B-Disease
damage I-Disease
( O
rifle O
criteria O
) O
were O
used O
to O
define O
cin B-Disease
and O
its O
incidence O
in O
the O
study O
population O
. O

accordingly O
, O
among O
the O
15 O
cin B-Disease
patients O
( O
18 O
. O

75 O
% O
) O
, O
7 O
. O

5 O
% O
of O
the O
patients O
in O
group O
a O
had O
increased O
risk O
and O
3 O
. O

75 O
% O
had O
renal B-Disease
injury I-Disease
, O
whereas O
5 O
% O
of O
group O
b O
had O
increased O
risk O
and O
2 O
. O

5 O
% O
had O
renal B-Disease
injury I-Disease
. O

whereas O
33 O
. O

3 O
% O
of O
the O
patients O
with O
cin B-Disease
were O
among O
those O
who O
received O
the O
proper O
dosage O
of O
cm O
, O
the O
percentage O
increased O
to O
66 O
. O

6 O
% O
among O
those O
who O
received O
larger O
doses O
, O
with O
a O
significant O
difference O
in O
the O
incidence O
of O
cin B-Disease
related O
to O
the O
different O
dosages O
of O
cm O
( O
p O
= O
0 O
. O

14 O
) O
. O

among O
the O
15 O
patients O
with O
cin B-Disease
, O
6 O
had O
cyanotic O
congenital B-Disease
heart I-Disease
diseases I-Disease
, O
but O
the O
incidence O
did O
not O
differ O
significantly O
from O
that O
for O
the O
noncyanotic O
patients O
( O
p O
= O
0 O
. O

243 O
) O
. O

although O
clinically O
silent O
, O
cin B-Disease
is O
not O
rare O
in O
pediatrics O
. O

the O
incidence O
depends O
on O
dosage O
but O
not O
on O
the O
type O
of O
consumed O
nonionic O
cm O
, O
nor O
on O
the O
presence O
of O
cyanosis B-Disease
, O
and O
although O
cin B-Disease
usually O
is O
reversible O
, O
more O
concern O
is O
needed O
for O
the O
prevention O
of O
such O
a O
complication O
in O
children O
. O

renal O
function O
and O
hemodynamics O
during O
prolonged O
isoflurane O
- O
induced O
hypotension B-Disease
in O
humans O
. O

the O
effect O
of O
isoflurane O
- O
induced O
hypotension B-Disease
on O
glomerular O
function O
and O
renal O
blood O
flow O
was O
investigated O
in O
20 O
human O
subjects O
. O

hypotension B-Disease
was O
induced O
for O
236 O
. O

9 O
+ O
/ O
- O
15 O
. O

1 O
min O
by O
increasing O
the O
isoflurane O
inspired O
concentration O
to O
maintain O
a O
mean O
arterial O
pressure O
of O
59 O
. O

8 O
+ O
/ O
- O
0 O
. O

4 O
mmhg O
. O

gfr O
and O
erpf O
decreased O
with O
the O
induction O
of O
anesthesia O
but O
not O
significantly O
more O
during O
hypotension B-Disease
. O

renal O
vascular O
resistance O
increased O
during O
anesthesia O
but O
decreased O
when O
hypotension B-Disease
was O
induced O
, O
allowing O
the O
maintenance O
of O
renal O
blood O
flow O
. O

we O
conclude O
that O
renal O
compensatory O
mechanisms O
are O
preserved O
during O
isoflurane O
- O
induced O
hypotension B-Disease
and O
that O
renal O
function O
and O
hemodynamics O
quickly O
return O
to O
normal O
when O
normotension O
is O
resumed O
. O

brainstem B-Disease
dysgenesis I-Disease
in O
an O
infant O
prenatally O
exposed O
to O
cocaine O
. O

many O
authors O
described O
the O
effects O
on O
the O
fetus O
of O
maternal O
cocaine B-Disease
abuse I-Disease
during O
pregnancy O
. O

vasoconstriction O
appears O
to O
be O
the O
common O
mechanism O
of O
action O
leading O
to O
a O
wide O
range O
of O
fetal B-Disease
anomalies I-Disease
. O

we O
report O
on O
an O
infant O
with O
multiple B-Disease
cranial I-Disease
- I-Disease
nerve I-Disease
involvement I-Disease
attributable O
to O
brainstem B-Disease
dysgenesis I-Disease
, O
born O
to O
a O
cocaine B-Disease
- I-Disease
addicted I-Disease
mother O
. O

objective O
: O
the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
effect O
of O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
on O
trabecular O
bone O
mineral O
density O
( O
bmd O
) O
in O
children O
and O
adolescents O
. O

results O
: O
hyperprolactinemia B-Disease
was O
present O
in O
49 O
% O
of O
83 O
boys O
( O
n O
= O
41 O
) O
treated O
with O
risperidone O
for O
a O
mean O
of O
2 O
. O

9 O
years O
. O

serum O
testosterone O
concentration O
increased O
with O
pubertal O
status O
but O
was O
not O
affected O
by O
hyperprolactinemia B-Disease
. O

of O
13 O
documented O
fractures B-Disease
, O
3 O
occurred O
after O
risperidone O
and O
ssris O
were O
started O
, O
and O
none O
occurred O
in O
patients O
with O
hyperprolactinemia B-Disease
. O

conclusions O
: O
this O
is O
the O
first O
study O
to O
link O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
and O
ssri O
treatment O
to O
lower O
bmd O
in O
children O
and O
adolescents O
. O

fear O
- O
potentiated O
startle B-Disease
, O
but O
not O
light O
- O
enhanced O
startle B-Disease
, O
is O
enhanced O
by O
anxiogenic O
drugs O
. O

rationale O
and O
objectives O
: O
the O
light O
- O
enhanced O
startle B-Disease
paradigm O
( O
les O
) O
is O
suggested O
to O
model O
anxiety B-Disease
, O
because O
of O
the O
non O
- O
specific O
cue O
and O
the O
long O
- O
term O
effect O
. O

in O
contrast O
, O
the O
fear O
- O
potentiated O
startle B-Disease
( O
fps O
) O
is O
suggested O
to O
model O
conditioned O
fear O
. O

furthermore O
, O
yohimbine O
increased O
baseline O
startle B-Disease
amplitude O
in O
the O
les O
, O
while O
mcpp O
suppressed O
baseline O
startle B-Disease
in O
both O
the O
les O
and O
fps O
and O
ptz O
suppressed O
baseline O
startle B-Disease
in O
the O
fps O
. O

rosaceiform O
dermatitis B-Disease
associated O
with O
topical O
tacrolimus O
treatment O
. O

we O
describe O
herein O
3 O
patients O
who O
developed O
rosacea B-Disease
- O
like O
dermatitis B-Disease
eruptions B-Disease
while O
using O
0 O
. O

3 O
% O
or O
0 O
. O

1 O
% O
tacrolimus O
ointment O
for O
facial B-Disease
dermatitis I-Disease
. O

skin O
biopsy O
specimens O
showed O
telangiectasia B-Disease
and O
noncaseating O
epithelioid O
granulomatous O
tissue O
formation O
in O
the O
papillary O
to O
mid O
dermis O
. O

continuous O
topical O
use O
of O
immunomodulators O
such O
as O
tacrolimus O
or O
pimecrolimus O
should O
be O
regarded O
as O
a O
potential O
cause O
of O
rosaceiform O
dermatitis B-Disease
, O
although O
many O
cases O
have O
not O
been O
reported O
. O

coenzyme O
q10 O
treatment O
ameliorates O
acute O
cisplatin O
nephrotoxicity B-Disease
in O
mice O
. O

the O
nephroprotective O
effect O
of O
coenzyme O
q10 O
was O
investigated O
in O
mice O
with O
acute B-Disease
renal I-Disease
injury I-Disease
induced O
by O
a O
single O
i O
. O

p O
. O

injection O
of O
cisplatin O
( O
5 O
mg O
/ O
kg O
) O
. O

coenzyme O
q10 O
significantly O
compensated O
deficits O
in O
the O
antioxidant O
defense O
mechanisms O
( O
reduced O
glutathione O
level O
and O
superoxide O
dismutase O
activity O
) O
, O
suppressed O
lipid O
peroxidation O
, O
decreased O
the O
elevations O
of O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
, O
nitric O
oxide O
and O
platinum O
ion O
concentration O
, O
and O
attenuated O
the O
reductions O
of O
selenium O
and O
zinc O
ions O
in O
renal O
tissue O
resulted O
from O
cisplatin O
administration O
. O

also O
, O
histopathological O
renal B-Disease
tissue I-Disease
damage I-Disease
mediated O
by O
cisplatin O
was O
ameliorated O
by O
coenzyme O
q10 O
treatment O
. O

it O
was O
concluded O
that O
coenzyme O
q10 O
represents O
a O
potential O
therapeutic O
option O
to O
protect O
against O
acute O
cisplatin O
nephrotoxicity B-Disease
commonly O
encountered O
in O
clinical O
practice O
. O

reversible O
cholestasis B-Disease
with O
bile B-Disease
duct I-Disease
injury I-Disease
following O
azathioprine O
therapy O
. O

a O
67 O
- O
year O
- O
old O
patient O
, O
with O
primary O
polymyositis B-Disease
and O
without O
previous O
evidence O
of O
liver B-Disease
disease I-Disease
, O
developed O
clinical O
and O
biochemical O
features O
of O
severe O
cholestasis B-Disease
3 O
months O
after O
initiation O
of O
azathioprine O
therapy O
. O

liver O
biopsy O
showed O
cholestasis B-Disease
with O
both O
cytological O
and O
architectural O
alterations O
of O
interlobular O
bile O
ducts O
. O

it O
is O
believed O
that O
this O
is O
the O
first O
reported O
case O
of O
reversible O
azathioprine O
- O
induced O
cholestasis B-Disease
associated O
with O
histological O
evidence O
of O
bile B-Disease
duct I-Disease
injury I-Disease
. O

dopamine O
is O
not O
essential O
for O
the O
development O
of O
methamphetamine O
- O
induced O
neurotoxicity B-Disease
. O

it O
is O
widely O
believed O
that O
dopamine O
( O
da O
) O
mediates O
methamphetamine O
( O
meth O
) O
- O
induced O
toxicity B-Disease
to O
brain O
dopaminergic O
neurons O
, O
because O
drugs O
that O
interfere O
with O
da O
neurotransmission O
decrease O
toxicity B-Disease
, O
whereas O
drugs O
that O
increase O
da O
neurotransmission O
enhance O
toxicity B-Disease
. O

here O
we O
show O
that O
the O
recently O
reported O
ability O
of O
l O
- O
dihydroxyphenylalanine O
to O
reverse O
the O
protective O
effect O
of O
alpha O
- O
methyl O
- O
para O
- O
tyrosine O
on O
meth O
- O
induced O
da O
neurotoxicity B-Disease
is O
also O
confounded O
by O
drug O
effects O
on O
body O
temperature O
. O

further O
, O
we O
show O
that O
mice O
genetically O
engineered O
to O
be O
deficient O
in O
brain O
da O
develop O
meth O
neurotoxicity B-Disease
, O
as O
long O
as O
the O
thermic O
effects O
of O
meth O
are O
preserved O
. O

in O
addition O
, O
we O
demonstrate O
that O
mice O
genetically O
engineered O
to O
have O
unilateral O
brain O
da O
deficits O
develop O
meth O
- O
induced O
dopaminergic B-Disease
deficits I-Disease
that O
are O
of O
comparable O
magnitude O
on O
both O
sides O
of O
the O
brain O
. O

taken O
together O
, O
these O
findings O
demonstrate O
that O
da O
is O
not O
essential O
for O
the O
development O
of O
meth O
- O
induced O
dopaminergic O
neurotoxicity B-Disease
and O
suggest O
that O
mechanisms O
independent O
of O
da O
warrant O
more O
intense O
investigation O
. O

swallowing O
- O
induced O
atrial B-Disease
tachyarrhythmia I-Disease
triggered O
by O
salbutamol O
: O
case O
report O
and O
review O
of O
the O
literature O
. O

on O
electrocardiogram O
, O
episodes O
of O
atrial B-Disease
tachyarrhythmia I-Disease
were O
recorded O
immediately O
after O
swallowing O
; O
24 O
- O
hour O
holter O
monitoring O
recorded O
several O
events O
. O

the O
arrhythmia B-Disease
resolved O
after O
therapy O
with O
atenolol O
, O
but O
recurred O
a O
year O
later O
. O

after O
stopping O
the O
beta O
- O
agonist O
, O
and O
after O
a O
week O
with O
the O
atenolol O
, O
the O
arrhythmia B-Disease
disappeared O
. O

discussion O
: O
swallowing O
- O
induced O
atrial B-Disease
tachyarrhythmia I-Disease
( O
siat B-Disease
) O
is O
a O
rare O
phenomenon O
. O

fewer O
than O
50 O
cases O
of O
siat B-Disease
have O
been O
described O
in O
the O
literature O
. O

this O
article O
summarizes O
all O
the O
cases O
published O
, O
creating O
a O
comprehensive O
review O
of O
the O
current O
knowledge O
and O
approach O
to O
siat B-Disease
. O

it O
discusses O
demographics O
, O
clinical O
characteristics O
and O
types O
of O
arrhythmia B-Disease
, O
postulated O
mechanisms O
of O
siat B-Disease
, O
and O
different O
treatment O
possibilities O
such O
as O
medications O
, O
surgery O
, O
and O
radiofrequency O
catheter O
ablation O
( O
rfca O
) O
. O

conclusion O
: O
salbutamol O
is O
presented O
here O
as O
a O
possible O
trigger O
for O
siat B-Disease
. O

although O
it O
is O
difficult O
to O
define O
causality O
in O
a O
case O
report O
, O
it O
is O
logical O
to O
think O
that O
a O
beta O
- O
agonist O
like O
salbutamol O
( O
known O
to O
induce O
tachycardia B-Disease
) O
may O
be O
the O
trigger O
of O
adrenergic O
reflexes O
originating O
in O
the O
esophagus O
while O
swallowing O
and O
that O
a O
beta O
- O
blocker O
such O
as O
atenolol O
( O
that O
blocks O
the O
adrenergic O
activity O
) O
may O
relieve O
it O
. O

the O
ability O
of O
insulin O
treatment O
to O
reverse O
or O
prevent O
the O
changes O
in O
urinary O
bladder O
function O
caused O
by O
streptozotocin O
- O
induced O
diabetes B-Disease
mellitus I-Disease
. O

the O
effects O
of O
insulin O
treatment O
on O
in O
vivo O
and O
in O
vitro O
urinary O
bladder O
function O
in O
streptozotocin O
- O
diabetic B-Disease
rats O
were O
investigated O
. O

diabetes B-Disease
of O
2 O
months O
duration O
resulted O
in O
decreases O
in O
body O
weight O
and O
increases O
in O
fluid O
consumption O
, O
urine O
volume O
, O
frequency O
of O
micturition O
, O
and O
average O
volume O
per O
micturition O
; O
effects O
which O
were O
prevented O
by O
insulin O
treatment O
. O

insulin O
treatment O
also O
prevented O
the O
increases O
in O
contractile O
responses O
of O
bladder O
body O
strips O
from O
diabetic B-Disease
rats O
to O
nerve O
stimulation O
, O
atp O
, O
and O
bethanechol O
. O

diabetes B-Disease
of O
4 O
months O
duration O
also O
resulted O
in O
decreases O
in O
body O
weight O
, O
and O
increases O
in O
fluid O
consumption O
, O
urine O
volume O
, O
frequency O
of O
micturition O
, O
and O
average O
volume O
per O
micturition O
, O
effects O
which O
were O
reversed O
by O
insulin O
treatment O
for O
the O
final O
2 O
months O
of O
the O
study O
. O

insulin O
treatment O
reversed O
the O
increases O
in O
contractile O
responses O
of O
bladder O
body O
strips O
from O
diabetic B-Disease
rats O
to O
nerve O
stimulation O
, O
atp O
, O
and O
bethanechol O
. O

the O
data O
indicate O
that O
the O
effects O
of O
streptozotocin O
- O
induced O
diabetes B-Disease
on O
urinary O
bladder O
function O
are O
both O
prevented O
and O
reversed O
by O
insulin O
treatment O
. O

glutamatergic O
neurotransmission O
mediated O
by O
nmda O
receptors O
in O
the O
inferior O
colliculus O
can O
modulate O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

the O
present O
study O
examined O
the O
influence O
of O
excitatory O
amino O
acid O
- O
mediated O
mechanisms O
in O
the O
ic O
on O
the O
catalepsy B-Disease
induced O
by O
the O
dopamine O
receptor O
blocker O
haloperidol O
administered O
systemically O
( O
1 O
or O
0 O
. O

5 O
mg O
/ O
kg O
) O
in O
rats O
. O

haloperidol O
- O
induced O
catalepsy B-Disease
was O
challenged O
with O
prior O
intracollicular O
microinjections O
of O
glutamate O
nmda O
receptor O
antagonists O
, O
mk O
- O
801 O
( O
15 O
or O
30 O
mmol O
/ O
0 O
. O

5 O
microl O
) O
and O
ap7 O
( O
10 O
or O
20 O
nmol O
/ O
0 O
. O

5 O
microl O
) O
, O
or O
of O
the O
nmda O
receptor O
agonist O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
, O
20 O
or O
30 O
nmol O
/ O
0 O
. O

5 O
microl O
) O
. O

the O
results O
showed O
that O
intracollicular O
microinjection O
of O
mk O
- O
801 O
and O
ap7 O
previous O
to O
systemic O
injections O
of O
haloperidol O
significantly O
attenuated O
the O
catalepsy B-Disease
, O
as O
indicated O
by O
a O
reduced O
latency O
to O
step O
down O
from O
a O
horizontal O
bar O
. O

these O
findings O
suggest O
that O
glutamate O
- O
mediated O
mechanisms O
in O
the O
neural O
circuits O
at O
the O
ic O
level O
influence O
haloperidol O
- O
induced O
catalepsy B-Disease
and O
participate O
in O
the O
regulation O
of O
motor O
activity O
. O

severe O
congestive B-Disease
heart I-Disease
failure I-Disease
patient O
on O
amiodarone O
presenting O
with O
myxedemic B-Disease
coma I-Disease
: O
a O
case O
report O
. O

this O
is O
a O
case O
report O
of O
myxedema B-Disease
coma I-Disease
secondary O
to O
amiodarone O
- O
induced O
hypothyroidism B-Disease
in O
a O
patient O
with O
severe O
congestive B-Disease
heart I-Disease
failure I-Disease
( O
chf B-Disease
) O
. O

to O
our O
knowledge O
and O
after O
reviewing O
the O
literature O
there O
is O
one O
case O
report O
of O
myxedema B-Disease
coma I-Disease
during O
long O
term O
amiodarone O
therapy O
. O

myxedema B-Disease
coma I-Disease
is O
a O
life O
threatening O
condition O
that O
carries O
a O
mortality O
reaching O
as O
high O
as O
20 O
% O
with O
treatment O
. O

patients O
with O
chf B-Disease
on O
amiodarone O
may O
suffer O
serious O
morbidity O
and O
mortality O
from O
hypothyroidism B-Disease
, O
and O
thus O
may O
deserve O
closer O
follow O
up O
for O
thyroid O
stimulating O
hormone O
( O
tsh O
) O
levels O
. O

this O
case O
report O
carries O
an O
important O
clinical O
application O
given O
the O
frequent O
usage O
of O
amiodarone O
among O
chf B-Disease
patients O
. O

the O
myriad O
clinical O
presentation O
of O
myxedema B-Disease
coma I-Disease
and O
its O
serious O
morbidity O
and O
mortality O
stresses O
the O
need O
to O
suspect O
this O
clinical O
syndrome O
among O
chf B-Disease
patients O
presenting O
with O
hypotension B-Disease
, O
weakness B-Disease
or O
other O
unexplained O
symptoms O
. O

effects O
of O
active O
constituents O
of O
crocus O
sativus O
l O
. O

, O
crocin O
on O
streptozocin O
- O
induced O
model O
of O
sporadic O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
in O
male O
rats O
. O

in O
the O
present O
study O
, O
the O
effect O
of O
crocins O
on O
sporadic O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
induced O
by O
intracerebroventricular O
( O
icv O
) O
streptozocin O
( O
stz O
) O
in O
male O
rats O
was O
investigated O
. O

in O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
groups O
, O
rats O
were O
injected O
with O
stz O
- O
icv O
bilaterally O
( O
3 O
mg O
/ O
kg O
) O
in O
first O
day O
and O
3 O
days O
later O
, O
a O
similar O
stz O
- O
icv O
application O
was O
repeated O
. O

in O
addition O
, O
crocin O
in O
the O
mentioned O
dose O
could O
significantly O
attenuated O
learning B-Disease
and I-Disease
memory I-Disease
impairment I-Disease
in O
treated O
stz O
- O
injected O
group O
in O
passive O
avoidance O
test O
. O

conclusion O
: O
therefore O
, O
these O
results O
demonstrate O
the O
effectiveness O
of O
crocin O
( O
30 O
mg O
/ O
kg O
) O
in O
antagonizing O
the O
cognitive B-Disease
deficits I-Disease
caused O
by O
stz O
- O
icv O
in O
rats O
and O
its O
potential O
in O
the O
treatment O
of O
neurodegenerative B-Disease
diseases I-Disease
such O
as O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

serotonin O
6 O
receptor O
gene O
is O
associated O
with O
methamphetamine O
- O
induced O
psychosis B-Disease
in O
a O
japanese O
population O
. O

background O
: O
altered O
serotonergic O
neural O
transmission O
is O
hypothesized O
to O
be O
a O
susceptibility O
factor O
for O
psychotic B-Disease
disorders I-Disease
such O
as O
schizophrenia B-Disease
. O

the O
serotonin O
6 O
( O
5 O
- O
ht6 O
) O
receptor O
is O
therapeutically O
targeted O
by O
several O
second O
generation O
antipsychotics O
, O
such O
as O
clozapine O
and O
olanzapine O
, O
and O
d O
- O
amphetamine O
- O
induced O
hyperactivity B-Disease
in O
rats O
is O
corrected O
with O
the O
use O
of O
a O
selective O
5 O
- O
ht6 O
receptor O
antagonist O
. O

these O
animal O
models O
were O
considered O
to O
reflect O
the O
positive O
symptoms O
of O
schizophrenia B-Disease
, O
and O
the O
above O
evidence O
suggests O
that O
altered O
5 O
- O
ht6 O
receptors O
are O
involved O
in O
the O
pathophysiology O
of O
psychotic B-Disease
disorders I-Disease
. O

the O
symptoms O
of O
methamphetamine O
( O
meth O
) O
- O
induced O
psychosis B-Disease
are O
similar O
to O
those O
of O
paranoid B-Disease
type I-Disease
schizophrenia I-Disease
. O

therefore O
, O
we O
conducted O
an O
analysis O
of O
the O
association O
of O
the O
5 O
- O
ht6 O
gene O
( O
htr6 O
) O
with O
meth O
- O
induced O
psychosis B-Disease
. O

method O
: O
using O
five O
tagging O
snps O
( O
rs6693503 O
, O
rs1805054 O
, O
rs4912138 O
, O
rs3790757 O
and O
rs9659997 O
) O
, O
we O
conducted O
a O
genetic O
association O
analysis O
of O
case O
- O
control O
samples O
( O
197 O
meth O
- O
induced O
psychosis B-Disease
patients O
and O
337 O
controls O
) O
in O
the O
japanese O
population O
. O

results O
: O
rs6693503 O
was O
associated O
with O
meth O
- O
induced O
psychosis B-Disease
patients O
in O
the O
allele O
/ O
genotype O
- O
wise O
analysis O
. O

in O
the O
haplotype O
- O
wise O
analysis O
, O
we O
detected O
an O
association O
between O
two O
markers O
( O
rs6693503 O
and O
rs1805054 O
) O
and O
three O
markers O
( O
rs6693503 O
, O
rs1805054 O
and O
rs4912138 O
) O
in O
htr6 O
and O
meth O
- O
induced O
psychosis B-Disease
patients O
, O
respectively O
. O

conclusion O
: O
htr6 O
may O
play O
an O
important O
role O
in O
the O
pathophysiology O
of O
meth O
- O
induced O
psychosis B-Disease
in O
the O
japanese O
population O
. O

neural O
correlates O
of O
s O
- O
ketamine O
induced O
psychosis B-Disease
during O
overt O
continuous O
verbal O
fluency O
. O

the O
glutamatergic O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptor O
has O
been O
implicated O
in O
the O
pathophysiology O
of O
schizophrenia B-Disease
. O

administered O
to O
healthy O
volunteers O
, O
a O
subanesthetic O
dose O
of O
the O
non O
- O
competitive O
nmda O
receptor O
antagonist O
ketamine O
leads O
to O
psychopathological O
symptoms O
similar O
to O
those O
observed O
in O
schizophrenia B-Disease
. O

in O
patients O
with O
schizophrenia B-Disease
, O
ketamine O
exacerbates O
the O
core O
symptoms O
of O
illness O
, O
supporting O
the O
hypothesis O
of O
a O
glutamatergic B-Disease
dysfunction I-Disease
. O

ketamine O
elicited O
psychosis B-Disease
like O
psychopathology O
. O

ketamine O
induces O
activation O
changes O
in O
healthy O
subjects O
similar O
to O
those O
observed O
in O
patients O
with O
schizophrenia B-Disease
, O
particularly O
in O
frontal O
and O
temporal O
brain O
regions O
. O

our O
results O
provide O
further O
support O
for O
the O
hypothesis O
of O
an O
nmda O
receptor O
dysfunction O
in O
the O
pathophysiology O
of O
schizophrenia B-Disease
. O

long O
- O
term O
prognosis O
for O
transplant O
- O
free O
survivors O
of O
paracetamol O
- O
induced O
acute B-Disease
liver I-Disease
failure I-Disease
. O

background O
: O
the O
prognosis O
for O
transplant O
- O
free O
survivors O
of O
paracetamol O
- O
induced O
acute B-Disease
liver I-Disease
failure I-Disease
remains O
unknown O
. O

aim O
: O
to O
examine O
whether O
paracetamol O
- O
induced O
acute B-Disease
liver I-Disease
failure I-Disease
increases O
long O
- O
term O
mortality O
. O

methods O
: O
we O
followed O
up O
all O
transplant O
- O
free O
survivors O
of O
paracetamol O
- O
induced O
acute B-Disease
liver I-Disease
injury I-Disease
, O
hospitalized O
in O
a O
danish O
national O
referral O
centre O
during O
1984 O
- O
2004 O
. O

we O
compared O
age O
- O
specific O
mortality O
rates O
from O
1 O
year O
post O
- O
discharge O
through O
2008 O
between O
those O
in O
whom O
the O
liver B-Disease
injury I-Disease
led O
to O
an O
acute B-Disease
liver I-Disease
failure I-Disease
and O
those O
in O
whom O
it O
did O
not O
. O

on O
average O
, O
age O
- O
specific O
mortality O
rates O
were O
slightly O
higher O
for O
the O
101 O
patients O
whose O
paracetamol O
- O
induced O
liver B-Disease
injury I-Disease
had O
caused O
an O
acute B-Disease
liver I-Disease
failure I-Disease
( O
adjusted O
mortality O
rate O
ratio O
= O
1 O
. O

70 O
, O
95 O
% O
ci O
1 O
. O

2 O
- O
2 O
. O

85 O
) O
, O
but O
the O
association O
was O
age O
- O
dependent O
, O
and O
no O
survivors O
of O
acute B-Disease
liver I-Disease
failure I-Disease
died O
of O
liver B-Disease
disease I-Disease
, O
whereas O
suicides O
were O
frequent O
in O
both O
groups O
. O

these O
observations O
speak O
against O
long O
- O
term O
effects O
of O
acute B-Disease
liver I-Disease
failure I-Disease
. O

more O
likely O
, O
the O
elevated O
mortality O
rate O
ratio O
resulted O
from O
incomplete O
adjustment O
for O
the O
greater O
prevalence O
of O
substance B-Disease
abuse I-Disease
among O
survivors O
of O
acute B-Disease
liver I-Disease
failure I-Disease
. O

conclusions O
: O
paracetamol O
- O
induced O
acute B-Disease
liver I-Disease
failure I-Disease
did O
not O
affect O
long O
- O
term O
mortality O
. O

clinical O
follow O
- O
up O
may O
be O
justified O
by O
the O
cause O
of O
the O
liver B-Disease
failure I-Disease
, O
but O
not O
by O
the O
liver B-Disease
failure I-Disease
itself O
. O

in O
vivo O
characterization O
of O
a O
dual O
adenosine O
a2a O
/ O
a1 O
receptor O
antagonist O
in O
animal O
models O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

the O
in O
vivo O
characterization O
of O
a O
dual O
adenosine O
a O
( O
2a O
) O
/ O
a O
( O
1 O
) O
receptor O
antagonist O
in O
several O
animal O
models O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
is O
described O
. O

compound O
1 O
is O
a O
potent O
a O
( O
2a O
) O
/ O
a O
( O
1 O
) O
receptor O
antagonist O
in O
vitro O
( O
a O
( O
2a O
) O
k O
( O
i O
) O
= O
4 O
. O

1 O
nm O
; O
a O
( O
1 O
) O
k O
( O
i O
) O
= O
17 O
. O

0 O
nm O
) O
that O
has O
excellent O
activity O
, O
after O
oral O
administration O
, O
across O
a O
number O
of O
animal O
models O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
including O
mouse O
and O
rat O
models O
of O
haloperidol O
- O
induced O
catalepsy B-Disease
, O
mouse O
model O
of O
reserpine O
- O
induced O
akinesia B-Disease
, O
rat O
6 O
- O
hydroxydopamine O
( O
6 O
- O
ohda O
) O
lesion O
model O
of O
drug O
- O
induced O
rotation O
, O
and O
mptp O
- O
treated O
non O
- O
human O
primate O
model O
. O

effects O
of O
the O
hippocampal O
deep O
brain O
stimulation O
on O
cortical O
epileptic B-Disease
discharges O
in O
penicillin O
- O
induced O
epilepsy B-Disease
model O
in O
rats O
. O

aim O
: O
experimental O
and O
clinical O
studies O
have O
revealed O
that O
hippocampal O
dbs O
can O
control O
epileptic B-Disease
activity O
, O
but O
the O
mechanism O
of O
action O
is O
obscure O
and O
optimal O
stimulation O
parameters O
are O
not O
clearly O
defined O
. O

the O
aim O
was O
to O
evaluate O
the O
effects O
of O
high O
frequency O
hippocampal O
stimulation O
on O
cortical O
epileptic B-Disease
activity O
in O
penicillin O
- O
induced O
epilepsy B-Disease
model O
. O

results O
: O
high O
frequency O
hippocampal O
dbs O
suppressed O
the O
acute O
penicillin O
- O
induced O
cortical O
epileptic B-Disease
activity O
independent O
from O
stimulus O
intensity O
. O

conclusion O
: O
our O
results O
revealed O
that O
continuous O
high O
frequency O
stimulation O
of O
the O
hippocampus O
suppressed O
acute O
cortical O
epileptic B-Disease
activity O
effectively O
without O
causing O
secondary O
epileptic B-Disease
discharges O
. O

these O
results O
are O
important O
in O
terms O
of O
defining O
the O
optimal O
parameters O
of O
hippocampal O
dbs O
in O
patients O
with O
epilepsy B-Disease
. O

ccnu O
( O
lomustine O
) O
toxicity B-Disease
in O
dogs O
: O
a O
retrospective O
study O
( O
2002 O
- O
7 O
) O
. O

objective O
: O
to O
describe O
the O
incidence O
of O
haematological B-Disease
, I-Disease
renal I-Disease
, I-Disease
hepatic I-Disease
and I-Disease
gastrointestinal I-Disease
toxicities I-Disease
in O
tumour O
- O
bearing O
dogs O
receiving O
1 O
- O
( O
2 O
- O
chloroethyl O
) O
- O
3 O
- O
cyclohexyl O
- O
1 O
- O
nitrosourea O
( O
ccnu O
) O
. O

results O
: O
of O
the O
206 O
dogs O
treated O
with O
ccnu O
, O
185 O
met O
the O
inclusion O
criteria O
for O
at O
least O
one O
class O
of O
toxicity B-Disease
. O

ccnu O
was O
used O
most O
commonly O
in O
the O
treatment O
of O
lymphoma B-Disease
, O
mast B-Disease
cell I-Disease
tumour I-Disease
, O
brain B-Disease
tumour I-Disease
, O
histiocytic B-Disease
tumours I-Disease
and O
epitheliotropic B-Disease
lymphoma I-Disease
. O

throughout O
treatment O
, O
56 O
. O

9 O
% O
of O
dogs O
experienced O
neutropenia B-Disease
, O
34 O
. O

2 O
% O
experienced O
anaemia B-Disease
and O
14 O
. O

2 O
% O
experienced O
thrombocytopenia B-Disease
. O

gastrointestinal B-Disease
toxicosis I-Disease
was O
detected O
in O
37 O
. O

8 O
% O
of O
dogs O
, O
the O
most O
common O
sign O
of O
which O
was O
vomiting B-Disease
( O
24 O
. O

3 O
% O
) O
. O

potential O
renal O
toxicity B-Disease
and O
elevated O
alanine O
transaminase O
( O
alt O
) O
concentration O
were O
reported O
in O
12 O
. O

2 O
% O
and O
48 O
. O

8 O
% O
of O
dogs O
, O
respectively O
. O

the O
incidence O
of O
hepatic B-Disease
failure I-Disease
was O
1 O
. O

2 O
% O
. O

conclusions O
: O
ccnu O
- O
associated O
toxicity B-Disease
in O
dogs O
is O
common O
, O
but O
is O
usually O
not O
life O
threatening O
. O

central O
vein B-Disease
thrombosis I-Disease
and O
topical O
dipivalyl O
epinephrine O
. O

a O
report O
is O
given O
on O
an O
83 O
- O
year O
- O
old O
female O
who O
acquired O
central O
vein B-Disease
thrombosis I-Disease
in O
her O
seeing O
eye O
one O
day O
after O
having O
started O
topical O
medication O
with O
dipivalyl O
epinephrine O
for O
advanced O
glaucoma B-Disease
discovered O
in O
the O
other O
eye O
. O

benzylacyclouridine O
reverses O
azidothymidine O
- O
induced O
marrow B-Disease
suppression I-Disease
without O
impairment O
of O
anti O
- O
human O
immunodeficiency B-Disease
virus O
activity O
. O

increased O
extracellular O
concentrations O
of O
uridine O
( O
urd O
) O
have O
been O
reported O
to O
reduce O
, O
in O
vitro O
, O
azidothymidine O
( O
azt O
) O
- O
induced O
inhibition O
of O
human O
granulocyte O
- O
macrophage O
progenitor O
cells O
without O
impairment O
of O
its O
antihuman O
immunodeficiency B-Disease
virus O
( O
hiv O
) O
activity O
. O

because O
of O
the O
clinical O
toxicities B-Disease
associated O
with O
chronic O
urd O
administration O
, O
the O
ability O
of O
benzylacyclouridine O
( O
bau O
) O
to O
effect O
, O
in O
vivo O
, O
azt O
- O
induced O
anemia B-Disease
and O
leukopenia B-Disease
was O
assessed O
. O

this O
agent O
inhibits O
urd O
catabolism O
and O
, O
in O
vivo O
, O
increases O
the O
plasma O
concentration O
of O
urd O
in O
a O
dose O
- O
dependent O
manner O
, O
without O
urd O
- O
related O
toxicity B-Disease
. O

in O
mice O
rendered O
anemic B-Disease
and O
leukopenic B-Disease
by O
the O
administration O
of O
azt O
for O
28 O
days O
in O
drinking O
water O
( O
1 O
. O

5 O
mg O
/ O
ml O
) O
, O
the O
continued O
administration O
of O
azt O
plus O
daily O
bau O
( O
300 O
mg O
/ O
kg O
, O
orally O
) O
partially O
reversed O
azt O
- O
induced O
anemia B-Disease
and O
leukopenia B-Disease
( O
p O
less O
than O
. O

5 O
) O
, O
increased O
peripheral O
reticulocytes O
( O
to O
4 O
. O

9 O
% O
, O
p O
less O
than O
. O

1 O
) O
, O
increased O
cellularity O
in O
the O
marrow O
, O
and O
improved O
megaloblastosis B-Disease
. O

when O
coadministered O
with O
azt O
from O
the O
onset O
of O
drug O
administration O
, O
bau O
reduced O
azt O
- O
induced O
marrow B-Disease
toxicity I-Disease
. O

lethal O
anuria B-Disease
complicating O
high O
dose O
ifosfamide O
chemotherapy O
in O
a O
breast B-Disease
cancer I-Disease
patient O
with O
an O
impaired B-Disease
renal I-Disease
function I-Disease
. O

a O
sixty O
- O
year O
- O
old O
woman O
with O
advanced O
breast B-Disease
cancer I-Disease
, O
previously O
treated O
with O
cisplatin O
, O
developed O
an O
irreversible O
lethal O
renal B-Disease
failure I-Disease
with O
anuria B-Disease
, O
the O
day O
after O
5 O
g O
/ O
m2 O
bolus O
ifosfamide O
. O

postrenal B-Disease
failure I-Disease
was O
excluded O
by O
echography O
. O

a O
prerenal O
component O
could O
have O
contributed O
to O
renal B-Disease
failure I-Disease
because O
of O
a O
transient O
hypotension B-Disease
, O
due O
to O
an O
increasing O
ascitis O
, O
occurring O
just O
before O
anuria B-Disease
. O

ifosfamide O
is O
a O
known O
nephrotoxic B-Disease
drug O
with O
demonstrated O
tubulopathies B-Disease
. O

we O
strongly O
suspect O
that O
this O
lethal O
anuria B-Disease
was O
mainly O
due O
to O
ifosfamide O
, O
occurring O
in O
a O
patient O
having O
received O
previous O
cisplatin O
chemotherapy O
and O
with O
poor O
kidney O
perfusion O
due O
to O
transient O
hypotension B-Disease
. O

we O
recommend O
careful O
use O
of O
ifosfamide O
in O
patients O
pretreated O
with O
nephrotoxic B-Disease
chemotherapy O
and O
inadequate O
renal O
perfusion O
. O

the O
effects O
of O
intrathecal O
administration O
of O
prostaglandins O
on O
pain B-Disease
responses O
in O
conscious O
mice O
were O
evaluated O
by O
using O
hot O
plate O
and O
acetic O
acid O
writhing O
tests O
. O

prostaglandin O
d2 O
( O
0 O
. O

5 O
- O
3 O
ng O
/ O
mouse O
) O
had O
a O
hyperalgesic B-Disease
action O
on O
the O
response O
to O
a O
hot O
plate O
during O
a O
3 O
- O
60 O
min O
period O
after O
injection O
. O

prostaglandin O
e2 O
showed O
a O
hyperalgesic B-Disease
effect O
at O
doses O
of O
1 O
pg O
to O
10 O
ng O
/ O
mouse O
, O
but O
the O
effect O
lasted O
shorter O
( O
3 O
- O
30 O
min O
) O
than O
that O
of O
prostaglandin O
d2 O
. O

the O
hyperalgesic B-Disease
effect O
of O
prostaglandin O
d2 O
was O
blocked O
by O
simultaneous O
injection O
of O
a O
substance O
p O
antagonist O
( O
greater O
than O
or O
equal O
to O
100 O
ng O
) O
but O
not O
by O
ah6809 O
, O
a O
prostanoid O
ep1 O
- O
receptor O
antagonist O
. O

conversely O
, O
prostaglandin O
e2 O
- O
induced O
hyperalgesia B-Disease
was O
blocked O
by O
ah6809 O
( O
greater O
than O
or O
equal O
to O
500 O
ng O
) O
but O
not O
by O
the O
substance O
p O
antagonist O
. O

prostaglandin O
f2 O
alpha O
had O
little O
effect O
on O
pain B-Disease
responses O
. O

these O
results O
demonstrate O
that O
both O
prostaglandin O
d2 O
and O
prostaglandin O
e2 O
exert O
hyperalgesia B-Disease
in O
the O
spinal O
cord O
, O
but O
in O
different O
ways O
. O

d O
- O
penicillamine O
in O
the O
treatment O
of O
localized B-Disease
scleroderma I-Disease
. O

localized B-Disease
scleroderma I-Disease
has O
no O
recognized O
internal O
organ O
involvement O
but O
may O
be O
disfiguring O
and O
disabling O
when O
the O
cutaneous O
lesions O
are O
extensive O
or O
affect O
children O
. O

there O
is O
no O
accepted O
or O
proven O
treatment O
for O
localized B-Disease
scleroderma I-Disease
. O

case O
reports O
of O
11 O
patients O
with O
severe O
, O
extensive O
localized B-Disease
scleroderma I-Disease
who O
were O
treated O
with O
d O
- O
penicillamine O
are O
summarized O
in O
this O
article O
. O

joint O
stiffness O
and O
contractures B-Disease
also O
improved O
. O

d O
- O
penicillamine O
caused O
nephrotic B-Disease
syndrome I-Disease
in O
1 O
patient O
and O
milder O
reversible O
proteinuria B-Disease
in O
3 O
other O
patients O
; O
none O
developed O
renal B-Disease
insufficiency I-Disease
. O

these O
data O
suggest O
that O
d O
- O
penicillamine O
may O
be O
effective O
in O
severe O
cases O
of O
localized B-Disease
scleroderma I-Disease
. O

cerebral B-Disease
sinus I-Disease
thrombosis I-Disease
as O
a O
potential O
hazard O
of O
antifibrinolytic O
treatment O
in O
menorrhagia B-Disease
. O

we O
describe O
a O
42 O
- O
year O
- O
old O
woman O
who O
developed O
superior O
sagittal B-Disease
and I-Disease
left I-Disease
transverse I-Disease
sinus I-Disease
thrombosis I-Disease
associated O
with O
prolonged O
epsilon O
- O
aminocaproic O
acid O
therapy O
for O
menorrhagia B-Disease
. O

this O
antifibrinolytic O
agent O
has O
been O
used O
in O
women O
with O
menorrhagia B-Disease
to O
promote O
clotting O
and O
reduce O
blood B-Disease
loss I-Disease
. O

although O
increased O
risk O
of O
thromboembolic B-Disease
disease I-Disease
has O
been O
reported O
during O
treatment O
with O
epsilon O
- O
aminocaproic O
acid O
, O
cerebral B-Disease
sinus I-Disease
thrombosis I-Disease
has O
not O
been O
previously O
described O
. O

seizure B-Disease
activity O
with O
imipenem O
therapy O
: O
incidence O
and O
risk O
factors O
. O

two O
elderly O
patients O
with O
a O
history O
of O
either O
cerebral B-Disease
vascular I-Disease
accident I-Disease
( O
cva B-Disease
) O
or O
head B-Disease
trauma I-Disease
and O
no O
evidence O
of O
renal B-Disease
disease I-Disease
developed O
seizures B-Disease
while O
receiving O
maximum O
doses O
of O
imipenem O
/ O
cilastatin O
. O

neither O
patient O
had O
reported O
previous O
seizures B-Disease
or O
seizure B-Disease
- O
like O
activity O
nor O
was O
receiving O
anticonvulsant O
agents O
. O

all O
seizures B-Disease
were O
controlled O
with O
therapeutic O
doses O
of O
phenytoin O
. O

both O
patients O
had O
received O
maximum O
doses O
of O
other O
beta O
- O
lactam O
antibiotics O
without O
evidence O
of O
seizure B-Disease
activity O
. O

midline O
b3 O
serotonin O
nerves O
in O
rat O
medulla O
are O
involved O
in O
hypotensive B-Disease
effect O
of O
methyldopa O
. O

previous O
experiments O
in O
this O
laboratory O
have O
shown O
that O
microinjection O
of O
methyldopa O
onto O
the O
ventrolateral O
cells O
of O
the O
b3 O
serotonin O
neurons O
in O
the O
medulla O
elicits O
a O
hypotensive B-Disease
response O
mediated O
by O
a O
projection O
descending O
into O
the O
spinal O
cord O
. O

in O
spontaneously O
hypertensive B-Disease
, O
stroke B-Disease
- O
prone O
rats O
, O
microinjection O
of O
methyldopa O
into O
the O
area O
of O
the O
midline O
b3 O
serotonin O
cell O
group O
in O
the O
ventral O
medulla O
caused O
a O
potent O
hypotension B-Disease
of O
30 O
- O
40 O
mm O
hg O
, O
which O
was O
maximal O
2 O
- O
3 O
h O
after O
administration O
and O
was O
abolished O
by O
the O
serotonin O
neurotoxin O
5 O
, O
7 O
- O
dihydroxytryptamine O
( O
5 O
, O
7 O
- O
dht O
) O
injected O
intracerebroventricularly O
. O

however O
, O
intraspinal O
injection O
of O
5 O
, O
7 O
- O
dht O
to O
produce O
a O
more O
selective O
lesion O
of O
only O
descending O
serotonin O
projections O
in O
the O
spinal O
cord O
did O
not O
affect O
this O
hypotension B-Disease
. O

it O
is O
concluded O
therefore O
that O
, O
unlike O
the O
ventrolateral O
b3 O
cells O
which O
mediate O
a O
methyldopa O
- O
induced O
hypotension B-Disease
via O
descending O
projections O
, O
the O
midline O
serotonin O
b3 O
cells O
in O
the O
medulla O
contribute O
to O
the O
hypotensive B-Disease
action O
of O
methyldopa O
, O
either O
by O
way O
of O
an O
ascending O
projection O
which O
does O
not O
pass O
through O
the O
median O
forebrain O
bundle O
, O
or O
through O
a O
projection O
restricted O
to O
the O
caudal O
brainstem O
. O

antiarrhythmic O
plasma O
concentrations O
of O
cibenzoline O
on O
canine O
ventricular B-Disease
arrhythmias I-Disease
. O

using O
two O
- O
stage O
coronary O
ligation O
- O
, O
digitalis O
- O
, O
and O
adrenaline O
- O
induced O
canine O
ventricular B-Disease
arrhythmias I-Disease
, O
antiarrhythmic O
effects O
of O
cibenzoline O
were O
examined O
and O
the O
minimum O
effective O
plasma O
concentration O
for O
each O
arrhythmia B-Disease
model O
was O
determined O
. O

cibenzoline O
suppressed O
all O
the O
arrhythmias B-Disease
, O
and O
the O
minimum O
effective O
plasma O
concentrations O
for O
arrhythmias B-Disease
induced O
by O
24 O
- O
h O
coronary O
ligation O
, O
48 O
- O
h O
coronary O
ligation O
, O
digitalis O
, O
and O
adrenaline O
were O
1 O
. O

9 O
+ O
/ O
- O
0 O
. O

9 O
( O
by O
8 O
mg O
/ O
kg O
i O
. O

v O
. O

) O
, O
1 O
. O

6 O
+ O
/ O
- O
0 O
. O

5 O
( O
by O
8 O
mg O
/ O
kg O
i O
. O

v O
. O

) O
, O
0 O
. O

6 O
+ O
/ O
- O
0 O
. O

2 O
( O
by O
2 O
mg O
/ O
kg O
i O
. O

v O
. O

) O
, O
and O
3 O
. O

5 O
+ O
/ O
- O
1 O
. O

3 O
( O
by O
5 O
mg O
/ O
kg O
i O
. O

v O
. O

) O
micrograms O
/ O
ml O
, O
respectively O
( O
mean O
+ O
/ O
- O
sdm O
, O
n O
= O
6 O
- O
7 O
) O
. O

the O
concentration O
for O
adrenaline O
- O
induced O
arrhythmia B-Disease
was O
significantly O
higher O
than O
those O
for O
the O
other O
types O
of O
arrhythmias B-Disease
. O

because O
cibenzoline O
had O
only O
weak O
hypotensive B-Disease
and O
sinus O
node O
depressive B-Disease
effects O
and O
was O
found O
to O
be O
orally O
active O
when O
given O
to O
coronary O
ligation O
arrhythmia B-Disease
dogs O
, O
its O
clinical O
usefulness O
is O
expected O
. O

although O
there O
have O
been O
anecdotal O
reports O
of O
cardiac B-Disease
toxicity I-Disease
associated O
with O
fluorouracil O
( O
5 O
- O
fu O
) O
therapy O
, O
this O
phenomenon O
has O
not O
been O
studied O
in O
a O
systematic O
fashion O
. O

we O
prospectively O
performed O
continuous O
ambulatory O
ecg O
monitoring O
on O
25 O
patients O
undergoing O
5 O
- O
fu O
infusion O
for O
treatment O
of O
solid O
tumors B-Disease
in O
order O
to O
assess O
the O
incidence O
of O
ischemic B-Disease
st O
changes O
. O

anginal B-Disease
episodes O
were O
rare O
: O
only O
one O
patient O
had O
angina B-Disease
( O
during O
5 O
- O
fu O
infusion O
) O
. O

the O
incidence O
of O
ischemic B-Disease
episodes O
per O
patient O
per O
hour O
was O
0 O
. O

5 O
+ O
/ O
- O
0 O
. O

2 O
prior O
to O
5 O
- O
fu O
infusion O
v O
0 O
. O

13 O
+ O
/ O
- O
0 O
. O

3 O
during O
5 O
- O
fu O
infusion O
( O
p O
less O
than O
. O

1 O
) O
; O
the O
duration O
of O
ecg O
changes O
was O
0 O
. O

6 O
+ O
/ O
- O
0 O
. O

3 O
minutes O
per O
patient O
per O
hour O
before O
5 O
- O
fu O
v O
1 O
. O

9 O
+ O
/ O
- O
0 O
. O

5 O
minutes O
per O
patient O
per O
hour O
during O
5 O
- O
fu O
( O
p O
less O
than O
. O

1 O
) O
. O

ecg O
changes O
were O
more O
common O
among O
patients O
with O
known O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

there O
were O
two O
cases O
of O
sudden B-Disease
death I-Disease
, O
both O
of O
which O
occurred O
at O
the O
end O
of O
the O
chemotherapy O
course O
. O

we O
conclude O
that O
5 O
- O
fu O
infusion O
is O
associated O
with O
a O
significant O
increase O
in O
silent O
st O
segment O
deviation O
suggestive O
of O
ischemia B-Disease
, O
particularly O
among O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

our O
study O
group O
consisted O
of O
74 O
hiv O
- O
positive O
homosexual O
men O
belonging O
to O
groups O
ii O
b O
, O
iii O
and O
iv O
c2 O
from O
the O
centers O
for O
disease O
control O
( O
cdc O
) O
classification O
of O
hiv B-Disease
disease I-Disease
. O

symptomatic O
adverse O
effects O
were O
present O
in O
96 O
% O
of O
subjects O
, O
most O
commonly O
nausea B-Disease
( O
64 O
% O
) O
, O
fatigue B-Disease
( O
55 O
% O
) O
and O
headache B-Disease
( O
49 O
% O
) O
. O

bone O
marrow O
changes O
occurred O
rapidly O
as O
demonstrated O
by O
megaloblastosis B-Disease
in O
95 O
% O
of O
65 O
specimens O
at O
week O
18 O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
national O
project O
on O
the O
prevention O
of O
mother O
- O
to O
- O
infant O
infection B-Disease
by I-Disease
hepatitis I-Disease
b I-Disease
virus I-Disease
in O
japan O
. O

in O
japan O
, O
a O
nationwide O
prevention O
program O
against O
mother O
- O
to O
- O
infant O
infection B-Disease
by I-Disease
hepatitis I-Disease
b I-Disease
virus I-Disease
( O
hbv O
) O
started O
in O
1985 O
. O

these O
infants O
are O
treated O
with O
two O
injections O
of O
hepatitis B-Disease
b I-Disease
immune O
globulin O
( O
hbig O
) O
and O
at O
least O
three O
injections O
of O
plasma O
derived O
hepatitis O
b O
vaccine O
. O

involvement O
of O
the O
mu O
- O
opiate O
receptor O
in O
peripheral O
analgesia B-Disease
. O

intradermal O
injection O
of O
mu O
, O
but O
not O
delta O
or O
kappa O
opioid O
- O
agonists O
, O
however O
, O
produced O
dose O
- O
dependent O
inhibition O
of O
prostaglandin O
e2 O
- O
induced O
hyperalgesia B-Disease
. O

morphine O
did O
not O
, O
however O
, O
alter O
the O
hyperalgesia B-Disease
induced O
by O
8 O
- O
bromo O
cyclic O
adenosine O
monophosphate O
. O

involvement O
of O
locus O
coeruleus O
and O
noradrenergic O
neurotransmission O
in O
fentanyl O
- O
induced O
muscular B-Disease
rigidity I-Disease
in O
the O
rat O
. O

whereas O
muscular B-Disease
rigidity I-Disease
is O
a O
well O
- O
known O
side O
effect O
that O
is O
associated O
with O
high O
- O
dose O
fentanyl O
anesthesia O
, O
a O
paucity O
of O
information O
exists O
with O
regard O
to O
its O
underlying O
mechanism O
( O
s O
) O
. O

such O
an O
induced O
muscular B-Disease
rigidity I-Disease
by O
the O
narcotic O
agent O
was O
significantly O
antagonized O
or O
even O
reduced O
by O
prior O
electrolytic O
lesions O
of O
the O
locus O
coeruleus O
or O
pretreatment O
with O
the O
alpha O
- O
adrenoceptor O
blocker O
, O
prazosin O
. O

it O
is O
speculated O
that O
the O
induction O
of O
muscular B-Disease
rigidity I-Disease
by O
fentanyl O
may O
involve O
the O
coerulospinal O
noradrenergic O
fibers O
to O
the O
spinal O
motoneurons O
. O

dexmedetomidine O
, O
acting O
through O
central O
alpha O
- O
2 O
adrenoceptors O
, O
prevents O
opiate O
- O
induced O
muscle B-Disease
rigidity I-Disease
in O
the O
rat O
. O

the O
highly O
- O
selective O
alpha O
- O
2 O
adrenergic O
agonist O
dexmedetomidine O
( O
d O
- O
med O
) O
is O
capable O
of O
inducing O
muscle B-Disease
flaccidity I-Disease
and O
anesthesia O
in O
rats O
and O
dogs O
. O

intense O
generalized O
muscle B-Disease
rigidity I-Disease
is O
an O
undesirable O
side O
effect O
of O
potent O
opiate O
agonists O
. O

although O
the O
neurochemistry O
of O
opiate O
- O
induced O
rigidity B-Disease
has O
yet O
to O
be O
fully O
elucidated O
, O
recent O
work O
suggests O
a O
role O
for O
a O
central O
adrenergic O
mechanism O
. O

in O
the O
present O
study O
, O
the O
authors O
determined O
if O
treatment O
with O
d O
- O
med O
prevents O
the O
muscle B-Disease
rigidity I-Disease
caused O
by O
high O
- O
dose O
alfentanil O
anesthesia O
in O
the O
rat O
. O

in O
contrast O
, O
d O
- O
med O
prevented O
alfentanil O
- O
induced O
muscle B-Disease
rigidity I-Disease
in O
a O
dose O
- O
dependent O
fashion O
. O

the O
high O
- O
dose O
d O
- O
med O
animals O
were O
flaccid O
, O
akinetic B-Disease
, O
and O
lacked O
a O
startle B-Disease
response O
during O
the O
entire O
experimental O
period O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
a O
repeated O
treatment O
with O
fluvoxamine O
( O
twice O
daily O
for O
14 O
days O
) O
potentiated O
in O
mice O
and O
in O
rats O
( O
weaker O
) O
the O
amphetamine O
- O
induced O
hyperactivity B-Disease
. O

the O
hyperactivity B-Disease
induced O
by O
nomifensine O
in O
mice O
remained O
unaffected O
by O
fluvoxamine O
. O

protective O
effect O
of O
a O
specific O
platelet O
- O
activating O
factor O
antagonist O
, O
bn O
52021 O
, O
on O
bupivacaine O
- O
induced O
cardiovascular B-Disease
impairments I-Disease
in O
rats O
. O

administration O
of O
the O
local O
anaesthetic O
bupivacaine O
( O
1 O
. O

5 O
or O
2 O
mg O
/ O
kg O
, O
i O
. O

v O
. O

) O
to O
rats O
elicited O
a O
marked O
decrease B-Disease
of I-Disease
mean I-Disease
arterial I-Disease
blood I-Disease
pressure I-Disease
( I-Disease
mbp I-Disease
) I-Disease
and I-Disease
heart I-Disease
rate I-Disease
( I-Disease
hr I-Disease
) I-Disease
leading O
to O
death O
( O
in O
67 O
% O
or O
90 O
% O
of O
animals O
respectively O
) O
. O

intravenous O
injection O
of O
the O
specific O
platelet O
- O
activating O
factor O
( O
paf O
) O
antagonist O
bn O
52021 O
( O
10 O
mg O
/ O
kg O
) O
, O
30 O
min O
before O
bupivacaine O
administration O
( O
2 O
mg O
/ O
kg O
i O
. O

v O
. O

) O
suppressed O
both O
the O
decrease B-Disease
of I-Disease
mbp I-Disease
and I-Disease
hr I-Disease
. O

when O
bn O
52021 O
( O
20 O
mg O
/ O
kg O
i O
. O

v O
. O

) O
was O
injected O
immediately O
after O
bupivacaine O
( O
2 O
mg O
/ O
kg O
) O
, O
a O
partial O
reversion O
of O
the O
decrease B-Disease
of I-Disease
mbp I-Disease
and I-Disease
hr I-Disease
was O
observed O
, O
whereas O
the O
dose O
of O
10 O
mg O
/ O
kg O
was O
ineffective O
. O

since O
the O
administration O
of O
bn O
52021 O
, O
at O
all O
doses O
studied O
, O
did O
not O
alter O
mbp O
and O
hr O
at O
the O
doses O
used O
, O
the O
bulk O
of O
these O
results O
clearly O
demonstrate O
a O
protective O
action O
of O
bn O
52021 O
, O
a O
specific O
antagonist O
of O
paf O
, O
against O
bupivacaine O
- O
induced O
cardiovascular B-Disease
toxicity I-Disease
. O

thus O
, O
consistent O
with O
its O
direct O
effect O
on O
heart O
, O
paf O
appears O
to O
be O
implicated O
in O
bupivacaine O
- O
induced O
cardiovascular B-Disease
alterations I-Disease
. O

the O
epidemiology O
of O
the O
acute O
flank B-Disease
pain I-Disease
syndrome O
from O
suprofen O
. O

until O
physicians O
began O
reporting O
an O
unusual O
acute O
flank B-Disease
pain I-Disease
syndrome O
to O
the O
spontaneous O
reporting O
system O
, O
700 O
, O
0 O
persons O
used O
the O
drug O
in O
the O
united O
states O
. O

case O
patients O
were O
more O
likely O
to O
be O
men O
( O
odds O
ratio O
, O
3 O
. O

8 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O

2 O
- O
12 O
. O

1 O
) O
, O
suffer O
from O
hay B-Disease
fever I-Disease
and O
asthma B-Disease
( O
odds O
ratio O
, O
3 O
. O

4 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O

0 O
- O
11 O
. O

9 O
) O
; O
to O
participate O
in O
regular O
exercise O
( O
odds O
ratio O
, O
5 O
. O

9 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O

1 O
- O
30 O
. O

7 O
) O
, O
especially O
in O
the O
use O
of O
nautilus O
equipment O
( O
p O
= O
0 O
. O

2 O
) O
; O
and O
to O
use O
alcohol O
( O
odds O
ratio O
, O
4 O
. O

4 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O

1 O
- O
17 O
. O

5 O
) O
. O

possible O
risk O
factors O
included O
young O
age O
, O
concurrent O
use O
of O
other O
analgesic O
agents O
( O
especially O
ibuprofen O
) O
, O
preexisting O
renal B-Disease
disease I-Disease
, O
a O
history O
of O
kidney B-Disease
stones I-Disease
, O
a O
history O
of O
gout B-Disease
, O
a O
recent O
increase O
in O
activity O
, O
a O
recent O
increase O
in O
sun O
exposure O
, O
and O
residence O
in O
the O
sunbelt O
. O

phlorizin O
- O
induced O
glycosuria B-Disease
does O
not O
prevent O
gentamicin O
nephrotoxicity B-Disease
in O
rats O
. O

because O
rats O
with O
streptozotocin O
- O
induced O
diabetes B-Disease
mellitus I-Disease
( O
dm B-Disease
) O
have O
a O
high O
solute O
diuresis O
( O
glycosuria B-Disease
of O
10 O
to O
12 O
g O
/ O
day O
) O
, O
we O
have O
suggested O
that O
this O
may O
in O
part O
be O
responsible O
for O
their O
resistance O
to O
gentamicin O
- O
induced O
acute B-Disease
renal I-Disease
failure I-Disease
( O
arf B-Disease
) O
. O

the O
protection O
from O
gentamicin O
nephrotoxicity B-Disease
was O
studied O
in O
non O
- O
diabetic B-Disease
rats O
with O
chronic O
solute O
diuresis O
induced O
by O
blockage O
of O
tubular O
glucose O
reabsorption O
with O
phlorizin O
( O
p O
) O
. O

dm B-Disease
rats O
with O
mild O
glycosuria B-Disease
( O
similar O
in O
degree O
to O
that O
of O
the O
p O
treated O
animals O
) O
were O
also O
studied O
. O

group O
1 O
( O
p O
alone O
) O
received O
p O
, O
360 O
mg O
/ O
day O
, O
for O
15 O
days O
; O
group O
ii O
( O
p O
+ O
gentamicin O
) O
; O
group O
iii O
( O
gentamicin O
alone O
) O
and O
group O
iv O
( O
mild O
dm B-Disease
+ O
gentamicin O
) O
. O

nephrotoxic B-Disease
doses O
( O
40 O
mg O
/ O
kg O
body O
wt O
/ O
day O
) O
of O
gentamicin O
were O
injected O
during O
the O
last O
nine O
days O
of O
study O
to O
the O
animals O
of O
groups O
ii O
to O
iv O
. O

in O
group O
i O
, O
p O
induced O
a O
moderate O
and O
stable O
glycosuria B-Disease
( O
3 O
. O

9 O
+ O
/ O
- O
0 O
. O

1 O
g O
/ O
day O
, O
se O
) O
, O
and O
no O
functional O
or O
morphologic O
evidence O
of O
renal B-Disease
dysfunction I-Disease
( O
baseline O
ccr O
2 O
. O

1 O
+ O
/ O
- O
0 O
. O

1 O
ml O
/ O
min O
, O
undetectable O
lysozymuria O
) O
or O
damage O
( O
tubular B-Disease
necrosis I-Disease
score O
[ O
maximum O
4 O
] O
, O
zero O
) O
. O

in O
group O
ii O
, O
p O
did O
not O
prevent O
gentamicin O
- O
arf B-Disease
( O
maximal O
decrease O
in O
ccr O
at O
day O
9 O
. O

89 O
% O
, O
p O
less O
than O
0 O
. O

1 O
; O
peak O
lysozymuria O
, O
1863 O
+ O
/ O
- O
321 O
micrograms O
/ O
day O
; O
and O
tubular B-Disease
necrosis I-Disease
score O
, O
3 O
. O

9 O
+ O
/ O
- O
0 O
. O

1 O
) O
. O

these O
values O
were O
not O
different O
from O
those O
of O
group O
iii O
: O
maximal O
decrease O
in O
ccr O
73 O
% O
( O
p O
less O
than O
0 O
. O

1 O
) O
; O
lysozymuria O
, O
2147 O
+ O
/ O
- O
701 O
micrograms O
/ O
day O
; O
tubular B-Disease
necrosis I-Disease
score O
, O
3 O
. O

8 O
+ O
/ O
- O
0 O
. O

1 O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
catalepsy B-Disease
induced O
by O
combinations O
of O
ketamine O
and O
morphine O
: O
potentiation O
, O
antagonism O
, O
tolerance O
and O
cross O
- O
tolerance O
in O
the O
rat O
. O

previous O
studies O
demonstrated O
that O
both O
ketamine O
and O
morphine O
induced O
analgesia B-Disease
and O
catalepsy B-Disease
in O
the O
rat O
. O

pre O
- O
treatment O
with O
ketamine O
produced O
cross O
- O
tolerance O
to O
morphine O
, O
whereas O
pretreatment O
with O
morphine O
did O
not O
induce O
cross O
- O
tolerance O
to O
ketamine O
but O
rather O
augmented O
the O
cataleptic B-Disease
response O
; O
this O
augmentation O
was O
attributed O
to O
residual O
morphine O
in O
the O
brain O
. O

latency O
to O
the O
loss O
of O
righting O
reflex O
, O
rigidity B-Disease
and O
behavior O
on O
recovery O
, O
reflected O
the O
relative O
predominance O
of O
ketamine O
or O
morphine O
in O
each O
combination O
. O

naloxone O
inhibited O
the O
induced O
cataleptic B-Disease
effects O
. O

while O
the O
mutual O
potentiation O
, O
antagonism O
and O
tolerance O
suggest O
common O
mechanisms O
for O
the O
induced O
catalepsy B-Disease
, O
differences O
in O
latency O
, O
rigidity B-Disease
and O
behavior O
, O
asymmetry O
of O
cross O
- O
tolerance O
and O
a O
widely O
- O
different O
id50 O
for O
naloxone O
would O
argue O
against O
an O
action O
at O
a O
single O
opioid O
site O
. O

hydrocortisone O
- O
induced O
hypertension B-Disease
in O
humans O
: O
pressor O
responsiveness O
and O
sympathetic O
function O
. O

although O
diastolic O
blood O
pressure O
remained O
unchanged O
, O
systolic O
blood O
pressure O
increased O
from O
119 O
to O
135 O
mm O
hg O
( O
sed O
+ O
/ O
- O
3 O
. O

4 O
, O
p O
less O
than O
0 O
. O

1 O
) O
, O
associated O
with O
an O
increased B-Disease
cardiac I-Disease
output I-Disease
( O
5 O
. O

85 O
- O
7 O
. O

73 O
l O
/ O
min O
, O
sed O
+ O
/ O
- O
0 O
. O

46 O
, O
p O
less O
than O
0 O
. O

1 O
) O
. O

the O
rise B-Disease
in I-Disease
resting I-Disease
blood I-Disease
pressure I-Disease
with O
hydrocortisone O
is O
associated O
with O
an O
increased B-Disease
cardiac I-Disease
output I-Disease
( O
presumably O
due O
to O
increased O
blood O
volume O
) O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
neuromuscular B-Disease
blockade I-Disease
with O
magnesium O
sulfate O
and O
nifedipine O
. O

a O
patient O
who O
received O
tocolysis O
with O
nifedipine O
developed O
neuromuscular B-Disease
blockade I-Disease
after O
500 O
mg O
of O
magnesium O
sulfate O
was O
administered O
. O

this O
reaction O
demonstrates O
that O
nifedipine O
can O
seriously O
potentiate O
the O
toxicity B-Disease
of O
magnesium O
. O

chronic O
carbamazepine O
inhibits O
the O
development O
of O
local O
anesthetic O
seizures B-Disease
kindled O
by O
cocaine O
and O
lidocaine O
. O

the O
effects O
of O
carbamazepine O
( O
cbz O
) O
treatment O
on O
local O
anesthetic O
- O
kindled O
seizures B-Disease
and O
lethality O
were O
evaluated O
in O
different O
stages O
of O
the O
kindling O
process O
and O
under O
different O
methods O
of O
cbz O
administration O
. O

chronic O
oral O
cbz O
inhibited O
the O
development O
of O
both O
lidocaine O
- O
and O
cocaine O
- O
induced O
seizures B-Disease
, O
but O
had O
little O
effect O
on O
the O
fully O
developed O
local O
anesthetic O
seizures B-Disease
. O

chronic O
cbz O
also O
decreased O
the O
incidence O
of O
seizure B-Disease
- O
related O
mortality O
in O
the O
cocaine O
- O
injected O
rats O
. O

acute O
cbz O
over O
a O
range O
of O
doses O
( O
15 O
- O
50 O
mg O
/ O
kg O
) O
had O
no O
effect O
on O
completed O
lidocaine O
- O
kindled O
or O
acute O
cocaine O
- O
induced O
seizures B-Disease
. O

repeated O
i O
. O

p O
. O

injection O
of O
cbz O
( O
15 O
mg O
/ O
kg O
) O
also O
was O
without O
effect O
on O
the O
development O
of O
lidocaine O
- O
or O
cocaine O
- O
kindled O
seizures B-Disease
. O

the O
differential O
effects O
of O
cbz O
depending O
upon O
stage O
of O
seizure B-Disease
development O
suggest O
that O
distinct O
mechanisms O
underlie O
the O
development O
versus O
maintenance O
of O
local O
anesthetic O
- O
kindled O
seizures B-Disease
. O

magnetic O
resonance O
imaging O
of O
cerebral O
venous B-Disease
thrombosis I-Disease
secondary O
to O
nan O
low O
- O
dose O
nan O
birth O
control O
pills O
. O

the O
clinical O
and O
radiographic O
features O
of O
cerebral O
deep B-Disease
venous I-Disease
thrombosis I-Disease
in O
a O
21 O
- O
year O
- O
old O
white O
woman O
are O
presented O
. O

beta O
- O
2 O
- O
adrenoceptor O
- O
mediated O
hypokalemia B-Disease
and O
its O
abolishment O
by O
oxprenolol O
. O

the O
time O
course O
and O
concentration O
- O
effect O
relationship O
of O
terbutaline O
- O
induced O
hypokalemia B-Disease
was O
studied O
, O
using O
computer O
- O
aided O
pharmacokinetic O
- O
dynamic O
modeling O
. O

subsequently O
we O
investigated O
the O
efficacy O
of O
oxprenolol O
in O
antagonizing O
such O
hypokalemia B-Disease
, O
together O
with O
the O
pharmacokinetic O
interaction O
between O
both O
drugs O
. O

in O
spite O
of O
higher O
terbutaline O
concentrations O
after O
oxprenolol O
pretreatment O
, O
the O
hypokalemia B-Disease
was O
almost O
completely O
antagonized O
by O
the O
beta O
2 O
- O
blocking O
action O
. O

a O
dystonia B-Disease
- O
like O
syndrome O
after O
neuropeptide O
( O
msh O
/ O
acth O
) O
stimulation O
of O
the O
rat O
locus O
ceruleus O
. O

the O
movement B-Disease
disorder I-Disease
investigated O
in O
these O
studies O
has O
some O
features O
in O
common O
with O
human O
idiopathic O
dystonia B-Disease
, O
and O
information O
obtained O
in O
these O
studies O
may O
be O
of O
potential O
clinical O
benefit O
. O

however O
, O
it O
is O
not O
certain O
as O
to O
the O
following O
: O
( O
a O
) O
what O
receptors O
were O
stimulated O
by O
the O
acth O
n O
- O
terminal O
fragments O
at O
the O
lc O
that O
resulted O
in O
this O
disorder O
; O
( O
b O
) O
whether O
ne O
, O
released O
onto O
purkinje O
cell O
synapses O
located O
at O
terminals O
of O
the O
ceruleo O
- O
cerebellar O
pathway O
, O
did O
indeed O
cause O
the O
long O
- O
term O
depression B-Disease
at O
purkinje O
cell O
synapses O
( O
previously O
described O
by O
others O
) O
that O
resulted O
in O
the O
long O
duration O
of O
the O
movement B-Disease
disorder I-Disease
; O
( O
c O
) O
whether O
the O
inhibition O
of O
inhibitory O
purkinje O
cells O
resulted O
in O
disinhibition O
or O
increased O
excitability O
of O
the O
unilateral O
cerebellar O
fastigial O
or O
interpositus O
nuclei O
, O
the O
output O
targets O
of O
the O
purkinje O
cell O
axons O
, O
that O
may O
have O
been O
an O
important O
contributing O
factor O
to O
this O
disorder O
. O

enhanced O
stimulus O
- O
induced O
neurotransmitter O
overflow O
in O
epinephrine O
- O
induced O
hypertensive B-Disease
rats O
is O
not O
mediated O
by O
prejunctional O
beta O
- O
adrenoceptor O
activation O
. O

gaba O
involvement O
in O
naloxone O
induced O
reversal O
of O
respiratory B-Disease
paralysis I-Disease
produced O
by O
thiopental O
. O

no O
agent O
is O
yet O
available O
to O
reverse O
respiratory B-Disease
paralysis I-Disease
produced O
by O
cns O
depressants O
, O
such O
as O
general O
anesthetics O
. O

in O
this O
study O
naloxone O
reversed O
respiratory B-Disease
paralysis I-Disease
induced O
by O
thiopental O
in O
rats O
. O

50 O
mg O
/ O
kg O
, O
i O
. O

v O
. O

thiopental O
produced O
respiratory B-Disease
arrest I-Disease
with O
further O
increase O
in O
gaba O
and O
decrease O
in O
glutamate O
again O
in O
cortex O
and O
brain O
stem O
without O
affecting O
any O
of O
the O
amino O
acids O
studied O
in O
four O
regions O
of O
rat O
brain O
. O

naloxone O
( O
2 O
. O

5 O
mg O
/ O
kg O
, O
i O
. O

v O
. O

) O
reversed O
respiratory B-Disease
paralysis I-Disease
, O
glutamate O
and O
gaba O
levels O
to O
control O
values O
in O
brain O
stem O
and O
cortex O
with O
no O
changes O
in O
caudate O
or O
cerebellum O
. O

these O
data O
suggest O
naloxone O
reverses O
respiratory B-Disease
paralysis I-Disease
produced O
by O
thiopental O
and O
involves O
gaba O
in O
its O
action O
. O

diazepam O
facilitates O
reflex O
bradycardia B-Disease
in O
conscious O
rats O
. O

also O
, O
reflex O
bradycardia B-Disease
was O
produced O
in O
rats O
by O
intravenous O
infusion O
of O
adrenaline O
( O
1 O
. O

25 O
- O
2 O
. O

5 O
micrograms O
kg O
- O
1 O
) O
. O

intravenous O
pretreatment O
of O
the O
rats O
with O
diazepam O
, O
although O
causing O
no O
change O
in O
the O
adrenaline O
- O
induced O
pressor O
effect O
, O
did O
enhance O
the O
adrenaline O
- O
induced O
reflex O
bradycardia B-Disease
. O

however O
, O
the O
diazepam O
enhancement O
of O
adrenaline O
- O
induced O
reflex O
bradycardia B-Disease
was O
antagonized O
by O
pretreatment O
of O
rats O
with O
an O
intravenous O
dose O
of O
picrotoxin O
( O
an O
agent O
blocks O
chloride O
channels O
by O
binding O
to O
sites O
associated O
with O
the O
benzodiazepine O
- O
gaba O
- O
chloride O
channel O
macromolecular O
complex O
) O
. O

the O
data O
indicate O
that O
diazepam O
acts O
through O
the O
benzodiazepine O
- O
gaba O
- O
chloride O
channel O
macromolecular O
complex O
within O
the O
central O
nervous O
system O
to O
facilitate O
reflex O
bradycardia B-Disease
mediated O
through O
baroreceptor O
reflexes O
in O
response O
to O
an O
acute O
increase O
in O
arterial O
pressure O
. O

initial O
potassium O
loss O
and O
hypokalaemia B-Disease
during O
chlorthalidone O
administration O
in O
patients O
with O
essential O
hypertension B-Disease
: O
the O
influence O
of O
dietary O
sodium O
restriction O
. O

to O
investigate O
the O
initial O
potassium O
loss O
and O
development O
of O
hypokalaemia B-Disease
during O
the O
administration O
of O
an O
oral O
diuretic O
, O
metabolic O
balance O
studies O
were O
performed O
in O
ten O
patients O
with O
essential O
hypertension B-Disease
who O
had O
shown O
hypokalaemia B-Disease
under O
prior O
oral O
diuretic O
treatment O
. O

reversal O
of O
neuroleptic O
- O
induced O
catalepsy B-Disease
by O
novel O
aryl O
- O
piperazine O
anxiolytic O
drugs O
. O

the O
novel O
anxiolytic O
drug O
, O
buspirone O
, O
reverses O
catalepsy B-Disease
induced O
by O
haloperidol O
. O

a O
series O
of O
aryl O
- O
piperazine O
analogues O
of O
buspirone O
and O
other O
5 O
- O
hydroxytryptaminergic O
agonists O
were O
tested O
for O
their O
ability O
to O
reverse O
haloperidol O
induced O
catalepsy B-Disease
. O

those O
drugs O
with O
strong O
affinity O
for O
5 O
- O
hydroxytryptamine1a O
receptors O
were O
able O
to O
reverse O
catalepsy B-Disease
. O

however O
, O
inhibition O
of O
postsynaptic O
5 O
- O
ht O
receptors O
neither O
inhibited O
nor O
potentiated O
reversal O
of O
catalepsy B-Disease
and O
leaves O
open O
the O
question O
as O
to O
the O
site O
or O
mechanism O
for O
this O
effect O
. O

use O
of O
glycopyrronium O
5 O
micrograms O
kg O
- O
1 O
provided O
greater O
cardiovascular O
stability O
and O
, O
given O
1 O
min O
before O
the O
edrophonium O
, O
was O
sufficient O
to O
minimize O
early O
, O
edrophonium O
- O
induced O
bradycardias B-Disease
. O

induction O
of O
ventricular B-Disease
fibrillation I-Disease
and O
decrease O
of O
aortic O
pressure O
. O

frequencies O
of O
ventricular B-Disease
fibrillation I-Disease
were O
significantly O
lower O
( O
p O
less O
than O
0 O
. O

5 O
) O
after O
iopentol O
( O
0 O
% O
) O
and O
iohexol O
( O
3 O
% O
) O
than O
after O
metrizoate O
( O
22 O
% O
) O
. O

it O
has O
been O
suggested O
that O
adenylate O
cyclase O
inhibition O
may O
be O
important O
in O
the O
development O
of O
both O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
and O
hypothyroidism B-Disease
during O
lithium O
treatment O
. O

hypothyroidism B-Disease
developed O
in O
eight O
patients O
while O
they O
were O
taking O
lithium O
. O

impaired O
umax O
was O
found O
in O
both O
euthyroid O
and O
hypothyroid B-Disease
patients O
while O
some O
hypothyroid B-Disease
patients O
concentrated O
their O
urine O
well O
. O

remodelling O
of O
nerve O
structure O
in O
experimental O
isoniazid O
neuropathy B-Disease
in O
the O
rat O
. O

the O
neuropathy B-Disease
caused O
by O
a O
single O
dose O
of O
isoniazid O
in O
rats O
was O
studied O
with O
a O
computer O
- O
assisted O
morphometric O
method O
. O

multicenter O
, O
double O
- O
blind O
, O
multiple O
- O
dose O
, O
parallel O
- O
groups O
efficacy O
and O
safety O
trial O
of O
azelastine O
, O
chlorpheniramine O
, O
and O
placebo O
in O
the O
treatment O
of O
spring B-Disease
allergic I-Disease
rhinitis I-Disease
. O

azelastine O
, O
a O
novel O
antiallergic O
medication O
, O
was O
compared O
with O
chlorpheniramine O
maleate O
and O
placebo O
for O
efficacy O
and O
safety O
in O
the O
treatment O
of O
spring B-Disease
allergic I-Disease
rhinitis I-Disease
in O
a O
multicenter O
, O
double O
- O
blind O
, O
multiple O
- O
dose O
, O
parallel O
- O
groups O
study O
. O

subjects O
ranged O
in O
age O
from O
18 O
to O
60 O
years O
of O
age O
and O
had O
at O
least O
a O
2 O
- O
year O
history O
of O
spring B-Disease
allergic I-Disease
rhinitis I-Disease
, O
confirmed O
by O
positive O
skin O
test O
to O
spring O
aeroallergens O
. O

drowsiness B-Disease
and O
altered B-Disease
taste I-Disease
perception I-Disease
were O
increased O
significantly O
over O
placebo O
only O
in O
the O
high O
- O
dose O
azelastine O
group O
. O

azelastine O
appears O
to O
be O
a O
safe O
, O
efficacious O
medication O
for O
seasonal B-Disease
allergic I-Disease
rhinitis I-Disease
. O

toxicity B-Disease
due O
to O
remission O
inducing O
drugs O
in O
rheumatoid B-Disease
arthritis I-Disease
. O

twenty O
- O
five O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
( O
ra B-Disease
) O
who O
developed O
toxicity B-Disease
while O
taking O
remission O
inducing O
drugs O
and O
30 O
without O
toxicity B-Disease
were O
studied O
for O
possible O
associations O
with O
class O
i O
and O
ii O
hla O
antigens O
. O

a O
strong O
association O
has O
been O
found O
between O
nephritis B-Disease
and O
dermatitis B-Disease
due O
to O
tiopronin O
( O
a O
d O
- O
penicillamine O
like O
compound O
) O
and O
class O
i O
antigens O
b35 O
- O
cw4 O
, O
and O
between O
dermatitis B-Disease
due O
to O
gold O
thiosulphate O
and O
b35 O
. O

compared O
to O
healthy O
controls O
a O
lower O
dr5 O
frequency O
was O
observed O
in O
patients O
with O
ra B-Disease
except O
for O
the O
tiopronin O
related O
nephritis B-Disease
group O
. O

transient O
contralateral B-Disease
rotation I-Disease
following O
unilateral O
substantia B-Disease
nigra I-Disease
lesion I-Disease
reflects O
susceptibility O
of O
the O
nigrostriatal O
system O
to O
exhaustion O
by O
amphetamine O
. O

following O
unilateral O
6 O
- O
ohda O
induced O
sn B-Disease
lesion I-Disease
, O
a O
transient O
period O
of O
contralateral B-Disease
rotation I-Disease
has O
been O
reported O
to O
precede O
the O
predominant O
ipsilateral B-Disease
circling I-Disease
. O

in O
order O
to O
clarify O
the O
nature O
of O
this O
initial O
contralateral B-Disease
rotation I-Disease
we O
examined O
the O
effect O
of O
the O
duration O
of O
recovery O
period O
after O
the O
lesion O
, O
on O
amphetamine O
- O
induced O
rotational B-Disease
behavior I-Disease
. O

such O
contralateral B-Disease
rotation I-Disease
may O
result O
from O
either O
degeneration O
- O
induced O
breakdown O
of O
the O
da O
pool O
, O
or O
lesion O
- O
induced O
increase O
of O
da O
turnover O
in O
the O
spared O
neurons O
. O

a O
substantial O
degree O
of O
contralateral O
preference O
was O
still O
evident O
when O
amphetamine O
was O
administered O
for O
the O
first O
time O
24 O
days O
after O
lesioning O
, O
indicating O
involvement O
of O
spared O
cells O
in O
the O
contralateral B-Disease
rotation I-Disease
. O

however O
, O
regardless O
of O
the O
duration O
of O
recovery O
( O
and O
irrespective O
of O
either O
lesion O
volume O
, O
amphetamine O
dose O
, O
or O
post O
- O
lesion O
motor O
exercise O
) O
, O
amphetamine O
- O
induced O
rotation B-Disease
tended O
to O
become O
gradually O
more O
ipsilateral O
as O
the O
observation O
session O
progressed O
, O
and O
all O
rats O
circled O
ipsilaterally O
to O
the O
lesion O
in O
response O
to O
further O
amphetamine O
injections O
. O

these O
findings O
suggest O
that O
amphetamine O
has O
an O
irreversible O
effect O
on O
the O
post O
- O
lesion O
da O
pool O
contributing O
to O
contralateral B-Disease
rotation I-Disease
. O

mitomycin O
c O
associated O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
. O

mitomycin O
c O
associated O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
( O
hus B-Disease
) O
is O
a O
potentially O
fatal O
but O
uncommon O
condition O
that O
is O
not O
yet O
widely O
recognised O
. O

it O
consists O
of O
microangiopathic O
hemolytic B-Disease
anemia I-Disease
, O
thrombocytopenia B-Disease
and O
progressive O
renal B-Disease
failure I-Disease
associated O
with O
mitomycin O
c O
treatment O
and O
affects O
about O
10 O
% O
of O
patients O
treated O
with O
this O
agent O
. O

the O
renal B-Disease
failure I-Disease
usually O
develops O
about O
8 O
- O
10 O
mth O
after O
start O
of O
mitomycin O
c O
treatment O
and O
the O
mortality O
is O
approximately O
60 O
% O
from O
renal B-Disease
failure I-Disease
or O
pulmonary B-Disease
edema I-Disease
. O

renal B-Disease
lesions I-Disease
are O
similar O
to O
those O
seen O
in O
idiopathic O
hus B-Disease
and O
include O
arteriolar O
fibrin O
thrombi B-Disease
, O
expanded O
subendothelial O
zones O
in O
glomerular O
capillary O
walls O
, O
ischemic B-Disease
wrinkling O
of O
glomerular O
basement O
membranes O
and O
mesangiolysis O
. O

we O
describe O
the O
clinical O
course O
and O
pathological O
findings O
in O
a O
65 O
yr O
- O
old O
man O
with O
gastric B-Disease
adenocarcinoma I-Disease
who O
developed O
renal B-Disease
failure I-Disease
and O
thrombocytopenia B-Disease
while O
on O
treatment O
with O
mitomycin O
c O
and O
died O
in O
pulmonary B-Disease
edema I-Disease
. O

ketanserin O
pretreatment O
reverses O
alfentanil O
- O
induced O
muscle B-Disease
rigidity I-Disease
. O

systemic O
pretreatment O
with O
ketanserin O
, O
a O
relatively O
specific O
type O
- O
2 O
serotonin O
receptor O
antagonist O
, O
significantly O
attenuated O
the O
muscle B-Disease
rigidity I-Disease
produced O
in O
rats O
by O
the O
potent O
short O
- O
acting O
opiate O
agonist O
alfentanil O
. O

following O
placement O
of O
subcutaneous O
electrodes O
in O
each O
animal O
' O
s O
left O
gastrocnemius O
muscle O
, O
rigidity B-Disease
was O
assessed O
by O
analyzing O
root O
- O
mean O
- O
square O
electromyographic O
activity O
. O

chlordiazepoxide O
at O
doses O
up O
to O
10 O
mg O
/ O
kg O
failed O
to O
significantly O
influence O
the O
rigidity B-Disease
produced O
by O
alfentanil O
. O

despite O
the O
absence O
of O
rigidity B-Disease
, O
animals O
that O
received O
ketanserin O
( O
greater O
than O
0 O
. O

31 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
followed O
by O
alfentanil O
were O
motionless O
, O
flaccid O
, O
and O
less O
responsive O
to O
external O
stimuli O
than O
were O
animals O
receiving O
alfentanil O
alone O
. O

these O
results O
, O
in O
combination O
with O
previous O
work O
, O
suggest O
that O
muscle B-Disease
rigidity I-Disease
, O
a O
clinically O
relevant O
side O
- O
effect O
of O
parenteral O
narcotic O
administration O
, O
may O
be O
partly O
mediated O
via O
serotonergic O
pathways O
. O

pretreatment O
with O
type O
- O
2 O
serotonin O
antagonists O
may O
be O
clinically O
useful O
in O
attenuating O
opiate O
- O
induced O
rigidity B-Disease
, O
although O
further O
studies O
will O
be O
necessary O
to O
assess O
the O
interaction O
of O
possibly O
enhanced O
cns O
, O
cardiovascular B-Disease
, I-Disease
and I-Disease
respiratory I-Disease
depression I-Disease
. O

the O
patient O
' O
s O
subjective O
assessment O
of O
mood O
rating O
, O
an O
objective O
test O
of O
performance O
, O
a O
test O
for O
amnesia B-Disease
, O
and O
vital O
signs O
were O
recorded O
for O
up O
to O
300 O
min O
after O
administration O
of O
the O
trial O
drug O
. O

no O
significant O
differences O
between O
the O
two O
groups O
were O
observed O
for O
mood O
rating O
, O
amnesia B-Disease
, O
or O
vital O
signs O
. O

chorea B-Disease
associated O
with O
oral O
contraception O
. O

three O
patients O
developed O
chorea B-Disease
while O
receiving O
oral O
contraceptives O
. O

two O
were O
young O
patients O
whose O
chorea B-Disease
developed O
long O
after O
treatment O
had O
been O
started O
and O
disappeared O
soon O
after O
it O
had O
been O
discontinued O
. O

the O
third O
patient O
had O
acute O
amphetamine O
- O
induced O
chorea B-Disease
after O
prolonged O
oral O
contraception O
. O

prolonged O
administration O
of O
female O
sex O
hormones O
is O
a O
possible O
cause O
of O
chorea B-Disease
in O
women O
who O
have O
not O
previously O
had O
chorea B-Disease
or O
rheumatic B-Disease
fever I-Disease
. O

co O
- O
carcinogenic B-Disease
effect O
of O
retinyl O
acetate O
on O
forestomach B-Disease
carcinogenesis I-Disease
of O
male O
f344 O
rats O
induced O
with O
butylated O
hydroxyanisole O
. O

the O
potential O
modifying O
effect O
of O
retinyl O
acetate O
( O
ra O
) O
on O
butylated O
hydroxyanisole O
( O
bha O
) O
- O
induced O
rat O
forestomach B-Disease
tumorigenesis I-Disease
was O
examined O
. O

in O
groups O
given O
2 O
% O
bha O
, O
although O
marked O
hyperplastic O
changes O
of O
the O
forestomach O
epithelium O
were O
observed O
in O
all O
animals O
, O
co O
- O
administration O
of O
0 O
. O

25 O
% O
ra O
significantly O
( O
p O
less O
than O
0 O
. O

5 O
) O
increased O
the O
incidence O
of O
forestomach B-Disease
tumors I-Disease
( O
squamous B-Disease
cell I-Disease
papilloma I-Disease
and O
carcinoma B-Disease
) O
to O
60 O
% O
( O
9 O
/ O
15 O
, O
2 O
rats O
with O
carcinoma B-Disease
) O
from O
15 O
% O
( O
3 O
/ O
20 O
, O
one O
rat O
with O
carcinoma B-Disease
) O
in O
the O
group O
given O
ra O
- O
free O
water O
. O

in O
rats O
given O
1 O
% O
bha O
, O
ra O
co O
- O
administered O
at O
a O
dose O
of O
0 O
. O

5 O
, O
0 O
. O

1 O
, O
0 O
. O

2 O
or O
0 O
. O

25 O
% O
showed O
a O
dose O
- O
dependent O
enhancing O
effect O
on O
the O
development O
of O
the O
bha O
- O
induced O
epithelial B-Disease
hyperplasia I-Disease
. O

tumors B-Disease
, O
all O
papillomas B-Disease
, O
were O
induced O
in O
3 O
rats O
( O
17 O
% O
) O
with O
0 O
. O

25 O
% O
ra O
and O
in O
one O
rat O
( O
10 O
% O
) O
with O
0 O
. O

5 O
% O
ra O
co O
- O
administration O
. O

these O
findings O
indicate O
that O
ra O
acted O
as O
a O
co O
- O
carcinogen O
in O
the O
bha O
forestomach B-Disease
carcinogenesis I-Disease
of O
the O
rat O
. O

a O
prospective O
study O
on O
the O
dose O
dependency O
of O
cardiotoxicity B-Disease
induced O
by O
mitomycin O
c O
. O

since O
1975 O
mitomycin O
c O
( O
mmc O
) O
has O
been O
suggested O
to O
be O
cardiotoxic B-Disease
, O
especially O
when O
combined O
with O
or O
given O
following O
doxorubicin O
. O

one O
of O
the O
patients O
developed O
cardiac B-Disease
failure I-Disease
after O
30 O
mg O
m O
- O
2 O
mmc O
and O
only O
150 O
mg O
m O
- O
2 O
doxorubicin O
. O

the O
cardiac B-Disease
failure I-Disease
was O
predicted O
by O
a O
drop O
in O
ef O
determined O
during O
a O
cold O
pressor O
test O
. O

none O
of O
the O
other O
patients O
developed O
clinical O
cardiotoxicity B-Disease
, O
nor O
did O
the O
studied O
parameters O
change O
. O

based O
on O
the O
combined O
data O
from O
the O
present O
study O
and O
the O
literature O
, O
we O
suggest O
that O
mmc O
- O
related O
cardiotoxicity B-Disease
is O
dose O
dependent O
, O
occurring O
at O
cumulative O
dose O
levels O
of O
30 O
mg O
m O
- O
2 O
or O
more O
, O
mainly O
in O
patients O
also O
( O
previously O
or O
simultaneously O
) O
treated O
with O
doxorubicin O
. O

reversible O
cerebral B-Disease
lesions I-Disease
associated O
with O
tiazofurin O
usage O
: O
mr O
demonstration O
. O

we O
report O
our O
results O
with O
magnetic O
resonance O
( O
mr O
) O
in O
demonstrating O
reversible O
cerebral B-Disease
abnormalities I-Disease
concurrent O
with O
the O
use O
of O
this O
drug O
. O

receptor O
mechanisms O
of O
nicotine O
- O
induced O
locomotor B-Disease
hyperactivity I-Disease
in O
chronic O
nicotine O
- O
treated O
rats O
. O

these O
results O
suggest O
that O
chronic O
nicotine O
- O
treated O
rats O
develop O
locomotor B-Disease
hyperactivity I-Disease
in O
response O
to O
nicotine O
initially O
due O
to O
increases O
of O
both O
the O
density O
of O
nicotinic O
receptors O
and O
da O
concentration O
, O
followed O
by O
inducing O
da O
receptor O
supersensitivity O
in O
the O
striatum O
. O

amelioration O
of O
bendrofluazide O
- O
induced O
hypokalemia B-Disease
by O
timolol O
. O

the O
beta O
adrenergic O
blocking O
drug O
, O
timolol O
, O
tended O
to O
correct O
the O
hypokalemia B-Disease
of O
short O
- O
term O
bendrofluazide O
treatment O
in O
6 O
healthy O
male O
subjects O
and O
although O
the O
effect O
was O
small O
it O
was O
significant O
. O

st B-Disease
. I-Disease

anthony B-Disease
' I-Disease
s I-Disease
fire I-Disease
, O
then O
and O
now O
: O
a O
case O
report O
and O
historical O
review O
. O

a O
rare O
case O
of O
morbid O
vasospasm B-Disease
, O
together O
with O
striking O
angiographic O
findings O
, O
is O
described O
secondary O
to O
the O
ingestion O
of O
methysergide O
by O
a O
48 O
- O
year O
- O
old O
woman O
. O

a O
discussion O
of O
the O
history O
of O
ergot O
includes O
its O
original O
discovery O
, O
the O
epidemics O
of O
gangrene B-Disease
that O
it O
has O
caused O
through O
the O
ages O
and O
its O
past O
and O
present O
role O
in O
the O
management O
of O
migraine B-Disease
headache I-Disease
. O

despite O
the O
advent O
of O
calcium O
channel O
blockers O
and O
beta O
- O
adrenergic O
antagonists O
, O
ergot O
preparations O
continue O
to O
play O
a O
major O
role O
in O
migraine B-Disease
therapy O
, O
so O
that O
the O
danger O
of O
st B-Disease
. I-Disease

anthony B-Disease
' I-Disease
s I-Disease
fire I-Disease
persists O
. O

group O
ii O
also O
showed O
a O
significant O
decrease O
of O
chronic O
nephrotoxicity B-Disease
secondary O
to O
long O
- O
term O
therapy O
with O
cyclosporine O
. O

we O
think O
that O
even O
these O
lower O
dosages O
of O
cyclosporine O
can O
cause O
chronic O
nephrotoxicity B-Disease
and O
that O
further O
modification O
of O
the O
immunosuppressive O
regimen O
is O
required O
to O
completely O
abolish O
this O
toxic O
side O
effect O
. O

ethopropazine O
and O
benztropine O
in O
neuroleptic O
- O
induced O
parkinsonism B-Disease
. O

in O
a O
12 O
- O
week O
controlled O
study O
ethopropazine O
was O
compared O
to O
benztropine O
in O
the O
treatment O
of O
parkinsonism B-Disease
induced O
by O
fluphenazine O
enanthate O
in O
60 O
schizophrenic B-Disease
outpatients O
. O

ethopropazine O
and O
benztropine O
were O
found O
to O
be O
equally O
effective O
in O
controlling O
parkinsonian B-Disease
symptoms I-Disease
and O
were O
as O
efficacious O
as O
procyclidine O
, O
their O
previous O
antiparkinsonian O
drug O
. O

however O
, O
benztropine O
treated O
patients O
had O
a O
significant O
increase O
in O
tardive B-Disease
dyskinesia I-Disease
compared O
to O
their O
condition O
during O
procyclindine O
treatment O
, O
and O
significantly O
more O
anxiety B-Disease
and O
depression B-Disease
than O
ethopropazine O
treated O
patients O
. O

this O
suggests O
that O
benztropine O
is O
not O
the O
anticholinergic O
drug O
of O
choice O
in O
the O
treatment O
of O
neuroleptic O
- O
induced O
parkinsonian B-Disease
symptoms I-Disease
, O
because O
of O
its O
more O
toxic O
central O
and O
peripheral O
atropinic O
effect O
. O

quinidine O
phenylethylbarbiturate O
- O
induced O
fulminant O
hepatitis B-Disease
in O
a O
pregnant O
woman O
. O

we O
report O
the O
case O
of O
a O
19 O
- O
year O
- O
old O
laotian O
patient O
affected O
by O
fulminant O
hepatitis B-Disease
during O
the O
third O
trimester O
of O
her O
pregnancy O
after O
a O
1 O
- O
month O
administration O
of O
quinidine O
phenylethylbarbiturate O
. O

quinidine O
itself O
or O
phenylethylbarbiturate O
may O
be O
responsible O
for O
fulminant O
hepatitis B-Disease
in O
this O
patient O
. O

mechanisms O
of O
myocardial B-Disease
ischemia I-Disease
induced O
by O
epinephrine O
: O
comparison O
with O
exercise O
- O
induced O
ischemia B-Disease
. O

the O
role O
of O
epinephrine O
in O
eliciting O
myocardial B-Disease
ischemia I-Disease
was O
examined O
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

objective O
signs O
of O
ischemia B-Disease
and O
factors O
increasing O
myocardial O
oxygen O
consumption O
were O
compared O
during O
epinephrine O
infusion O
and O
supine O
bicycle O
exercise O
. O

both O
epinephrine O
and O
exercise O
produced O
myocardial B-Disease
ischemia I-Disease
as O
evidenced O
by O
st O
segment O
depression B-Disease
and O
angina B-Disease
. O

however O
, O
the O
mechanisms O
of O
myocardial B-Disease
ischemia I-Disease
induced O
by O
epinephrine O
were O
significantly O
different O
from O
those O
of O
exercise O
. O

exercise O
- O
induced O
myocardial B-Disease
ischemia I-Disease
was O
marked O
predominantly O
by O
increased O
heart O
rate O
and O
rate O
- O
pressure O
product O
with O
a O
minor O
contribution O
of O
end O
- O
diastolic O
volume O
, O
while O
epinephrine O
- O
induced O
ischemia B-Disease
was O
characterized O
by O
a O
marked O
increase O
in O
contractility O
and O
a O
less O
pronounced O
increase O
in O
heart O
rate O
and O
rate O
- O
pressure O
product O
. O

these O
findings O
indicate O
that O
ischemia B-Disease
produced O
by O
epinephrine O
, O
as O
may O
occur O
during O
states O
of O
emotional O
distress O
, O
has O
a O
mechanism O
distinct O
from O
that O
due O
to O
physical O
exertion O
. O

cb O
3717 O
, O
n10 O
- O
propargyl O
- O
5 O
, O
8 O
- O
dideazafolic O
acid O
, O
is O
a O
tight O
- O
binding O
inhibitor O
of O
thymidylate O
synthase O
( O
ts O
) O
whose O
cytotoxicity B-Disease
is O
mediated O
solely O
through O
the O
inhibition O
of O
this O
enzyme O
. O

as O
inhibitors O
of O
isolated O
l1210 O
ts O
, O
cb O
3717 O
di O
- O
, O
tri O
- O
, O
tetra O
- O
and O
pentaglutamate O
are O
26 O
- O
, O
87 O
- O
, O
119 O
- O
and O
114 O
- O
fold O
more O
potent O
than O
cb O
3717 O
, O
respectively O
, O
and O
their O
formation O
may O
, O
therefore O
, O
be O
an O
important O
determinant O
of O
cb O
3717 O
cytotoxicity B-Disease
. O

in O
early O
clinical O
studies O
with O
cb O
3717 O
, O
activity O
has O
been O
seen O
in O
breast B-Disease
cancer I-Disease
, O
ovarian B-Disease
cancer I-Disease
, O
hepatoma B-Disease
, O
and O
mesothelioma B-Disease
. O

toxicities B-Disease
included O
hepatotoxicity B-Disease
, O
malaise B-Disease
, O
and O
dose O
- O
limiting O
nephrotoxicity B-Disease
. O

preliminary O
results O
at O
400 O
and O
500 O
mg O
/ O
m2 O
suggest O
that O
a O
reduction O
in O
nephrotoxicity B-Disease
may O
have O
been O
achieved O
with O
only O
1 O
instance O
of O
renal B-Disease
toxicity I-Disease
in O
10 O
patients O
. O

hepatotoxicity B-Disease
and O
malaise B-Disease
are O
again O
the O
most O
frequent O
side O
effects O
. O

type B-Disease
b I-Disease
hepatitis I-Disease
after O
needle O
- O
stick O
exposure O
: O
prevention O
with O
hepatitis B-Disease
b I-Disease
immune O
globulin O
. O

hepatitis B-Disease
b I-Disease
immune O
globulin O
( O
hbig O
) O
and O
immune O
serum O
globulin O
( O
isg O
) O
were O
examined O
in O
a O
randomized O
, O
double O
- O
blind O
trial O
to O
assess O
their O
relative O
efficacies O
in O
preventing O
type B-Disease
b I-Disease
hepatitis I-Disease
after O
needle O
- O
stick O
exposure O
to O
hepatitis O
b O
surface O
antigen O
( O
hbsag O
) O
- O
positive O
donors O
. O

clinical O
hepatitis B-Disease
developed O
in O
1 O
. O

4 O
% O
of O
hbig O
and O
in O
5 O
. O

9 O
% O
of O
isg O
recipients O
( O
p O
= O
0 O
. O

16 O
) O
, O
and O
seroconversion O
( O
anti O
- O
hbs O
) O
occurred O
in O
5 O
. O

6 O
% O
and O
20 O
. O

7 O
% O
of O
them O
respectively O
( O
p O
less O
than O
0 O
. O

1 O
) O
. O

hepatitis B-Disease
b I-Disease
immune O
globulin O
remained O
significantly O
superior O
to O
isg O
in O
preventing O
type B-Disease
b I-Disease
hepatitis I-Disease
even O
when O
the O
analysis O
was O
confined O
to O
these O
two O
high O
- O
risk O
subgroups O
. O

the O
efficacy O
of O
isg O
in O
preventing O
type B-Disease
b I-Disease
hepatitis I-Disease
cannot O
be O
ascertained O
because O
a O
TRUE O
placebo O
group O
was O
not O
included O
. O

production O
of O
autochthonous O
prostate B-Disease
cancer I-Disease
in O
lobund O
- O
wistar O
rats O
by O
treatments O
with O
n O
- O
nitroso O
- O
n O
- O
methylurea O
and O
testosterone O
. O

more O
than O
50 O
% O
of O
lobund O
- O
wistar O
( O
l O
- O
w O
) O
strain O
rats O
developed O
large O
, O
palpable O
prostate B-Disease
adenocarcinomas I-Disease
( O
pas B-Disease
) O
following O
treatments O
with O
n O
- O
nitroso O
- O
n O
- O
methylurea O
( O
cas O
: O
684 O
- O
93 O
- O
5 O
) O
and O
testosterone O
propionate O
[ O
( O
tp O
) O
cas O
: O
57 O
- O
85 O
- O
2 O
] O
, O
and O
most O
of O
the O
tumor B-Disease
- O
bearing O
rats O
manifested O
metastatic O
lesions O
. O

within O
the O
same O
timeframe O
, O
no O
l O
- O
w O
rat O
developed O
a O
similar O
palpable O
pa B-Disease
when O
treated O
only O
with O
tp O
. O

in O
l O
- O
w O
rats O
, O
tp O
acted O
as O
a O
tumor B-Disease
enhancement O
agent O
, O
with O
primary O
emphasis O
on O
the O
development O
of O
prostate B-Disease
cancer I-Disease
. O

relative O
efficacy O
and O
toxicity B-Disease
of O
netilmicin O
and O
tobramycin O
in O
oncology O
patients O
. O

we O
prospectively O
compared O
the O
efficacy O
and O
safety O
of O
netilmicin O
sulfate O
or O
tobramycin O
sulfate O
in O
conjunction O
with O
piperacillin O
sodium O
in O
118 O
immunocompromised O
patients O
with O
presumed O
severe O
infections B-Disease
. O

nephrotoxicity B-Disease
occurred O
in O
a O
similar O
proportion O
in O
patients O
treated O
with O
netilmicin O
and O
tobramycin O
( O
17 O
% O
vs O
11 O
% O
) O
. O

ototoxicity B-Disease
occurred O
in O
four O
( O
9 O
. O

5 O
% O
) O
of O
42 O
netilmicin O
and O
piperacillin O
and O
in O
12 O
( O
22 O
% O
) O
of O
54 O
tobramycin O
and O
piperacillin O
- O
treated O
patients O
. O

we O
conclude O
that O
aminoglycoside O
- O
associated O
ototoxicity B-Disease
was O
less O
severe O
and O
more O
often O
reversible O
with O
netilmicin O
than O
with O
tobramycin O
. O

urinary O
enzymes O
and O
protein O
patterns O
as O
indicators O
of O
injury B-Disease
to I-Disease
different I-Disease
regions I-Disease
of I-Disease
the I-Disease
kidney I-Disease
. O

acute B-Disease
experimental I-Disease
models I-Disease
of I-Disease
renal I-Disease
damage I-Disease
to O
the O
proximal O
tubular O
, O
glomerular O
, O
and O
papillary O
regions O
of O
the O
rat O
were O
produced O
by O
administration O
of O
hexachloro O
- O
1 O
: O
3 O
- O
butadiene O
( O
hcbd O
) O
, O
puromycin O
aminonucleoside O
( O
pan O
) O
, O
and O
2 O
- O
bromoethylamine O
( O
bea O
) O
, O
respectively O
. O

several O
routine O
indicators O
of O
nephrotoxicity B-Disease
, O
the O
enzymes O
alkaline O
phosphatase O
and O
n O
- O
acetyl O
- O
beta O
- O
glucosaminidase O
, O
and O
the O
molecular O
weight O
of O
protein B-Disease
excretion I-Disease
were O
determined O
on O
urine O
samples O
. O

tubular O
damage O
produced O
by O
hcbd O
or O
bea O
was O
discriminated O
both O
quantitatively O
and O
qualitatively O
from O
glomerular B-Disease
damage I-Disease
produced O
by O
pan O
. O

the O
latter O
was O
characterized O
by O
a O
pronounced O
increase O
in O
protein B-Disease
excretion I-Disease
, O
especially O
proteins O
with O
molecular O
weight O
greater O
than O
40 O
, O
0 O
da O
. O

in O
contrast O
, O
protein B-Disease
excretion I-Disease
in O
tubular O
damage O
was O
raised O
only O
slightly O
and O
characterized O
by O
excretion B-Disease
of I-Disease
proteins I-Disease
of O
a O
wide O
range O
of O
molecular O
weights O
. O

it O
is O
concluded O
that O
both O
selective O
urinary O
enzymes O
and O
the O
molecular O
weight O
pattern O
of O
urinary O
proteins O
can O
be O
used O
to O
provide O
diagnostic O
information O
about O
the O
possible O
site O
of O
renal B-Disease
damage I-Disease
. O

a O
catch O
in O
the O
reye B-Disease
. O

twenty O
- O
six O
cases O
of O
reye B-Disease
syndrome I-Disease
from O
the O
children O
' O
s O
hospital O
, O
camperdown O
, O
australia O
, O
occurring O
between O
1973 O
and O
1982 O
were O
reviewed O
. O

of O
these O
, O
20 O
cases O
met O
the O
us O
public O
health O
service O
centers O
for O
disease O
control O
criteria O
for O
the O
diagnosis O
of O
reye B-Disease
syndrome I-Disease
. O

pathologic O
confirmation O
of O
the O
diagnosis O
of O
reye B-Disease
syndrome I-Disease
was O
accomplished O
in O
90 O
% O
of O
the O
cases O
. O

the O
incidence O
of O
reye B-Disease
syndrome I-Disease
in O
new O
south O
wales O
, O
australia O
, O
is O
estimated O
from O
this O
study O
to O
be O
approximately O
nine O
cases O
per O
1 O
million O
children O
compared O
with O
recent O
us O
data O
of O
ten O
to O
20 O
cases O
per O
1 O
million O
children O
and O
three O
to O
seven O
cases O
per O
1 O
million O
children O
in O
great O
britain O
. O

the O
mortality O
for O
these O
reye B-Disease
syndrome I-Disease
cases O
in O
australia O
was O
45 O
% O
as O
compared O
with O
a O
32 O
% O
case O
- O
fatality O
rate O
in O
the O
united O
states O
. O

reye B-Disease
syndrome I-Disease
may O
be O
disappearing O
from O
australia O
despite O
a O
total O
lack O
of O
association O
with O
salicylates O
or O
aspirin O
ingestion O
, O
since O
there O
were O
no O
cases O
found O
at O
the O
children O
' O
s O
hospital O
in O
1983 O
, O
1984 O
, O
or O
1985 O
. O

postpartum O
psychosis B-Disease
induced O
by O
bromocriptine O
. O

two O
multigravida O
patients O
with O
no O
prior O
psychiatric B-Disease
history O
were O
seen O
with O
postpartum O
psychosis B-Disease
, O
having O
received O
bromocriptine O
for O
inhibition B-Disease
of I-Disease
lactation I-Disease
. O

bromocriptine O
given O
in O
high O
doses O
has O
been O
associated O
with O
psychosis B-Disease
in O
patients O
receiving O
the O
drug O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

these O
cases O
demonstrate O
that O
bromocriptine O
may O
cause O
psychosis B-Disease
even O
when O
given O
in O
low O
doses O
. O

hyperglycemic B-Disease
acidotic I-Disease
coma I-Disease
and O
death O
in O
kearns B-Disease
- I-Disease
sayre I-Disease
syndrome I-Disease
. O

this O
paper O
presents O
the O
clinical O
and O
metabolic O
findings O
in O
two O
young O
boys O
with O
long O
- O
standing O
kearns B-Disease
- I-Disease
sayre I-Disease
syndrome I-Disease
. O

following O
short O
exposure O
to O
oral O
prednisone O
, O
both O
boys O
developed O
lethargy B-Disease
, O
increasing O
somnolence B-Disease
, O
polydipsia B-Disease
, O
polyphagia B-Disease
, O
and O
polyuria B-Disease
. O

both O
presented O
in O
the O
emergency O
room O
with O
profound O
coma B-Disease
, O
hypotension B-Disease
, O
severe O
hyperglycemia B-Disease
, O
and O
acidosis B-Disease
. O

nonketotic O
lactic B-Disease
acidosis I-Disease
was O
present O
in O
one O
and O
ketosis B-Disease
without O
a O
known O
serum O
lactate O
level O
was O
present O
in O
the O
other O
. O

respiratory B-Disease
failure I-Disease
rapidly O
ensued O
and O
both O
patients O
expired O
in O
spite O
of O
efforts O
at O
resuscitation O
. O

we O
believe O
these O
two O
cases O
represent O
a O
newly O
described O
and O
catastrophic O
metabolic B-Disease
- I-Disease
endocrine I-Disease
failure I-Disease
in O
the O
kearns B-Disease
- I-Disease
sayre I-Disease
syndrome I-Disease
. O

experimental O
cyclosporine O
nephrotoxicity B-Disease
: O
risk O
of O
concomitant O
chemotherapy O
. O

the O
role O
of O
cyclosporine O
( O
csa O
) O
alone O
or O
in O
combination O
with O
various O
chemotherapeutics O
in O
the O
development O
of O
renal B-Disease
toxicity I-Disease
was O
evaluated O
in O
rats O
. O

the O
combined O
administration O
of O
csa O
and O
various O
chemotherapeutic O
drugs O
with O
a O
nephrotoxic B-Disease
potential O
, O
such O
as O
gentamicin O
( O
at O
therapeutic O
doses O
) O
, O
amphothericin O
b O
and O
ketoconazole O
, O
which O
are O
frequently O
used O
in O
immunosuppressed O
patients O
, O
did O
not O
aggravate O
the O
csa O
induced O
toxicity B-Disease
in O
the O
rat O
model O
. O

gentamicin O
at O
toxic O
doses O
, O
however O
, O
increased O
csa O
nephrotoxicity B-Disease
. O

thus O
, O
the O
nephrotoxicity B-Disease
induced O
by O
csa O
has O
a O
different O
pathogenetic O
mechanism O
. O

diuretics O
, O
potassium O
and O
arrhythmias B-Disease
in O
hypertensive B-Disease
coronary B-Disease
disease I-Disease
. O

it O
has O
been O
proposed O
that O
modest O
changes O
in O
plasma O
potassium O
can O
alter O
the O
tendency O
towards O
cardiac B-Disease
arrhythmias I-Disease
. O

if O
this O
were O
so O
, O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
might O
be O
especially O
susceptible O
. O

thus O
, O
myocardial O
electrical O
excitability O
was O
measured O
in O
patients O
with O
mild O
essential O
hypertension B-Disease
and O
known O
coronary B-Disease
artery I-Disease
disease I-Disease
after O
8 O
weeks O
of O
treatment O
with O
a O
potassium O
- O
conserving O
diuretic O
( O
amiloride O
) O
and O
a O
similar O
period O
on O
a O
potassium O
- O
losing O
diuretic O
( O
chlorthalidone O
) O
in O
a O
randomised O
study O
. O

compared O
to O
amiloride O
treatment O
, O
the O
chlorthalidone O
phase O
was O
associated O
with O
an O
increased O
frequency O
of O
ventricular B-Disease
ectopic I-Disease
beats I-Disease
( O
24 O
- O
hour O
holter O
monitoring O
) O
and O
a O
higher O
lown O
grading O
, O
increased O
upslope O
and O
duration O
of O
the O
monophasic O
action O
potential O
, O
prolonged O
ventricular O
effective O
refractory O
period O
, O
and O
increased O
electrical O
instability O
during O
programmed O
ventricular O
stimulation O
. O

the O
above O
results O
indicate O
that O
because O
potassium O
- O
losing O
diuretic O
therapy O
can O
increase O
myocardial O
electrical O
excitability O
in O
patients O
with O
ischaemic B-Disease
heart I-Disease
disease I-Disease
, O
even O
minor O
falls O
in O
plasma O
potassium O
concentrations O
are O
probably O
best O
avoided O
in O
such O
patients O
. O

transketolase O
abnormality O
in O
tolazamide O
- O
induced O
wernicke B-Disease
' I-Disease
s I-Disease
encephalopathy I-Disease
. O